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ABSTRACT 
Transfusion services have a weak evidence base compared to many other modern healthcare 
practices. Diversity of platelet concentrate quality and deterioration of function during ageing is 
poorly understood and difficult to measure. No single test is currently suitable to assess concentrate 
quality for product development purposes or to confirm suitability of individual concentrates for 
clinical use. Many of the studies in this field investigate the in vitro association between concentrate 
age and test results. Not all quality indicators are equally informative because a number of storage 
associated changes correct upon infusion. This study aims to evaluate novel platelet quality 
assessment techniques that may be of use in determining platelet concentrate quality. 
The initial stages of the study involved development of reference methods and in vitro assessment of 
novel techniques for assessing platelet concentrate quality using out of date concentrates. Reference 
methods included swirl assessment, pH measurement, hypotonic shock response (HSR) and extent 
shape change (ESC) assays. Novel techniques investigated included the iZON impedance analyser, the 
ThromboLUX instrument, rotation thromboelastometry (ROTEM) and an automated, simplified 
version of the HSR test named the automated water expulsion (AWE) test. 
After initial technical development of the assays, a study of the test results obtained throughout 
platelet concentrate ageing in the laboratory and under different storage conditions was undertaken. 
This was followed by a small, proof of concept clinical trial, in which in vitro test results of platelet 
concentrate samples obtained from the giving set after platelet transfusion were compared to 
measures of transfusion outcome in myelodisplasia (MDS) patients. Transfusion efficacy was assessed 
using self assessment bleeding questionnaires and 1 hour post-transfusion corrected count 
increment (CCI). Although the number of patients included in the trial was too low to reach any 
definite conclusions, the ThromboLUX, ROTEM and AWE tests all showed enough potential to 
warrant further investigation as part of a larger clinical trial in the future.  
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1  INTRODUCTION 
1.1 Background 
Platelets are small, anucleate disc shaped cells that are present in the peripheral blood at a 
concentration of between 150 and 400 x 109/L in normal individuals. One third of the platelets in 
the peripheral circulation are sequestered in the spleen. Megakaryocyte fragments are released 
into the bone marrow sinusoids and subsequently divide to produce platelets (Junt et al, 2007; 
Schwertz et al, 2010). Mature platelets retain mitochondria and can therefore produce energy 
aerobically. Although they do not have a nucleus, platelets possess an mRNA transcriptome  and 
the necessary cellular machinery to translate this information into protein in a regulated fashion 
(Weyrich et al, 1998). The normal platelet lifespan is between 7 and 10 days in vivo and ageing, 
senescent cells undergo a form of programmed cell death that is not yet fully understood (Mason 
et al, 2007). 
Platelets play a critical role in primary haemostasis. They become activated in the presence of 
tissue damage and form a ‘primary haemostatic plug’ that limits immediate blood loss. To achieve 
this, the platelets link to the damaged tissue and to other platelets, primarily via interactions with 
von Willebrand Factor and collagen. Upon activation, platelets undergo degranulation, releasing a 
variety of biologically active molecules into the circulation. The platelet activation process 
requires strict regulation, as it could otherwise lead to inappropriate haemostasis and potentially 
harmful vessel occlusion. Regulation is achieved via a balance of stimulatory and inhibitory 
molecules and physical processes. Inhibitory factors released by the intact endothelium include 
nitric oxide (NO), prostacyclin and CD39, which are all critical in maintaining haemostatic balance 
(Watson et al, 2005). 
If platelet numbers or function becomes sufficiently impaired, spontaneous life threatening bleeding 
may take place. Patients may have congenital deficiencies in platelet function or may develop a 
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thrombocytopenia due to increased loss (for instance secondary to bleeding) or reduced platelet 
production (for instance due to chemotherapy) (Key et al, 2009). These patients may require platelet 
transfusion to treat or prevent bleeding episodes. 
In addition to their well characterised function in primary haemostasis, platelets play a role in 
several other biological processes. Platelet dense-granules and α-granules contain molecules 
involved in other haemostatic pathways, leukocyte chemotaxis and activation, inflammation, 
vasoconstriction, vasopermeability and tissue regeneration (Burgers et al, 1993; Watson et al, 
2005). Additional functions continue to be discovered and investigated. For instance platelets are 
involved in closure of the ductus arteriosus during neonatal development (Echtler et al, 2010) and 
in parasite clearance during malarial infection (McMoran et al, 2009). 
However, the biochemical balance governing platelet activation is not always optimal and platelet 
dysfunction is implicated in a variety of pathologies. Platelets are involved in atherosclerotic plaque 
formation and in development of arterial clots, leading to myocardial infarction or stroke, upon 
plaque rupture (Watson et al, 2005). Immune system interactions can lead to pathological immune 
cell recruitment and inflammation (Theilmeier et al, 1999; Blair et al, 2009; Boilard et al, 2010). 
Platelets can promote neutrophil extracellular trap (NET) release during sepsis. NETs damage the 
vasculature and hepatic tissue (Clark et al, 2007). Bacteria mediated alterations to platelet surfaces 
can increase their thrombogeneity, contributing to disseminated intravascular coagulation (DIC) 
(Grewal et al, 2008). In addition, platelet tissue regeneration properties can aid development of the 
neovasculature in malignancy (Italiano et al, 2008; Klement et al, 2009). 
1.1.1 Platelet concentrate production in the UK 
Therapeutic platelet concentrates are prepared from donor blood and transfused to treat 
quantitative or qualitative platelet deficiencies. They only have a shelf life of up to seven days 
following collection from the donor. This short lifespan leads to wastage and logistical challenges 
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in platelet concentrate provision (Estcourt et al, 2016). In the UK, all platelet concentrates are 
produced using either the pooled buffy coat method or aphaeresis (Walters, 2016). 
To prepare a pooled concentrate, four separate donations are used. Around 470mL of whole 
blood is collected from each donor into 63mL of citrate phosphate dextrose (CPD) anticoagulant. 
The donations are centrifuged and their red cell and plasma contents are removed to generate 
red cell concentrates and plasma derived products. The buffy coats remain in the original 
collection packs, which are connected together using a sterile connecting device. The platelets 
from all four donations are then passed through a leucodepletion filter into their final, breathable 
platelet concentrate bag along with a suitable suspension medium (Walters, 2016). 
Apheresis collection of platelets is achieved using a separation instrument. The donor’s blood is 
mixed with anticoagulant citrate dextrose (ACD) and drawn through a line into the machine, 
where it is gently centrifuged to separate the platelets (Walters, 2016). The remainder of the 
blood components are then returned to the donor’s circulation. The total platelet yield from 
apheresis donation is generally much greater than that of traditional whole blood donation: it is 
common to harvest two or three complete therapeutic platelet doses per donation. Apheresis 
platelets currently account for 57% of the UKs platelet transfusions, with pooled buffy coat 
platelets making up the remainder (Hontoria del Hoyo, 2017). 
In the UK, aphaeresis platelet concentrates contain platelets suspended in the donor’s plasma and 
pooled platelet concentrates contain platelets suspended in 30-50% plasma and 70-50% PAS 
(Walters, 2016). The PAS formulation used for standard pooled platelet concentrates is PAS-II, which 
is purchased as a product called SSP from MacoPharma UK Ltd (Twickenham, UK). MacoPharma UK 
Ltd also produce a PAS-III M product called SSP+ that is able to support platelet viability for up to 9 
days (Hornsey et al, 2006). This is used to reconstitute apheresis platelets to create a specialist low 
plasma product for patients who have allergic reactions to plasma components. This blood product is 
referred to by the NHSBT as ‘Platelets suspended in additive solution’ to distinguish it from standard 
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pooled or apheresis platelet concentrates (Walters, 2016). The formulations of SSP and SSP+ are 
shown in Table 1.1. 
Table 1.1: SSP and SSP+ formulations 
SSP SSP+ 
(Standard pooled platelet concentrates) (Platelets suspended in additive solution) 
 Sodium Chloride 6.75g/L  
 Sodium Acetate.3H2O 4.08g/L  
 Sodium Citrate.2H2O 2.94g/L  
 Water for Injection 1000 mL. 
 Sodium Chloride 69.3 mmol/L  
 Sodium Acetate Trihydrate 10.8 mmol/L  
 Sodium Acetate 32.5 mmol/L  
 Sodium Phosphate 28.2 mmol/L  
 Potassium Chloride 5 mmol/L  
 Magnesium Chloride/Sulphate 1.5 mmol/L 
 
1.1.2 Platelet concentrate use in the UK 
The most frequent indication for platelet transfusion is haematological malignancy, which 
accounts for 67% of platelet concentrate usage in the UK (Estcourt et al, 2016). The majority of 
transfusions given to treat haematological malignancy are administered to patients with a 
diagnosis of acute myeloid leukaemia (AML - 29%), lymphoma (18%), MDS (11%), myeloma / 
plasma cell dyscrasia (9%), acute lymphocytic leukaemia (ALL – 6%) or aplastic anaemia (5%) 
(Birchall et al, 2011). 
 The British Committee for Standards in Haematology (BCSH) publishes guidelines on the 
therapeutic and prophylactic administration of platelet concentrates (Estcourt et al, 2016). These 
include a comprehensive list of recommended transfusion thresholds for different clinical 
conditions and circumstances which range from maintaining a platelet count at more than 100 x 
109/L (for instance prior to neurosurgery) to withholding platelet transfusion regardless of count 
(e.g. for non-bleeding patients with chronic bone marrow failure or post autologous 
haematopoietic stem cell (HSC) transplant). They also cover the use of alternative treatments 
(such as tranexamic acid for reversal of anti-platelet therapy) and the selection of appropriate 
platelet products for specific patient subgroups (e.g. human leukocyte antigen (HLA) matched 
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platelets for patients with Glanzmann thrombasthenia). The transfusion thresholds most likely to 
be applied to patients with haematological malignancies are summarised in Table 1.2. 
Table 1.2: Summary of the main transfusion thresholds recommended by the BCSH guidelines that 
are likely to be relevant for patients with haematological malignancies 
Clinical Condition Standard 
Threshold 












-Consider maintaining platelet count above 20x109/L if 
there are additional risk factors for bleeding 
-Consider withholding prophylactic transfusions in post 
autologous HSC transplant patients who are otherwise well 
-These thresholds should be used as a guide for other (non-
bone marrow failure) patients with chronic disease in the 












-Patients with chronic bone marrow failure undergoing an 
intense course of treatment will likely need prophylactic 
transfusions 
-Chronic bleeding should be managed according to severity 
and it may be advised to initiate a prophylactic transfusion 







-Not routinely required prior to bone marrow biopsy, 
peripheral insertion of central catheters, removal of 
tunnelled CVCs or cataract surgery 
-Raise count above 20x109/L before venous central line 
insertion 
-Raise count above 30x109/L before lumbar puncture 
-Raise count above 80x109/L before epidural catheter 
insertion or removal 
-Raise count above 50x109/L before major surgery 
-Raise count above 100x109/L before neurosurgery or 
ophthalmic surgery involving the posterior of the eye 
-Raise count above 50x109/L before percutaneous liver 
biopsy 
-Correct bleeding risk factors (anaemia, uraemia) prior to 
renal biopsy. Avoid platelet transfusion because it 
effectiveness is limited. Consider use of desmopressin or 









-Maintain count above 50x109/L for severe bleeding 
-Maintain count above 100x109/L for multiple trauma, brain 
injury or spontaneous intracerebral bleed 
-Maintain count above 30x109/L for bleeding that is not 
severe or life threatening 
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1.1.3 Negative side effects of platelet transfusion 
Platelet concentrate transfusion may have negative clinical side effects due to reactions of the 
recipient’s immune system against the transfused material or by reactions of transfused immune 
elements against the recipient’s own tissues. Non-haemolytic febrile transfusion reaction (NHFTR) 
occurs due to reactions between recipient allo-antibodies and transfused non-red cell elements 
or due to high cytokine content of the transfused component. Transfusion associated acute lung 
injury (TRALI) occurs when recipient neutrophils become inappropriately activated in the lungs in 
response to donor immune factors such as anti-white blood cell (WBC) antibodies in the product, 
leading to tissue damage. Transfusion associated graft versus host disease (TA-GvHD) occurs 
when a recipient-reactive donor lymphocyte population becomes established in the recipient. 
Post transfusion purpura (PTP) results from reactions between recipient allo-antibodies (usually 
of a human platelet antibody specificity) and donor platelets. However, the recipients own 
platelets are also destroyed by an unknown mechanism (Delaney et al, 2016). 
Deficient platelet count incrementation after transfusion is referred to as platelet refractoriness. 
It is usually caused by recipient anti-HLA antibodies that react with antigens on donor platelets 
causing immunological clearance. The incidence of platelet refractoriness is reduced by platelet 
concentrate leucodepletion. In severe cases, HLA matched platelet concentrates may be required. 
Anaphylactic reactions to IgA can occur in in IgA deficient patients and may be life threatening 
(Delaney et al, 2016). 
Blood component transfusion may transmit infection. All donations are tested for hepatitis B virus 
(HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), syphilis and human T cell 
lymphotrophic virus (HTLV). Potential donors are excluded from giving blood if they are deemed 
to be at high risk of certain infections (e.g. high risk of Malaria as indicated by travel history). 
Additional tests, such as cytomegalovirus (CMV) typing, may be performed on selected donations 
to provide products suitable for vulnerable patients (Delaney et al, 2016). However, it is both 
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impractical and impossible to entirely exclude the possibility that a donation contains potentially 
infectious agents. Of particular concern to the UK Blood Transfusion Service is the prion disease, 
variant Creutzfeldt Jakob disease (CJD), for which no test is currently available (Blood Services 
Prion Working Group, 2010). 
The risk of bacterial contamination and transmission is much greater with platelet concentrates 
than with red cell units. Unlike red cell concentrates, platelet concentrates cannot be stored in 
refrigerated conditions as this triggers clustering of the GP1b von Willebrand receptor complex 
and promotes rapid macrophage mediated clearance of transfused platelets (Hoffmeister et al, 
2003a). A study of platelet and red cell transfusion in North America between 1998 and 2000 
found that transfusion transmitted bacteremia occurred following transfusion of 9.98-10.64 / 
million platelet concentrates (for single donor and pooled products respectively), compared to 
0.21 / million red cell concentrates (Kuehnert et al, 2001). Rates for fatal bacteraemia were 1.94-
2.22 and 0.13 / million concentrates respectively. 
Room temperature storage likely accounts for the high rate of bacterial contamination observed 
in platelet concentrates compared to red cell concentrates (Kuehnert et al, 2001). However, the 
National Health Service Blood and Transplant service (NHSBT) monitors platelet concentrates to 
detect bacterial infection, enabling identification and recall of contaminated units. Future 
advances in platelet concentrate preservation methodology may enable storage at 4⁰C and 
consequential reduction in bacterial contamination (Hoffmeister et al, 2003b). Also, methods of 
pathogen inactivation have been found to limit bacterial growth in platelet concentrates without 
significantly compromising concentrate quality (Lin et al, 2004; Wagner et al, 2009). 
1.1.4 Platelet quality 
It is important to ensure that platelet concentrate transfusion is effective so that patients are not 
exposed to transfusion associated risks without any clinical benefit. Platelet concentrate quality is 
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thought to vary between individual units and transfusion of poor quality concentrates may not 
deliver the expected level of clinical benefit to the recipient. Between 10 and 30% of platelet 
transfusions have been reported to be ineffective (Maurer-Spurej et al, 2009; Sigle et al, 2012). 
Individual platelet concentrates are thought to deteriorate at different rates (reviewed in Shrivastava, 
2009; Thon et al, 2008). If this is the case, some platelet concentrates that are still of good quality 
may be disposed of after seven days even though they would be clinically effective. Other platelet 
concentrates may deteriorate rapidly, becoming ineffective and potentially harmful to the patient, 
before the arbitrary seven day shelf life is reached. If these platelet concentrates could be reliably 
identified and discarded, it would prevent patient exposure to unnecessary transfusions. Patients 
who receive ineffective platelet concentrate transfusions usually require another transfusion, so 
preventing use of ineffective platelet concentrates should not greatly increase overall platelet 
concentrate demand. Also, in the longer term, good quality concentrates that are discarded when 
they reach their arbitrary expiry date could potentially be used. 
Deterioration of platelet concentrates during storage is referred to as the platelet storage lesion 
(PSL). Changes include appearance of reactive platelet morphology, altered surface protein / lipid 
constitution and increased de-granulation due to in vitro platelet activation (Kunicki et al, 1975; 
Fratantoni et al, 1984; Botchway et al, 2000; Curvers et al, 2004). Increasing apoptosis and 
microvesiculation reduce platelet viability (Bode et al, 1991; Chang et al, 1993). Metabolic and 
storage induced deterioration cause biochemical changes (Murphy et al, 1975; Bellhouse et al, 1987). 
The combined effect of all these factors is estimated to reduce the functionality of stored platelets by 
around 30% after five days (Wenzel et al, 2012). 
The degree of PSL observed in vitro is hypothesised to affect the lifespan and efficacy of transfused 
platelets in vivo (Apelseth et al, 2010; Holme et al, 1998; Mintz et al, 2005; Seghatchian  et al, 1997). 
If true, high quality concentrates may lead to greater, longer lasting, normalisation of haemostatic 
function. This could enable reduced frequency of transfusion, reduced exposure to transfusion 
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associated risks and reduced platelet concentrate provision requirements. However, not all features 
of the PSL are of equal relevance to the clinical efficacy of platelets after transfusion. A number of 
storage associated changes, including metabolic function, aggregation potential and expression of 
activation related surface markers, have been found to correct upon addition of fresh plasma or upon 
re-infusion (Ishikawa et al, 1987; Berger et al, 1998; Rinder et al, 2003; Miyaji et al, 2004). 
Better characterisation of the PSL and practically applicable methods for assessing it in vitro has the 
potential to prevent clinically effective platelet concentrates from being discarded simply because 
they have reached an arbitrary expiry date. It would also allow identification of concentrates that 
deteriorate more rapidly than average, becoming ineffective and possibly harmful to the patient 
before they have reached their expiry date. 
 
1.2  Factors that Affect the PSL 
1.2.1 Platelet deterioration 
Paglia et al (2014) suggest that the PSL is not a single, progressive process but, rather, a series of 
shifts in platelet metabolism that results in distinct phases of platelet concentrate deterioration. 
Between days 0 and 3 they observed active glycolysis, pentose phosphate pathway activity and 
glutathione metabolism in stored apheresis platelet concentrates. From day 4 to day 6 the 
tricarboxilic acid cycle and purine metabolism were upregulated and from day 7 until day 10 the 
platelets entered a period of increased deterioration of their metabolism. In light of these 
observations, it may be too simplistic to expect any single measure of platelet quality to bear 
relevance through all stages of platelet concentrate deterioration. 
Furthermore, the same team observed significant differences between the deterioration processes 
observed in apheresis units (as discussed above) and pooled buffy coat concentrates in a subsequent 
study (Paglia et al, 2015). A similar transition from active metabolism to metabolic decay pathways 
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was observed at day 4 in the buffy coat platelets. These concentrates, however, did not undergo a 
distinct shift from glycolysis to the tricarboxylic acid (TCA) cycle. Rather, they showed generally lower 
levels of activation and more gradual consumption of glucose. The two studies showed higher inter-
bag variability between the apheresis concentrates than the buffy coat concentrates.  
1.2.2 Platelet production methods 
Other teams have also observed differences between apheresis and pooled buffy coat concentrates. 
Apheresis concentrates have been found to have greater haemostatic potential (Böck et al, 2002) and 
lower levels of activation as storage progresses (Ali, 2011). Quintero et al (2015) found apheresis 
platelets to be under less oxidative stress and, therefore, to have lower degrees of PSL changes. 
Although apheresis concentrates appear preferable in several respects, the buffy coat components of 
whole blood donations are more widely available and the blood service has a duty not to waste any 
part of these donations unnecessarily wherever possible. A better understanding of the differences 
between the two components may enable optimisation of production and storage methods that 
raises the quality of pooled buffy coat concentrates to a level comparable with those produced by 
apheresis (Vassallo et al, 2006).  
1.2.3 Platelet additive solutions 
For several reasons it may be desirable to replace plasma as a storage medium for platelets with an 
artificial platelet additive solution (PAS). Firstly, use of PAS has been found to reduce incidence of 
allergic reactions such as transfusion related acute lung injury (TRALI) by reducing the concentration 
of white cell cytokines in the storage media (Azuma et al, 2009; Heddle et al, 1994; Van der Meer, 
2016). Secondly, careful manipulation of the platelet storage environment can be used to reduce the 
PSL by, for example, reducing glucose metabolism to limit production of lactic acid and 
consequentially reduction of pH (van der Meer, 2016). Finally, use of PAS has a potential application 
in supporting pathogen reduction, which is particularly relevant in platelet transfusion due to the 
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high rate of bacterial contamination observed due to the room temperature storage required for 
preservation of platelet viability (Kuehnert et al, 2001; Osman et al, 2016). 
A variety of different PAS formulations have been studied and some are in routine use (van der Meer, 
2016). Different additive solutions have different effects on the PSL. The potential to extend platelet 
shelf life by finding the optimal balance of contents and specifically targeting pro-PSL signalling 
pathways is a matter of considerable scientific interest (Leitner et al, 2016; Schubert et al, 2010). A 
number of compounds involved in lipid metabolism have been investigated recently and found to be 
potentially beneficial. These include high density lipoprotein-3 (HDL3) and apolipoprotein A1 
(Pienimaeki-Roemer et al, 2014), anandamide (Zhuang et al, 2014) and L-carnitine (Deyhim et al, 
2015). 
1.2.4 Platelet storage  
Following collection and processing, the conditions under which platelet concentrates are stored is 
also critical to maintaining their optimal quality. Firstly, all platelet concentrates require storage at 
room temperature because refrigeration leads to enhanced clearance of transfused platelets, 
possibly due to clustering of the glycoprotein-1b (GP1b) von Willebrand factor (vWF) receptor 
complex (Hoffmeister et al, 2003a). The pH of platelet concentrates decrease during storage with the 
accumulation of lactic acid due to glucose metabolism. This decrease is more rapid in the presence of 
anaerobic glucose metabolism (glycolysis), which results in greater lactic acid build up than aerobic 
metabolism (oxidative phosphorylation) due to its relative inefficiency (Murphy et al, 1975). Oxygen 
permeable containers are used to reduce the rate of pH decrease and prolong the lifespan of 
clinically useful platelets for transfusion (Murphy et al, 1975). Finally, an agitator is used to provide 
constant movement of the platelets within the concentrate throughout storage. This movement 
ensures that all platelets in the concentrate regularly come into contact with the oxygen permeable 
surface and prevents the development of localised anoxic areas (Torres et al, 2016).  
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1.2.5 Individual donor variability 
A degree of variability is observed between the results of in vitro test results obtained for different 
platelet concentrate units even when they are matched for age, collection method and storage 
factors (AuBuchon et al, 2005; Carvalho et al, 2006; Seghatchian, 2006a). The extent to which this 
variability reflects differences between the physiological make up of different donors, and the 
significance of any such differences to recipients, is not yet clear. Differences in platelet aggregation 
and platelet production of the critical haemostatic proteins tissue factor (TF) and tissue factor 
pathway inhibitor have been observed in the presence of oestrogen, suggesting a qualitative 
difference in platelets from male and female donors (Jayachandran et al, 2005a; Jayachandran et al, 
2005b). Qualitative platelet differences have been linked to underlying disease (e.g. diabetes) in the 
donor (Stratmann et al, 2005; Stringer et al, 2009) and a variety of metabolites, such as caffeine 
metabolites and fatty acid metabolites, have been found to affect either recovery or survival (Zimring 
et al, 2016). Recipient specific factors, including age, gender, body weight, medication and medical 
conditions, have also been found to influence the recovery and survival of transfused platelets 
(Slichter et al, 2005). 
  
1.3 Determining Transfusion Efficacy 
Radio-labelling of platelets prior to infusion enables very accurate measurement of recovery and 
survival and is the gold standard method for assessing transfusion efficacy. However, assessment of 
In vivo platelet concentrate efficacy has also historically been achieved using platelet count 
increments, which are easier, cheaper and less invasive to measure. 
1.3.1 Laboratory measures of efficacy 
One hour post-transfusion increments are used to assess recovery and 24 hour increments are used 
to assess survival (AuBuchon et al, 2005). In research for publication, these increments are usually 
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corrected for the patient’s body weight and the number of platelets transfused (Balduini et al, 2001; 
Elfath et al, 1999). However, CCIs are not always reliable predictors of bleeding due to analytical 
shortfalls, variable platelet reactability, variability in other elements of the haemostatic process and 
possibly additional, as yet unknown, factors. Time intervals between platelet concentrate 
transfusions have also been measured as an indicator of efficacy, although the reliability of this 
parameter as an outcome measure is determined by the extent to which platelet concentrate usage 
is informed by transfusion guidelines (Slichter et al, 2005). It is worth noting that platelet function 
deteriorates rapidly ex vivo, necessitating testing within as little as 2 hours of sampling (Watson et al, 
2005). Several platelet disorders affect both the functionality and number of platelets produced 
(Margaglione, 2005). 
1.3.2 Clinical bleeding assessment 
Measurement of platelet concentrate transfusion outcome could potentially be improved by 
assessing the degree of clinical bleeding (Stanworth et al, 2006). A variety of assessment methods 
have been used to this end, including that described by the World Health Organisation (WHO, 1979) 
and a modified version of the WHO criteria employed by the strategies for transfusion of platelets 
(SToP) study (Heddle et al, 2009). Clinical bleeding assessment would enable evaluation of platelet 
functionality in addition to incrementation. In addition, in vitro platelet function testing, performed 
on post platelet concentrate transfusion specimens drawn from the patient, may be of use in 
establishing the efficacy of transfused platelets. Suggested methods include thromboelastometry 
(Apelseth et al, 2010), thrombin generation measurement and assessment of whole blood platelet 
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1.4  Basic Laboratory Characterisation of Platelet Concentrate Quality 
A simple, easily applicable test of platelet concentrate quality would be highly useful to ensure that 
patients are not transfused with sub-standard products, to enable evidence based development of 
collection, processing and storage techniques and to aid the best possible management of this 
limited and valuable resource. There is currently no single test available that can be used to assess 
platelet concentrate quality. Those tests that are available all have drawbacks in terms of sensitivity, 
reproducibility and / or applicability in a routine screening environment.  
1.4.1 Current tests 
The NHSBT determines the volume, WBC count and total platelet yield of each platelet concentrate 
prior to release (Walters, 2016). The pH of platelet concentrates that remain within the NHSBT stock 
at the time of expiry is also measured and is expected to be between 6.4 and 7.4. A large number of 
additional tests, including some of those used to investigate platelet function in patients, have been 
applied to assessment of the PSL on a research basis. Many of these are too cumbersome to be 
routinely used for a high volume of tests. In addition, the clinical relevance of PSL assessment 
methods is often uncertain as many indicators of PSL development can revert to normal following 
transfusion (Rinder et al, 2003). 
1.4.2 Platelet count and mean platelet volume 
The NHSBT requires the platelet count of each concentrate to be >240 x 109 platelets / concentrate in 
order to achieve a therapeutic dose (Walters, 2016). However, if platelet concentration is too high, 
metabolic processes may result in accelerated quality deterioration (Murphy et al, 1975). Increased 
mean platelet volume (MPV) in clinical samples may indicate high platelet turnover or the presence 
of a platelet disorder (Briggs et al, 2004; Watson et al, 2005).  The MPV and the distribution of 
platelet sizes (platelet distribution width – PDW) may change during platelet concentrate storage in 
response to alterations of the platelets within the concentrate. It is difficult to predict the effect of 
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storage on these platelet indices. Aggregation of platelets can cause an increase in MPV and 
microvesiculation can cause a decrease in the MPV. Simultaneous occurrence of both of these 
changes would result in an increase in the PDW, although the MPV may remain unaltered 
(Seghatchian et al, 1997). 
The full blood count (FBC) is a standardised panel of test relating to the quantity of different types of 
common blood cells and their basic features such as size and granularity. It is usually performed on a 
dedicated analyser that reports all parameters for each sample tested. FBC results produced by 
different, mainstream analysers are generally considered to be comparable. Platelet count and MPV 
are both included in the standard FBC test panel. 
Impedance platelet counting methods are widely used, inexpensive and easily incorporated into high 
throughput systems. They detect and count cells as they move between two chambers of the system 
under the influence of an electrical charge. Impedance counts may be inaccurate in certain 
circumstances, for instance in the presence of fragmented / microcytic red cells or large platelets, 
which can prevent accurate separation of the two populations (Sandhaus et al, 2002). 
Fluorescent platelet counts may be more accurate than impedance counts in specific conditions. The 
fluorescent platelet count performed on Sysmex XN series automated analysers (as utilised in this 
study) uses an oxazine dye that attaches to the platelet RNA, enabling the test to distinguish platelets 
from other blood cells with better specificity and sensitivity, producing a more accurate count. 
1.4.3 Morphology 
The majority of platelets in a normal individual who is not bleeding are in a quiescent state and have 
a regular, discoid shape. Upon activation, platelets undergo actin remodelling which causes 
significant morphological alteration (Watson et al, 2005). The platelets become spherical and then 
assume a dendritic form (they develop spiny protrusions called filipodia). The morphology observed 
in platelet concentrates generally indicates increasing activation as the concentrate ages. 
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Platelet concentrates composed mainly of disk shaped platelets produce a characteristic light 
scattering pattern that is visible to the naked eye. This phenomenon is known as swirling and can be 
assessed inexpensively, easily and non-invasively in the transfusion laboratory (Bertolini et al, 1994). 
Swirl assessment comprises a simple visual observation and is therefore highly subjective. When 
good quality, discoid platelets are observed under a bright light, swirling patterns can be seen in the 
solution. These swirls disappear as the proportion of discoid platelets decreases and the quality of 
the concentrate deteriorates. Loss of swirling indicates an activation associated change in platelet 
morphology. The sensitivity and specificity of platelet concentrate swirling assessment are not 
optimal and it is a totally subjective technique. However, its ease of use and low cost makes it an 
appealing test that could possibly be incorporated into practice as a screening method. 
The Kunicki platelet score (Kunicki et al, 1975) is obtained by examining platelet morphology using 
phase contrast microscopy. Each cell is assigned to one of the following categories: discoid, spherical, 
dendritic or spread. Examples of these four different platelet morphology categories are shown in 
Figure 1.1. A multiplication factor of four, two, one or zero is applied to the percentage of platelets 
counted within each of these categories respectively. Scores of over 200 suggest acceptable platelet 
concentrate quality and extremely high or low morphology scores are thought to correlate with good 
and poor platelet concentrate quality respectively (Kunicki et al, 1975). 
             
Figure 1.1: Discoid (a), spherical (b), dendritic (c) and spread (d) platelets 
(taken from Chien et al, 2010) 
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However, correlation between platelet concentrate quality and retention of discoid shape is 
uncertain. Initial studies showed the two variables to be related (Holme et al, 1998; Kunicki et al, 
1975; Murphy et al, 1970) but these results are not universally reproducible (Mintz et al, 2005). This 
discrepancy is likely due to the ability of platelets to reverse the age related shape changes under 
certain conditions (Mintz et al, 2005; Rinder et al, 2003). In this case, the capacity to assume discoid 
morphology under optimal conditions (e.g. following transfusion) is likely to be a better indicator of 
platelet quality than the morphology score at any one, fixed point in time (Maurer-Spurej et al, 2006; 
Mintz  et al, 2005). 
The extent shape change (ESC) assay measures a similar variable to the Kunicki score. It utilises an 
aggregometer to spectrophotometrically detect changes in the amount of light transmitted through a 
platelet sample. The platelets are treated with ethylenediaminetetraacetic acid (EDTA) to prevent 
aggregation and then activated with adenosine diphosphate (ADP), which causes them to assume a 
spherical conformation and increases the optical density (OD) of the solution. Larger reductions in 
light transmission equate to higher levels of activation, greater shape change and a higher 
percentage of discoid platelets in the platelet concentrate under examination (Holme et al, 1998). 
1.4.4 Biochemistry  
The biochemistry observed within platelet concentrates changes throughout storage. This occurs due 
to both the normal ageing processes undergone by the platelets and artificially induced activation 
and apoptosis triggered or exacerbated by processing and storage. Some of these biochemical 
changes may be responsible for the reduction of platelet concentrate efficacy observed as the PSL 
develops and may, therefore, provide an effective measure of its extent. In addition, targeting these 
factors may enable development of less damaging processing and storage techniques and a means 
for their validation and monitoring. 
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Exposure to hypotonic conditions leads to an osmotic increase in platelet water content, which can 
be detected by an associated decrease in refractive index using an aggregometer as described for the 
ESC assay (Holme et al, 1998). This water influx can be corrected by metabolically healthy platelets 
with intact membranes, providing an indicator of platelet quality – the hypotonic shock response 
(HSR). ESC and HSR measurements have been found to correlate with clinical efficacy but again, only 
at extreme levels (Holme et al, 1998; Shrivastava, 2009). 
Exposure to a low pH environment induces the shape changes associated with platelet activation and 
quality deterioration within a platelet concentrate (Murphy et al, 1970). Morphological change is 
dramatic and irreversible at pH levels of <6.0 and is associated with poor in vivo recovery and survival 
of platelets (Murphy et al, 1970). Measurement of oxygen, carbon dioxide, bicarbonate, lactate, 
glucose consumption, adenosine triphosphate: adenosine diphosphate (ATP:ADP) ratio and 
intracellular calcium levels (which are controlled by ATP dependant mechanisms) have been used to 
assess platelet respiration in platelet concentrates. However, only pH and ATP:ADP ratio have been 
found to correlate with in vivo platelet viability and these measures only show a relationship at 
extreme levels (reviewed in Shrivastava, 2009). 
Although some of the traditional platelet concentrate quality measurements described above have 
shown correlation with platelet recovery and survival in vivo, they are not sensitive enough to be of 
great use in the routine assessment of platelet concentrate quality. Measurements of the pH, 
ATP:ADP ratio, morphological status and HSR reflect the extremes of the platelet quality scale but 
usually remain within the normal range for the entire shelf-life of modern concentrates (Cardigan et 
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1.5 Assessment of Functional Markers 
Platelets must be able to participate in four separate functional processes in order for effective 
primary haemostasis to be maintained. They must be able to adhere to exposed collagen at the 
site of tissue damage, become activated and undergo degranulation, aggregate with other 
platelets to form a primary platelet plug and provide a suitable (negatively charged) phospholipid 
surface to support thrombin generation (Watson et al, 2005). Assessment of any of these 
functions could potentially provide insight into the quality of the platelet concentrate under 
investigation. 
1.5.1 Surface glycoproteins 
A number of cell surface glycoproteins (GP) are essential for normal platelet function and are 
involved in adhesion, activation and granule release and aggregation (Watson et al, 2005). 
Genetic abnormalities that affect cell receptors critical to platelet function can cause rare 
heritable disorders of primary haemostasis e.g. Glanzmann thrombasthenia, Bernard Soulier 
disease or collagen receptor deficiency, which result from αIIbβ3, GpIb and GPIa/IIa or GpVI 
receptor abnormalities respectively (Margaglione, 2005). Flow cytometry can be used to 
demonstrate a lack or reduction of the affected glycoprotein on the platelet surface. It can also be 
used to quantify the ability of platelets to express markers of activation, such as P-selectin and 
pro-coagulant phospholipids and to release their granules (Watson et al, 2005).  
The expression, concentration and responsiveness of some GPs are altered during PC storage. 
αIIbβ3 is the most densely expressed GP on the platelet surface. The αIIbβ3 protein has fibrinogen 
and vWF binding sites, which are exposed following conformational change that occurs when 
platelets are activated (Watson et al, 2005; Metcalf et al, 1997). Although αIIbβ3 levels during PC 
storage have traditionally been thought to remain consistent (Metcalf et al, 1997), recent studies 
have observed a rise in gene expression of this receptor. Thon et al (2007) found GPIIIa mRNA to 
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be detectable and translationally active throughout the 10 day study period. However, the ability 
of αIIbβ3 to bind fibrinogen upon stimulation of activation has been found to deteriorate as the 
PCs age (Curvers et al, 2004). 
The GPIb-V-IX complex mediates platelet interactions with vWF and thrombin (Vicente et al, 
1990; Lozano et al, 1997). During PC storage, GPIb expression decreases due to metalloprotease 
mediated proteolytic cleavage (Metcalf et al, 1997; Michelson et al, 1988; Bergmeier et al, 2003). 
GPIb expression is observed to become completely absent on a proportion of platelets present in 
the concentrate (Michelson et al, 1988). A simultaneous increase in concentration of glycocalicin: 
the cleaved extracellular section of GPIbα, is observed in the supernatant. This is found to 
correlate with surface P-selectin expression, supernatant concentration of soluble P-selectin, 
Kunicki scores and biochemical variables (Kostelijk et al, 2000). Reduction of GPIb expression is 
accompanied by a diminished reactivity of the platelets to thrombin (Lozano et al, 1997). 
The GPV component of the GPIb-V-IX complex has a role in regulating platelet response to 
thrombin (Ramakrishnan et al, 2001). Levels of soluble GPV have been found to correlate with a 
variety of different PC quality indicators, including ESC, HSR, lactate concentration, glucose 
concentration, P-selectin expression and CD63 expression (Javela et al, 2005). GPVI is thought to 
function in association with the GPIb-V-IX complex, as disruption of either one of these 
glycoproteins has been found prevent aggregation when specific stimulation is applied to the 
other (Michelson, 2007). GPVI functions as a collagen receptor and is required for normal platelet 
activation to occur (Michelson, 2007; Poole et al, 1997). 
1.5.2 Assessment of platelet activation responses 
Defects affecting the storage pool of platelet granule contents can prevent effective secondary 
aggregation, which should occur as an amplification effect of primary platelet activation 
(Margaglione, 2005). Release of both α-granules and dense-granules is associated with increasing 
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activation status and has been observed as PCs age. Measuring the ratio of ATP:ADP in platelet 
rich plasma (PRP) can aid detection of storage pool deficiency in disorders such as Hermansky-
Pudlak syndrome (Iannello et al, 2003). 
ATP is present at a fairly consistent concentration within the cytoplasm of all cells and functions 
as a cellular energy currency. ADP acts as a biological signalling molecule involved in platelet 
function. It is stored in high concentrations in the dense granules of healthy platelets and is 
released upon activation. An increase in the PRP ATP:ADP ratio indicates a depleted pool of ADP 
to participate in platelet function. Dense-granule depletion has been demonstrated in PCs via 
increase of the ATP:ADP ratio (Rao et al, 1981; de Korte et al, 1990). ADP is preferentially 
degraded to AMP and hypoxanthine as it is actively expelled from the platelets, along with the 
other granule contents, into the supernatant. This observation has been confirmed by other 
groups (Botchway et al, 2000). 
A number of other analytes are known to be contained within the platelet granules and can be 
detected, at increasing levels, in the PC supernatant as the concentrate ages. As an example, Rao 
et al (1981) found that platelet factor-4 (PF-4) concentration within the supernatant increased as 
the PC aged and in response to processing. This reflects release of platelet α-granules, where PF-4 
is stored in fresh platelets.  
Another marker of granule release is increased expression of transmembrane proteins that are 
stored within the granules of resting platelets. This protein group includes P-selectin (CD62P), 
which is found on the internal α-granule membrane of resting platelets and CD63, which is stored 
on the dense granule membrane (Larson et al, 1989; Stenberg et al, 1985; Berman et al, 1986; 
Nishibori et al, 1993; Israels et al, 2005). Upon platelet activation, the granules migrate to the cell 
surface, expelling their contents into the surrounding environment, and the granule membrane 
fuses with the cell membrane. This results in the translocation of P-selectin to the platelet 
surface.  
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CD63 functions as a signal transducer that is involved in initiating the cytoskeleton remodelling 
process that enables platelet spreading to occur (Israels et al, 2005). At present, the exact 
pathways involved have not been fully elucidated and the usefulness of CD63 as a PC quality 
marker may benefit from further investigation. 
P-selectin is a cell adhesion molecule (CAM) expressed on activated platelets and endothelial cells 
(Larson et al, 1989; Stenberg et al, 1985; Berman et al, 1986). When expressed on the cell surface 
it is pro-thrombotic and enhances fibrin deposition (Palabrica et al, 1992; Mayadas et al, 1993; 
Hartwell et al, 1998). P-selectin glycoprotein ligand-1 (PSGL-1) is expressed on a wide range of 
leukocytes and is involved in their extravasion during inflammation and incorporation into 
platelet aggregates during clot formation (Sako et al, 1993; Vachino et al, 1995). 
P-selectin is proteolytically cleaved and shed from surface of platelets (Michelson et al, 1996). 
Measurements by flow cytometry can be used to detect either platelet bound P-selectin or 
soluble P-selectin. Although P-selectin levels may give an indication of in vitro PC activation 
status, P-selectin positive platelets have been found to lose this marker, whilst retaining 
functionality, following transfusion (Berger et al, 1998). These factors limit the usefulness of P-
selectin as a marker of PC quality (Holme et al, 1997; Bergmeier et al, 2003; Goodrich et al, 2006). 
1.5.3 Reduction in responsiveness 
Aggregation mediated changes in light transmission can be measured spectrophotometrically to 
assess platelet response to agonists such as collagen, ADP, adrenaline, arachadonic acid and 
ristocetin (Watson et al, 2005). More recently, it has become possible to measure platelet 
aggregation using an automated Sysmex coagulometer (Lawrie et al, 2014).  Platelet aggregation 
response to ADP and collagen exposure has been found to decrease significantly after PC storage 
(Botchway et al, 2000; Akay et al, 2007). As storage time increased, the potential for thrombin 
and ADP stimulated Ca2+ release deteriorated and activation using the PAR1 thrombin receptor 
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agonist, SFLLRN, generated reduced P-selectin expression and fibrinogen binding (Curvers et al, 
2004). The ability of platelets to bind to collagen under flow conditions and respond to this 
stimulus, in terms of Ca2+ release, was found to be significantly reduced after eight days of 
storage (Curvers et al, 2004). 
However, platelet aggregation responses are maintained in stored platelets, at levels consistent 
with those observed using fresh platelets, if certain combinations of stimulatory agonists are used 
(DiMinno et al, 1982). Simultaneous activation via multiple stimulatory pathways is more 
representative of the initiation of haemostasis in vivo and suggests that the poor efficacy 
observed in vitro may be misleading. Re-suspension of stored platelets in fresh or fresh frozen 
plasma has been found to lead to normalisation of aggregation and αIIbβ3 up-regulation upon 
activation (Ishikawa et al, 1987; Rinder et al, 2003). Comparison of aggregometry results from 
pre-transfusion PC samples and specimens drawn from patients following PC transfusion also 
indicate normalisation of the platelet aggregation response (Miyaji et al, 2004). 
1.5.4 Anionic phospholipid detection with annexin V 
In resting platelets, the anionic phospholipid content of the cell membrane is preferentially 
present on the internal surface. Upon platelet activation, increased intra-cellular calcium prompts 
externalisation of negatively charged, procoagulant membrane constituents such as 
phosphatidylserine (PS). This redistribution of charge enables coagulation factors to bind to the 
platelet surface and increases the efficiency of thrombin generation (Hemker et al, 2002). PS 
exposure can be measured by flow cytometry using the calcium binding protein annexin V or the 
opsonin lactadherin as probes (Metcalf et al, 1997; Albanyan et al, 2009). Both probes measure 
the degree of platelet activation and / or apoptosis, although lactadherin has been found to be 
more sensitive to low levels of PS expression (Albanyan et al, 2009). 
 
- 31 - 
Surface expression of PS is evident during apoptosis as well as platelet activation. This shared 
feature complicates distinction between activation and apoptosis in platelets compared to cells 
that only express PS during apoptosis (reviewed in Jackson et al, 2010). Experiments confirm 
these processes are separately initiated and regulated (Schoenwaelder et al, 2009; Leytin et al, 
2007). Further investigation of these processes and the differences between them is called for. 
1.5.5 Methods that replicate high shear environments 
A major drawback of many platelet test methods is that they do not replicate the in vivo 
circulatory conditions, which have a significant effect on primary haemostasis. The flow of blood 
through the vessels at pressure creates a high shear environment that influences the actions of 
some haemostatic elements. For instance, vWF circulates in a globular conformation but, upon 
binding to collagen and under the influence of shear forces, unwinds to reveal additional GP1bα 
(platelet binding) sites, dramatically increasing its avidity (Auton et al, 2010; Barg et al, 2007). The 
PFA-100 platelet function analyser addresses this problem by mimicking the high shear conditions 
found in vivo. This method determines the ability of whole blood to form a thrombus under high 
shear conditions and upon contact with collagen and either adrenaline or ADP (Fressinaud et al, 
1998). It is of use in assessing bleeding tendency in congenital disorders of primary haemostasis 
and may be helpful in monitoring response to anti-platelet therapies (Fressinaud et al, 1998; 
Marshall et al, 1997; Wuillemin et al, 2002). PFA analysis has been used to demonstrate weak but 
statistically significant reductions in aperture occlusion using modified collagen/adrenaline/ADP 
containing cartridges and addition of donor red cells (Beck, 2002). 
1.5.6 Global haemostatic assessment  
Another potential shortcoming of laboratory assessment of haemostatic function is that it rarely 
measures the combined effects of all elements of the haemostatic system and their interactions. 
Viscoelastic coagulometry techniques such as thromboelastography (TEG) and thromboelastometry 
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(ROTEM) measure clot formation features in whole blood (reviewed in Ganter et al, 2008). Resistance 
to rotation of a sample cup (TEG) or of a pin placed inside the sample cup (ROTEM) grows as a clot 
forms and is related to the clot size and strength. These point of care (POC) techniques allow rapid, 
holistic investigation of the combined ability of primary and secondary haemostatic mechanisms to 
form an effective clot. It also allows characterisation of clot breakdown features that may help put 
clot formation data into context and aid clinical bleeding / clotting risk assessment. These global 
assessment methods incorporate the contribution of all elements of the blood (platelets, red cells, 
white cells and plasma proteins) to generate a result. This may invalidate their use in separated blood 
components such as platelet concentrates as the red cells and white cells are absent. However, their 
potential to assess a wide range of platelet function indicators and ease of application make them a 
potentially useful tool for assessing platelet concentrate quality. 
The EXTEM test on the ROTEM uses an extrinsic coagulation pathway activator to initiate clotting of 
the sample via TF / factor VII interaction. The ROTEM FIBTEM test uses the same reagents with the 
addition of cytochalasin-D, which inhibits actin polymerisation to prevent platelet shape change and 
subsequent activation. The clot formation observed during FIBTEM tests is due to fibrin production 
without the added involvement of platelets (Nielsen et al, 2000).  The platelet contribution to the clot 
can then be determined by comparison with untreated reactions. Use of cytochalasin D in viscoelastic 
coagulometry testing has shown platelet activity to vary independently of platelet count in a rabbit 
model (Nielsen et al, 2000). 
There have been some doubts expressed regarding the sensitivity of ROTEM or TEG assays 
without further optimisation to poor platelet concentrate quality (Arbaeen et al, 2016; Bontekoe 
et al, 2014; McNulty et al, 1997). However, a number of studies have used thromboelastography 
or thromboelastometry as a measure of platelet concentrate quality under various circumstances, 
without any apparent justification or assessment of the methods relevance (Bynum et al, 2016; 
Ostrowski et al, 2011; Ponschab et al, 2015; Svendsen et al, 2007). 
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1.5.7 Thrombin generation 
The ability of the platelet phospholipid surface to support thrombin generation can be measured 
using a calibrated automated thrombogram (CAT) assay (Hemker et al, 2002). This is a semi-
automated method that enables measurement of the total thrombin production within a sample 
over time. The timing and magnitude of thrombin generation observed enables identification of 
hypo or hypercoagulability that may be of future use in monitoring this aspect of PC quality 
(Hemker et al, 2002). 
 
1.6 Microvesicles 
Small, membrane bound microvesicles (MV) are present in the blood. MV are formed when 
membrane encapsulated fragments bud off of parent cells. The origin of particular populations can 
be determined by analysis of their surface antigens, for instance, platelet MVs (PMV) carry platelet 
specific cell markers such as αIIbβ3, GP Ib and P-selectin (Heijnen et al, 1999; Horstman et al, 2004). 
The largest population of MV in the blood are those shed from platelets and they have been found to 
have a pro-coagulant function, which is evident from day one post collection (Curvers et al, 2004; 
Keuren et al, 2006; Wolf et al, 1967).  
PMV are present in platelet concentrates and rise in concentration throughout storage as the 
platelets age (Bode et al, 1991; Simak et al, 2006). Their release is increased during platelet activation 
and apoptosis (Tan et al, 2005). PMVs provide a source of coagulation promoting (negatively 
charged) phospholipids that may partially compensate for poor platelet viability in ageing platelet 
concentrates (Chang et al, 1993; Xiao et al, 2000). In addition, PMVs have been found to express 
activated protein C resistant factor Va (Magdeleyns et al, 2007). They are able to bind to fibrinogen, 
vWF and collagen under flow conditions (Keuren et al, 2007) and have been observed to reduce 
micro-vascular bleeding time following infusion into thrombocytopenic rabbits (McGill et al, 1987). 
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However, PMVs are also associated with inflammation and alteration of immune function, which may 
lead to pathological consequences post-transfusion (Simak et al, 2006; Sprague et al, 2008). Increases 
in PMV numbers are thought to correspond to a decrease in platelet concentrate quality as the 
capacity of platelets that have undergone microvesiculation to activate normally during clot 
formation is diminished. Analysis of MV is difficult due to their small size and incompletely 
characterised biological features (Harrison et al, 2010; Zwicker et al, 2009). However, a number of 
techniques for MV analysis are now available or under development. 
1.6.1 Functionality based measurement 
Functionality based assays have largely focussed on the pro-coagulant features of negatively 
charged phospholipid or TF bearing MV (Harrison et al, 2010). Enzyme linked immunosorbent 
assay (ELISA) or other capture based methods can be combined with functional assays or scaled 
up to assess multiple cell surface markers at once but give no information about the size 
distributions of the populations under investigation (Harrison et al, 2010; Lal et al, 2008). These 
methods limit assessment to populations of MV that are specifically targeted according to their 
functions or surface molecules and may overlook clinically significant MVs with different 
characteristics. 
1.6.2 Flow cytometry 
Flow cytometry has been extensively applied to MV analysis and the necessary equipment is 
widely available. Multicolour analysis enables simultaneous assessment of multiple surface 
antigens, potentially relating to multiple MV populations and use of calibration beads allows MV 
quantitation. The major drawback of flow cytometry based methods is the lower size limit for 
detection. MV of less than about 500 - 300nm (diameter) cannot be reliably distinguished from 
background noise using forward and side scatter alone (Harrison et al, 2010). Use of fluorescence 
can improve resolution of smaller MV but limits analysis to targeted populations. However, even 
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though large, detectable MVs form the minority, flow cytometry MV measurements appear to 
show correlation with disease (Harrison et al, 2010). 
1.6.3 Imaging and tracking of microvesicles 
Imaging techniques such as electron microscopy (EM) or atomic force microscopy (AFM) give 
morphological information and can be used to analyse a wide size range of MVs but are labour 
intensive and require specialist equipment and skilled operators (Harrison et al, 2010). Whilst EM 
is able to visualise all MV present in a sample, AFM requires the MV under analysis to be 
immobilised on a mica surface and is, therefore, limited to assessment of targeted populations. 
More user friendly techniques specifically designed for  tracking MV, such as the nanoparticle 
tracking analysis (NTA) instrument (Nanosight Ltd, 2009), have made MV analysis widely 
accessible and provide rapid measurement of size distribution and concentration.  
1.6.4 Microvesicle impedance methods 
Impedance methods are widely used for cell counting and have recently been adapted for MV 
enumeration. They can be combined with flow cytometric techniques to improve resolution of 
small MV (Zwicker et al, 2009). Also, there is potential in the application of impedance counting, 
sizing and electrophoretic characterisation as a stand-alone method. 
The iZON nanoparticle analyser produced by iZON Science Ltd is an impedance instrument that 
can measure the size and charge of small cells and particles such as MV. Measurement of MV is 
difficult, as very fine resolution is required to detect the smaller particles. Reduced pore size 
improves resolution but renders the instrument very prone to blockage by larger particles. The 
iZON analyser tackles this problem by enabling the user to vary the pore size to remove blockages 
during operation (Sowerby et al, 2007; Willmott et al, 2008). iZON Science Ltd claim that this 
technology enables the user to accurately quantitate, size and characterise  particles of between 
50nm and 2μm diameter (iZON Science Ltd, 2008). 
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1.6.5 ThromboLUX instrument 
Dynamic light scattering (DLS) measures the Doppler shift of light scattered by MV suspended in 
solution. The degree of Doppler shift is proportional to the Brownian motion of the particles, which 
is, in turn, related to their size. Large, irregularly shaped particles move more slowly than small, 
regularly shaped ones (Maurer-Spurej et al, 2007). As MV are theoretically uniformly spherical, DLS 
results are solely related to particle size (Xu et al, 2011). 
The ThromboLUX instrument measures the size and quantity of platelets and PMV by DLS and the 
response of these variables to temperature change (Maurer-Spurej et al, 2006; Maurer-Spurej et al, 
2007; Maurer-Spurej et al, 2009; Xu et al, 2011). Large, uniform sized platelets that can reverse 
temperature-induced changes and low MV numbers are associated with higher quality (fresher) 
platelet concentrates. A ‘platelet quality score’ in the range of 0-40 is generated. Scores above 14 
indicate satisfactory concentrate quality. The ThromboLUX score has been found to correlate with 1 
hour and 24 hour corrected count increments, representing platelet recovery and platelet survival 
respectively (Maurer-Spurej et al, 2009). 
The ThromboLUX instrument has undergone extensive beta testing at multiple international sites 
over recent years. The ThromboLUX score has been found to deteriorate with platelet concentrate 
age between tests carried out at days two and ten after platelet concentrate production (Middleburg 
et al, 2013). Its potential to measure MV and aggregate populations in platelet concentrates has also 
been demonstrated (Labrie et al, 2013). However, Kraemer et al (2015) did not find any correlation 
between the ThromboLUX score and the HSR or ESC and Raczat et al (2014) found it to be insensitive 
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1.7 Summary 
Platelets are a vital component of haemostasis and platelet transfusion is a life-saving procedure. 
Provision of safe, high quality platelet concentrates can be challenging and improvement and 
optimisation of platelet concentrate production techniques would be beneficial. Increased shelf-life 
of platelet concentrates would reduce wastage and identification of poor quality concentrates would 
prevent exposure of patients to unnecessary clinical risk. An inexpensive, quick and easy to use 
laboratory test would be a useful tool to aid in achieving all of these goals. 
Platelets are functionally complex cells that are not yet completely understood, either in terms of 
their function or their storage characteristics. A wide range of tests have been applied to platelet 
concentrates in an attempt to comprehensively characterise the PSL but many of them give unclear 
or conflicting results or do not correlate with observed clinical outcomes. In addition, most of these 
tests are not suitable for routine application. However, a small number of techniques show some 
potential for routine application and may provide relevant clinical information. A selection of suitable 
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1.8  Aims of the Study 
Platelet concentrate quality and functional deterioration during ageing is poorly understood and 
difficult to measure. No single test can be used to assess concentrate quality. The aim of this project 
is to investigate novel laboratory approaches to this problem, including the ThromboLUX platelet 
concentrate analyser, the iZON system, thromboelastometry and automation of existing tests.  
Following completion of the in vitro stages of the project, a proof of concept clinical study was 
undertaken. The aim of this study was to trial a method for assessing the ability of a panel of 
laboratory tests to predict transfusion outcome, as measured using platelet count increments, 
resolution / prevention of bleeding and adverse affects suffered by the patient. Tests were carried 
out on the remains of the platelet concentrate following transfusion. 
The specific project aims are set out in the list below: 
1. Select a panel of in vitro tests that have the potential to improve the assessment of 
platelet concentrate quality 
2. Set up and optimise the selected reference and novel tests in the laboratory 
3. Apply all reference and novel test methods to a sample of platelet concentrates 
throughout the ageing process to investigate the pattern of test results that are given 
over the entire concentrate lifespan and gain information relating to platelet 
concentrate ageing 
4. Further assess the most promising novel methods, alongside appropriate reference 
tests, in a small, proof of concept clinical trial  
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2  METHODS AND PRELIMINARY TEST DEVELOPMENT 
  
2.1  Samples and Platelet Concentrates 
Platelet rich plasma samples and platelet concentrate samples from a variety of sources were used 
for this study. Due to the limited availability of these samples, there are times when the selection of 
test samples used for a specific set of investigations were not optimal or the design of an experiment 
was modified to gain the maximum benefit from the specimens available at that time. It would have 
been preferable to be more consistent with regards to the type of testing undertaken with each novel 
method but this was an evolving project, carried out over a long period of time and tests were 
undertaken as new methods were developed or selected for inclusion. 
Platelet concentrate samples were available from several different sources. Initially, 25 expired 
platelet concentrates were obtained, over a period of about a year, from the clinical transfusion 
laboratory at OUH Trust. 23 of these expired at the end of day five after collection and the other two 
expired at the end of day seven (due to an NHSBT rule change at this time). They were, therefore, 
available for inclusion in the study from the beginning of day six or day eight respectively. 12 were 
pooled platelet concentrates and 13 were apheresis concentrates. FBC, iZON and ThromboLUX 
testing (including precision assessments) were carried out on all 25 concentrates. ESC and HSR testing 
was carried out on four of these concentrates and ROTEM testing was carried out on five of them. 
Samples from two of these concentrates were stored at inappropriate temperatures and then tested 
using the HSR, ESC, ROTEM and ThromboLUX methods. 
In each case, the whole platelet concentrate was stored in an air conditioned room in which the 
temperature was maintained and monitored at 22⁰C. It was kept in the original, breathable platelet 
bag and agitated on a platelet agitator. To draw samples for analysis, sterilised scissors were used to 
cut off the end of the outflow line. A small amount of concentrate was passed through the line to 
waste in order to flush it before samples were collected, although care was taken not to use lines 
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with visible debris or to leave any of the concentrate trapped in the line when resealing due to 
concerns that platelets trapped in the line would not undergo adequate agitation or oxygen 
exchange. Lines were re-sealed after sample collection with a heal sealer, enabling the whole process 
to be repeated from scratch for subsequent sampling events. 
A series of platelet concentrate sample swapping experiments was undertaken to investigate the 
potential for different ThromboLUX results due to variations in platelet concentrate processing 
practices in different countries. For this section of the study, an assortment of different platelet 
concentrate samples from various locations and with diverse quality features was obtained from a 
number of different international centres. Although the storage of these concentrates was not 
controlled in house by the study team, the required conditions were specified and controlled by the 
participating laboratories. 
Further to these preliminary experiments, ten fresh, pooled platelet concentrates were purchased 
over the course of a year from the NHSBT for comprehensive in vitro characterisation as they aged. 
They were produced using standard NHSBT methods in the Brentwood NHSBT processing centre and 
shipped on the day of pooling (the day after donation) to OUH Trust. Shipping was via a two hour 
temperature controlled service as routinely recommended for platelet transport. Platelet count, 
MPV, HSR, ESC, pH, swirl assessment, ROTEM testing and ThromboLUX analysis were carried out on 
all ten of these concentrates. The AWE test was developed during this phase of the study and, 
therefore, was only performed on the final four concentrates. Sampling and storage of platelet 
concentrates during this phase of the study was as for the expired concentrates discussed above. 
The final source of platelet concentrate specimens were samples obtained during the clinical trial. 
These samples consisted of the residual platelets left in the bag and the giving set following platelet 
transfusion. The volume was, therefore, limited and the platelet storage conditions in the period 
immediately prior to sample collection was relatively uncontrolled. The residual concentrate was 
harvested into an airtight specimen pot and stored at room temperature without agitation. For these 
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reasons, testing was always completed no more than two hours after collection unless specifically 
stated otherwise (e.g. for ‘aged’ samples) in the text. 
In addition to four of the fresh platelet concentrates purchased from the NHSBT and the six clinical 
trial samples, three PRP samples were used in the early development of the AWE test. They were 
prepared from whole blood collected into 3.2% buffered trisodium citrate using a minimal stasis 
technique to avoid venepuncture related platelet activation. The first tube taken during each 
venepuncture was discarded, all tubes were suitably filled and samples were checked to ensure no 
other signs of inferior quality (e.g. gross haemolysis, blood clots) were apparent. Immediately 
following collection, specimens were left undisturbed on the bench for 15 minutes at room 
temperature to allow platelets to revert to a resting state. They were then centrifuged at 150g for 10 
minutes. The PRP from all samples was harvested and, when multiple samples were available from a 
single venepuncture, pooled immediately after centrifugation. When PPP was also required, the 
residual sample was then centrifuged at 4500g for 7 minutes to enable the harvesting of the PPP. 
Analysis for all samples labelled as ‘fresh’ or ‘day 1’ was completed within 3 hours of venepuncture. 
‘Aged’ PRP samples were stored in capped, airtight containers at room temperature unless 
specifically stated otherwise. 
 
2.2  Ethical Approval 
Study specific ethical approval was not required for the in vitro part of the project. It was agreed at a 
departmental level, after discussions with the OUH Trust Research and Development Department 
that use of anonymised samples from healthy volunteers for small scale technical development of 
laboratory tests and as normal controls did not require ethical approval. Informed consent is 
obtained prior to blood donation and donors are notified that their tissue may be used for 
transfusion related research rather than transfused directly to a patient. All Platelet Concentrates are 
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anonymised by the NHSBT according to their normal protocol before they are supplied to the 
laboratory. No patient samples were used during this stage in the study. 
An ethical approval application was made for the clinical trial stage of the project and full 
approval was granted in April 2015. The application reference details are as follows: 
Study title:  The evaluation of novel platelet concentrate quality tests and their 
ability to predict response to platelet transfusion  
REC reference:  15/SC/0155  
IRAS project ID:  131997  
 
2.3  Reference Test Methods 
A limited panel of platelet concentrate quality reference tests were chosen for use in this study. Tests 
previously found to correlate with post-transfusion platelet function and those that covered as many 
different aspects of platelet function as possible were selected. Very complex or expensive tests were 
deemed to be beyond the scope of the study, which focused on analytical methods applicable to 
routine clinical practice. 
Swirl assessment is difficult to standardise and can be affected by environmental factors such as light 
quality. However, it is quick, simple, inexpensive and has been found in the past to relate to post-
transfusion platelet function (Bertolini et al, 1994) so its inclusion in the study appeared worthwhile. 
Both pH measurement and FBC (including platelet count and MPV) were freely available in our 
laboratory and were included to ensure concentrates complied with NHSBT expectations. These tests 
were also used to exclude the presence of very poor platelet quality. The HSR and ESC tests were 
selected as a more sensitive measure of platelet quality that could be performed using equipment 
that was readily available in our setting. As some of the only widely applicable platelet quality tests 
known to relate to post transfusion efficacy, these aggregation based methods were particularly 
desirable. The Kunicki score was also investigated due to its potential correlation with transfusion 
outcome but, ultimately, could not be performed using the equipment available. 
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2.3.1 Swirl 
Assessment of ‘swirl’ within the platelet concentrates was carried out visually according to methods 
demonstrated by NHSBT staff. The concentrates were held in front of a bright light source (e.g. a 50 
or 100 watt bulb) and moved around by hand as the contents were examined. ‘Swirl’ was apparent as 
a pattern of streaming light reflective swirls, most easily visualised in the parts of the bag where 
manipulation resulted in a thin layer of liquid. Results were recorded as positive or negative and no 
grading system was applied. No calibration or internal quality control of this method was possible. 
2.3.2 pH 
The pH of all concentrates was measured using a Hanna HI221 pH meter that was validated and 
maintained for routine diagnostic use in the Oxford University Hospitals (OUH) NHS Foundation Trust 
Haemophilia laboratory. A two point calibration was performed before each use, alternating between 
using pH 4 and pH 7 calibrators on one occasion and pH 7 and pH 10 calibrators on the next occasion. 
The probe was placed in the sample and the pH was displayed on the meter. 
2.3.3 Platelet count and volume 
During the early stages of this study, platelet count and MPV were determined using a Sysmex KX21 
(Milton Keynes, UK) FBC analyser. This automated cell counter was validated, maintained and quality 
controlled daily for routine diagnostic platelet count measurement in the OUH Haemophilia 
laboratory and used as an impedance technique to count platelets. During the final, clinical stage of 
the study, Sysmex XN10 analysers were used to determine platelet count and volume for all patient 
and platelet concentrate samples. In addition to impedance counts (using the same technology to the 
KX21 analyser described previously) these analysers were able to report a fluorescent platelet count. 
All reagents were supplied by Sysmex and quality control samples were processed every four hours. 
For both analysers, the suitably mixed aliquot of sample was presented for the test probe and a 
button was pressed to initiate measurement. The results were displayed on the analyser software 
and then printed out. 
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2.3.4 Kunicki morphology score 
The Kunicki morphology score is a useful reference method due to its correlation with clinical 
efficacy of platelet concentrate transfusion. An adaption of the method utilised by Maurer-Spurej 
et al (2009) that used light microscopy was initially trialled but the resolution of platelets was 
poor. A phase contrast system located in the Transfusion Department at the John Radcliffe 
Hospital was then trialled but the resolution of this microscope was also too poor to achieve 
acceptable quality results. In addition, neither of these systems had any capacity for image 
capture, making it difficult to record and confirm the results obtained using this highly subjective 
method. Unfortunately, in house measurements of the Kunicki Morphology Score were not 
possible but measurements have been performed by study collaborators at LightIntegra in 
Vancouver on occasion and are referred to in the section 3.5 below. 
2.3.5 ESC and HSR assays 
ESC and HSR assays were set up on a Helena Biosciences (Gateshead, UK) AggRAM aggregometer 
based on the methods described by Holme et al (1998).Both tests require the platelet concentrate 
sample to be diluted in platelet free plasma (Cryocheck normal reference plasma, Precision BioLogic, 
Canada) to give a count of around 300 x 109 platelets / L. All diluted samples tested within this project 
had platelet counts within the range of 270 – 330 x 109 / L. An aliquot of the normal plasma used to 
prepare the dilutions was read as a calibrator in every channel used for testing prior to running a 
platelet sample. This step was required by the preset measurement programmes in the software. The 
PRP OD value was used as part of the manual calculation for the ESC test but it did not, ultimately, 
contribute to the manually calculated HSR result. 
For the HSR, two 250µL diluted samples were placed into the aggregometer, which measured the OD 
of the samples at 650nm for the course of the test. After measuring the samples for one minute to 
detect spontaneous platelet aggregation, 125µL of Owren’s buffered saline (OBS) (Siemens, Frimley) 
was added to the control sample and 125µL of water was added to the test sample. Decreases in the 
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optical densities of both solutions were observed but the decrease in the test sample was higher 
when intact platelets were present as the platelets took up water by osmosis (see Figure 2.1 for an 
example). The extent by which the OD of the test sample corrected to the same level as the OD of the 
control sample in the four minutes after the addition of the water / saline was used to calculate the % 
HSR result using the following equation: 
 HSR = (Y4 x 100%) / (Y – S) 
Where Y is the difference between the starting OD and the OD of the maximum water response, Y4 is 
the difference between the maximum water response OD and the OD as measured four minutes 
after maximum response and S is the measured OD change in the saline control sample. 
 
 
Figure 2.1: Example HSR results. %HSR describes the degree by which the blue ‘test’ trace 
corrects to the level of the green ‘control’ trace. 
 
The ESC was performed using a similar method. 10µL of 0.1M EDTA (Sigma-Aldrich, Gillingham) was 
added to the diluted platelet sample to prevent platelet aggregation. 10µL of 1mM ADP (Sigma-
Aldrich, Gillingham) was added to the test samples and 10µL of OBS to the control samples. The ADP 
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2.2 for an example. The degree of increase was expressed as a percentage of the difference in OD 
between platelet rich plasma and platelet poor plasma. 
 
Figure 2.2: Example ESC results. %ESC describes the change in the red ‘test’ trace as a proportion 
of the difference between PPP (blank) and PRP prior to activation. 
 
In order to calculate the ESC percentage, the raw data was downloaded from the aggregometer into 
a Microsoft Excel spreadsheet and converted to OD using the following formula as advised by Helena 
Biosciences: 
Point Value x 0.000000001694600612 - 0.500302473804904 
The OD of water was used to define 100% transmission and the OD obtained from a blocked channel 
was used to define 0% transmission. The PPP and PRP % transmission values (X and Y respectively) 
were determined against this scale and used to calculate extinction values (E) as follows: 
 E = -log(T%/100) 
Thus: 
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 EPRP = -log(Y/100) 
The degree of shape change observed during the test, expressed as a percentage of X – Y, is referred 
to as A. The extinction of shape change was calculated as follows: 
 EShape Change = -log[(Y-A(X-Y)/100] 
The three calculated extinction values were then used to generate a final ESC percentage result using 
the formula below: 
 ESC = (EShape Change-EPRP)100%/(EPRP-EPPP) 
Neither of these methods required calibration and routine quality control samples are not 
commercially available for platelet aggregometry tests. However, normal PRP specimens were 
processed on this aggregometer on a regular basis to ensure the equipment and reagents were 
functioning as expected. 
 
2.4  Experimental Test Methods 
Four new in vitro tests were identified as being user friendly, inexpensive and having the potential to 
measure platelet concentrate quality. It the beginning of the study, the ThromboLUX and iZON 
analysers were loaned to the haemophilia laboratory at OUH Trust free of charge for the purposes of 
evaluation in this study. The initial project plan was to undertake a large clinical study comparing 
ThromboLUX score with transfusion outcome in partnership with the NHSBT. The iZON assessment 
was intended to make an interesting aside that could be carried out whilst the project planning and 
approval aspects of the ThromboLUX study were in process. 
 The ROTEM instrument was available for clinical testing in the OUH haemophilia laboratory. It was 
decided to include it in the study when it became clear that the ThromboLUX did not perform as 
anticipated and adaptation of the project plan was required. The HSR and ESC tests were also set up 
at this time and it subsequently became clear that the HSR test showed more pronounced changes 
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with presumed platelet concentrate quality decline than most of the other test methods. For this 
reason, the AWE test was developed in house in an attempt to replicate the HSR results in a manner 
that was easier to perform and interpret and less prone to operator error or technical inconsistencies 
(e.g. inaccurate pippetting or timing). AWE tests were carried out using Sysmex CS series analysers 
that were used for routine coagulation testing in the OUH haemophilia laboratory. 
2.4.1 iZON impedance analyser 
The iZON system (iZON Science Ltd, Oxford) was specifically designed for measurement of MV and 
had not previously been used to test platelets. The platelet testing protocol used in this study was 
developed in partnership between the study team and iZON Science Ltd. The iZON qNano system 
assessed in the project is shown in Figure 2.3 below. The instrument is controlled and the data is 
presented by the iZON control Suite software on a linked computer. The measurement chamber is 
the small silver cylinder on top of the gold instrument. Pressure is provided by the black compressor 
unit and the tubing that runs from it to plug into the top of the measurement chamber. Nanopore 
stretch is controlled by the black dial on the right hand side of the instrument and changes are 
recorded in the software. 
 
Figure 2.3: iZON qNano analyser and software. Image from iZON Science Ltd company website: 
www.izon.com 
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780nm beads were supplied by iZON Science Ltd and used to calibrate each run. Fixed, lyophilised 
platelets (Helena Biosciences Europe, Gateshead, UK) were prepared in 5mL tris buffered saline 
(Helena Biosciences Europe, Gateshead, UK) per vial. 40µL aliquots of this preparation were frozen at 
-40⁰C and one was thawed to run as a biological internal quality control sample alongside each test 
run. Assessment of quality control acceptability was qualitative. Platelet samples for analysis were 
diluted in isotonic saline (Sigma-Aldrich, Gillingham) to give a platelet count of about 10 x 109/L. 
Testing was carried out as follows: 
Instrument Setup: 
1. Turned on the iZON computer and loaded the iZON Control Suite software 
2. Turned on the qNano instrument and connected it to the computer via the USB hub 
3. Selected and fit the appropriate Nanopore – size 7P for platelet analysis (iZON Science Ltd) 
4. Pipetted 80µL of electrolyte solution (0.9% NaCl – Baxter, UK) into the lower chamber 
5. Fitted the upper chamber and added 80µL of electrolyte solution (0.9% NaCl – Baxter, UK) to it 
6. Measured the stretch applied to the Nanopore using electronic callipers (provided by iZON 
Science Ltd) and entered this value into the ‘Stretch’ box on the ‘Instrument Setup’ screen 
7. Clicked the ‘Turn On’ button on the ‘Instrument Setup’ screen and ensured a current was 
displayed 
8. Ensured that normal responsiveness to altered stretch and voltage was observed. 
9. Set the stretch and applied a voltage (45.5mm / 0.06v for platelets). Checked the current was 
100nA ±10nA 
Data Acquisition: 
10. Ensured the system was clean by acquiring data for 1 minute to check no events were recorded 
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11. Removed the electrolyte solution (NaCl) from the upper chamber and replaced it with 50 – 80µL 
of sample that had been inverted 8 times to mix 
12. Ensured the pore was open and that particles were detected 
13. Entered the ‘Data Acquisition’ page and pressed ‘Start’ to begin collecting events 
14. Collected at least 1000 events, ensuring that the trace remained stable during this time. 
Acquisition was paused while any instabilities were resolved 
15. Pressed stop and filled in appropriate sample information in the pop up box. The 780nm beads 
were analysed with each run and saved as a calibrator. Fixed platelet samples were analysed 
with each run as biological controls. 
16. When the sample analysis was completed, the sample was removed and the upper chamber was 
washed three times with electrolyte solution (0.9% NaCl – Baxter, UK) 
17. Steps 10 to 16 were repeated for each of the subsequent samples 
18. When data acquisition was completed, the Nanopore was removed, rinsed thoroughly with 
water, dried with a tissue and stored in a plastic cover 
Data Analysis: 
19. In the ‘Analysis’ screen, ‘Open Signal Traces’ was clicked to add previously acquired data to the 
List, which contained the data acquired during the current run 
20. The ‘Analyse the List’ button was clicked 
21. Individual signal traces were included in the data if the ‘Include trace in XML file’ option in the 
‘Data Output Settings’ box was checked. Inclusion of traces greatly increased the data file size 
and slowed analysis but was sometimes desirable to ensure the validity of individual events. 
‘Data Output Settings’ was accessed from the ‘Data Acquisition’ menu (click the lower right hand 
corner) under the ‘Acquire Data’ tab 
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22. ‘Open Particle Data Sets’ was clicked to open previously analysed data sets. These only included 
individual signal traces if they were generated during the original analysis. 
23. Individual events were selected by clicking on the relevant data point in a scatter-plot under the 
‘Analysis’ tab. This highlighted the event data in the ‘Translocation Data Points’ table at the 
bottom of the screen and enabled exclusion by unchecking the ‘Include’ box next to that event. 
24. Calibration was required for display of absolute (rather than relative) size. This was achieved by 
clicking on the specimens ‘Calibrated’ box in the ‘Particle Data Sets’ list. Any calibration sample 
that was open in the list can be selected and applied. 
25. Histogram BINs were individually calculated for each data set and needed to be altered to 
provide consistency when comparing multiple data sets. The desired BIN width was entered into 
the ‘View Settings’ box (accessed from the ‘View’ menu under the ‘Acquire’ tab). 
26. If additional data processing was required the event data could be accessed in Excel by right 
clicking on a specific sample in the ‘Particle Data Sets’ list and selecting ‘Export to CSV’. This 
generated a CSV document which was saved in the iZON file for the sample in question. 
2.4.2 ThromboLUX platelet quality analyser 
The ThromboLUX analyser (LightIntegra Technology, Vancouver) had been developed specifically 
for measuring platelet concentrate quality and trialled extensively by the developers, who had 
published the results of their work with the analyser in several articles (Maurer-Spurej et al, 2006; 
Maurer-Spurej et al, 2007; Maurer-Spurej et al, 2009). Because of this, it was anticipated that the 
instrument would work as stated and that, after a brief technical verification that the 
ThromboLUX was performing correctly, this study would rapidly move on to a straightforward 
beta evaluation. Plans were made to work with the NHSBT and an ethical approval application 
was prepared to recruit patients participating in the NHSBT TOPPS and ATHENA studies to a sub-
study undertaken to assess the ability of the ThromboLUX to predict transfusion efficacy. 
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When the ThromboLUX system was first delivered to OUH Trust in 2010, it had been redesigned 
from the prototype version that had been used during the initial evaluations. The new marketed 
version was a closed box system that was straightforward to use and could be applied either as a 
routine screening tool in the transfusion laboratory or on a point of care basis. See Figure 2.4. In 
addition, it had been adapted to use a disposable sample presentation system that drew a 
platelet concentrate specimen into a capillary tube when the analyser began the test. 
 
Figure 2.4: ThromboLUX analyser. Samples are presented in the holder at the front of the 
analyser, test details are input using the touch screen and results are displayed on the 
screen when the test is finished. Image from LightIntegra Technology company 
website: www.lightintegra.com 
Calibration of the optical aspects of the system was carried out by LightIntegra during installation 
and periodic maintenance. Routine calibrations during operating were not required. Vials of 
‘calibration beads’ were supplied by LightIntegra for use with the ThromboLUX instrument. 
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However, these were used as an internal quality control measure, rather than a calibration 
material. Test specimens were undiluted platelet concentrate samples. Early attempts to analyse 
PRP generated from whole blood samples resulted in analytical errors and did not produce results 
so ThromboLUX analysis of PRP was not included in the study. 
The ThromboLUX analytical method underwent several changes during the course of the study. 
The initial test method is shown below and subsequent changes are discussed afterwards. 
ThromboLUX Analysis: 
1. Switched on The ThromboLUX analyser and allowed to warm up for 30 minutes 
2. Touched the screen and entered username and password to log in 
3. Entered the settings menu to ensure the correct settings were applied for the sample in 
question. In particular, the correlation time and analysis viscosities needed to be altered 
between running calibration beads (water) and biological samples (plasma). The required 
values are shown in Table 2.1 below: 
Table 3.1: ThromboLUX viscosity settings 








Calibration Beads (Water) 120000 6.93e-04 6.93e-04 1.002e-03 
Biological (Plasma) 240000 6.93e-04 1.06e-03 1.56e-03 
 
 To alter any of the settings, the box in which the current setting was displayed was tapped, 
followed by the spanner at the bottom of the screen. The value was changed as required 
then the tick was tapped to return to the overview. 
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4. Selected the appropriate sampling method. Spiked disposables were inserted directly into 
platelet / calibration bead packs but carried a risk of introducing contaminants so were only 
used with platelet concentrates directly before disposal. Tubed disposables (designed to be 
sterile docked to platelet / calibration bead bags) were used in this study to withdraw 
samples from open containers. About 3mL of sample was withdrawn. 
5. The ‘Run Test’ (platelet concentrate samples) or ‘Maintenance Test’ (calibration bead 
samples) mode was selected as appropriate and sample identifiers were entered using a 
barcode scanner or keyboard 
6. The disposable was prepared and inserted into the test chamber. The arrow was tapped to 
initiate the test, which took about 20 minutes. 
7. Upon completion, the test results (including the ThromboLUX score) were displayed on the 
screen. They could be retrieved at later dates by entering the access log mode,  selecting  
test log or maintenance log as required and inserting a memory stick before clicking the 
download icon (down arrow). 
Data processing was all performed by the test software but a brief overview is given here for 
reference. Each sample was measured at 37⁰C, then at 20⁰C, then a second time at 37⁰C. The 
analyser measured the relative intensity of light (I) deflected by each particle category (MV, platelets 
and aggregates) and determined the mean radius (R) using dynamic light scattering principals. These 
measurements were used, along with the standard deviation (SD) of the measured particle radius, to 
calculate morphology values (M) for each particle categories as follows: 
(R – SD) x I = M 
The platelet M (PM) and MV M (MVM) readings were used to calculate the overall ThromboLUX 
score as follows: 
(PM37a – MVM37a) + (PM20 – MVM20) + (PM37b – MVM37b) = ThromboLUX score 
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Measurements for aggregates were not directly included in the calculation but influence the 
ThromboLUX score by reducing the relative light intensity of the platelet and MV sized particle 
categories. See Figure 2.5 for an overview of the test principal. 
 
Figure 2.5: Principal of the ThromboLUX test. Platelet and PMV size distributions are measured 
by DLS at 37⁰C, then 20⁰C, then 37⁰C again. A degree of activation is expected at 
20⁰C but should be largely reversed in the second 37⁰C measurement in good quality 
platelet concentrates. PMV numbers should be low in good quality concentrates. 
When preliminary results were not as expected (see chapter 3), the first ThromboLUX analyser (TL 
1) was exchanged for a second machine (TL 2). TL 2 had been re-engineered to accept samples 
presented in capillary tubes, rather than the disposable sampling system. Plain glass capillary 
tubes and a suitable syringe were provided by LightIntegra. At the time this change was made the 
software on the ThromboLUX analyser was upgraded to enable all tests (both maintenance and 
sample tests) to be run using a single setting, rather than selecting the ‘Test’ or ‘Maintenance’ 
mode separately as described in step 5. The TL 2 instrument software prompted the user to state 
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whether the specimen to be processed was a platelet concentrate sample of a calibration bead 
sample and automatically updated the viscosity settings appropriately. 
Further testing was carried out with TL 2 and it became clear that analytical issues had not been 
resolved. TL 2 was exchanged for a third instrument (TL 3) at the beginning of the sample 
swapping stage of our study. Shortly after this, it was decided that the way fluctuations in the 
data and outlying data points were handled by the existing software was not robust enough and a 
different software programme, called Thrombosight, was developed. This software was not run 
on board the analyser but as a standalone programme on a PC. ThromboLUX users were advised 
to disregard the score generated on the instrument. The ThromboLUX data was instead 
downloaded to memory stick, transferred to the Thrombosight programme and analysed by this 
programme to generate the ThromboLUX score. 
An additional technical overhaul was made between the end of the in vitro analysis of ageing 
platelet concentrates and the beginning of the clinical trial. The exact modifications made to the 
analyser at this point were not clear, excepting that it had been removed from OUH Trust without 
notice during the study team’s absence, ‘serviced and checked’, returned upon request and 
subsequently reinstalled in the haemophilia laboratory. The laser was realigned at this point and 
it is not clear what difference this made from the previous setup. The ThromboSight software was 
also updated, allowing the study team to access the relative light intensity result for the MV 
fraction of each specimen tested during the final part of the project.  
In addition to the software and hardware changes made to the analyser, there were a number of 
alterations in the result interpretation advice given by LightIntegra. Maurer-Spurej et al applied a 
cut-off value of 12 in their clinical study (Maurer-Spurej et al, 2009). We were told that scores 
above 14 were indicated satisfactory concentrate quality on receipt of TL 1 at the beginning of 
this study. The cut off value was changed to 16 when we began working with TL 2 and when TL 3 
was installed LightIntegra advised that they were no longer able to define a global cut off value. 
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At this point, it was recommended that all centres performing ThromboLUX analysis determine 
their own, locally assigned quality cut off value. 
2.4.3 Thromboelastometry  
The ROTEM instrument (Tem International GmbH) detects resistance to oscillation of a pin in a cup 
caused by development of a clot. See Figure 2.6 for an overview. As clot amplitude (size) increases, 
resistance to pin rotation increases in a proportional manner. This reduces the extent to which the 
pin turns. The degree by which the pin turns is determined by optical analysis of light deflected from 
the pin to a detector (Tem International GmbH, 2016).  
 
Figure 2.6: Principal of ROTEM analysis.  Image from LightIntegra Technology company website: 
https://www.rotem.de/en/methodology/thromboelastometry/ 
Resistance over time is displayed in graphical representation by the analyser. The clot amplitude is 
shown on the Y axis and the time since the test began is shown on the x axis. See Figure 2.7. 
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Figure 2.7: Example ROTEM results. An EXTEM result is shown on the left and a FIBTEM result is 
shown on the right. The contribution of the samples platelet activity to clot formation 
is equal to the difference between the two results. 
The ROTEMs software uses the raw light data to generate an amplitude measurement. Clot 
amplitude (A) can then be used to calculate clot elasticity (CE), which is preferential for use 
measuring platelet function (Solomon et al, 2015). The relationship is as follows: 
CE = (100 × A)/(100 − A) 
Clot elasticity may also be expressed in units of dyne/cm2 (G). The G value is 50 times the CE value 
reported by the ROTEM. 
There are a variety of different test protocols available from TEM for use on the ROTEM system, each 
with their own combination of reagents and pre-programmed pipetting procedure. For this study, the 
EXTEM and FIBTEM tests recommended for clinical analysis of platelet function were used. Both tests 
use a TF activator and the FIBTEM test also incorporates a platelet inhibitor (cytochalasin-D).  
The first ROTEM platelet concentrate tests included in this study were carried out using neat samples. 
However, the sensitivity of the method at such high platelet counts was a matter of concern so 
subsequent tests were carried out on both neat and diluted samples. Sample dilutions were prepared 
in Cryocheck normal reference plasma (Precision BioLogic, Canada) to give a platelet count of 300 x 
109 / L ± 10% as previously described. 
The test method used to perform the ROTEM tests were as follows: 
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1. Switch on the ROTEM instrument, ensure all cup holders are placed against the back panel 
and leave for 30 minutes to warm up 
2. Prepare sample dilutions as appropriate 
3. Remove EXTEM, FIBTEM and SarTEM (CaCl) reagents from the fridge and leave for 5 minutes 
to come to room temperature 
4. Log in to the ROTEM software and enter the ‘Analysis’ module 
5. Add appropriate sample identification information to each one of the four channels to be run 
6. Select the appropriate test for each of the four channels to be run. A typical run would 
consist of neat EXTEM in channel 1, neat FIBTEM in channel 2, diluted EXTEM in channel 3, 
diluted FIBTEM in channel 4. 
7. Place disposable cup and pin covers into cup holders for each of the channels to be used 
8. Select the first channel to be run and tap ‘Start’ 
9. Follow the pipetting instructions on screen. For EXTEM these are: 
 Select tip 
 Place in SarTEM reagent 
 Press button to draw up reagent 
 Press button to draw up air space 
 Place in EXTEM reagent 
 Hold over cup and press button to expel reagents into cup 
 Discard and replace tip 
 Place in mixed sample 
 Press button to draw up sample 
 Hold over sample cup and press button to expel sample into cup 
 Place tip in bottom corner of cup and press button to draw up test mixture 
 Hold tip over cup and press button to expel tip mixture into cup (for mixing) 
 Place cup holder onto measurement pin 
 Press button on screen to confirm beginning of test 
 
10. For FIBTEM the pipetting steps are: 
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 Select tip 
 Place in SarTEM reagent 
 Press button to draw up reagent 
 Hold over cup and press button to expel reagent into cup 
 Discard and replace tip 
 Place in FIBTEM reagent 
 Hold over cup and press button to expel reagent into cup 
 Discard and replace tip 
 Place in mixed sample 
 Press button to draw up sample 
 Hold over sample cup and press button to expel sample into cup 
 Place tip in bottom corner of cup and press button to draw up test mixture 
 Hold tip over cup and press button to expel tip mixture into cup (for mixing) 
 Place cup holder onto measurement pin 
 Press button on screen to confirm beginning of test 
11. Allow all channels to run for at least one hour then stop any channels that are still running 
and transfer the data to the archive by tapping the ‘Clear Channel’ button 
12. Data was retrieved from the Database module after analysis and transferred to a USB stick 
13. The data files were then opened in Microsoft Excel to access a spreadsheet containing all 
parameters, including G 
The ROTEM did not require any calibration but internal quality control samples were purchased from 
TEM Internationa GmbH and processed monthly as recommended by the company. 
To evaluate platelet function the G values were used to calculate platelet elasticity as follows: 
EXTEM G – FIBTEM G = Platelet G 
In some cases, the results were also standardised for platelet count as follows: 
(EXTEM G – FIBTEM G) / Platelet Count = G per Platelet 
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2.4.4 AWE test 
The AWE test is a simplified and automated version of the HSR performed on a Sysmex CS-5100 or 
CS-2100 analyser that was developed as part of this study. It is potentially transferable to other 
automated analysers. As with the HSR, the AWE test measures the ability of platelets to pump out 
water as a marker of their viability and ability to function. Platelet concentrate (or PRP) samples were 
placed into 2mL sample tubes, loaded into an analyser rack and placed on board the analyser. Up to 
ten samples could be placed into each rack and the analyser then automatically pipetted 120 µL of 
each sample to its own test cuvette. After 10 seconds, 60 µL of water was added to each test cuvette 
and absorbance at 575nm was recorded for the next 180 seconds. Initially the absorbance of the test 
samples decreased as the platelets took up the reagent water. After reaching a minimum level at 
around 20 seconds, the absorbance of test samples containing viable platelets began to increase as 
the platelets pumped out the water. 
The AWE test uses the Sysmex CS series immunoassay detection method to measure changes in OD 
that are reported in units of Absorbance per minute. This combination of settings is also used for 
measurement of prothrombin time in a routine clotting screen. The test reports the change in OD 
between the minimum absorbance recorded after addition of the water reagent and the absorbance 
level recorded after a period of recovery. There was, unfortunately, no option to blank each sample 
against its equivalent PPP sample within the current CS series software. 
A variety of different test settings were evaluated.  The test was trialled using both neat platelet 
concentrate samples and samples diluted in Cryocheck normal reference plasma (Precision 
BioLogic, Canada) to give a platelet count of 300 x 109/L (± 10%). Two different measurements 
were taken from each reaction trace: the variable result (VAR) refers to the degree of slope 
measured over the 15 second period during which the increase in OD is greatest and the fixed 
(FIX) result measured the slope over the 80 second period from 20 to 100 seconds. See Figure 2.8. 
Finally, all assays were performed in duplicate using both test cuvettes without stir-bars and test 
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cuvettes with stir-bars wherever possible in order to investigate the possible effect of samples 
settling during analysis. The stir bar tests are referred to as VSB (variable stir-bar) and FSB (fixed 
stir-bar). 
 
    
Figure 2.8: Example AWE results. A test performed using the VAR measurement settings is 
shown in the top picture and a test performed using the FIX measurement settings is 
shown in the bottom picture. The graphs show absorbance on the y axis and time in 
seconds on the x axis. The ‘slope’ recorded in the table on the right hand side is the 
result that is reported. This measurement reflects the change in OD between the two 
vertical blue lines on each graph.  
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3  IN VITRO RESULTS 
 
3.1  In-Vitro Results Introduction 
The first part of this study focused mainly upon establishing a panel of laboratory techniques to be 
taken forward into the clinical phase. All technical development and assessment was carried out 
using commercial quality control specimens where available, PRP samples taken from healthy 
volunteers and out of date platelet concentrates discarded by the OUH Transfusion laboratory when 
they expired at five or seven days old. 
A large proportion of this work focussed on determining the cause of the uniformly high 
ThromboLUX scores. It was initially unclear whether the problem was technical in nature or 
specimen related. Specimen related problems could be related to the age, transport or storage of 
the platelet concentrates being tested or could reflect some small but significant difference 
between UK platelet concentrates and those produced in Vancouver, where the ThromboLUX 
analyser was developed. Technical problems could be specific to a particular instrument or linked 
to the methodology in general. To aid distinction between these factors, a series of sample 
exchange experiments were undertaken with other sites using the ThromboLUX analyser. 
Following the initial development stage of the study, 10 pooled platelet concentrates were 
purchased from the NHSBT to gain further data with the ROTEM®, to try and establish a local cut-
off value for the ThromboLUX and apply all available methods to specimens that are more closely 
comparable with the platelet concentrates used in clinical practice. All concentrates were tested 
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3.2  In-Vitro Results Methods 
One of the challenges encountered during this project is the lack of reliable reference methods.  HSR, 
ESC, pH testing and swirl assessment were performed as reference methods. Swirl and pH were not 
assessed during the very earliest stages of the study as the initial aims were to detect subtle quality 
deteriorations that were thought unlikely to be measurable by these relatively insensitive techniques. 
However, both methods were added later to flag very poor quality concentrates that we suspected 
were not being detected by the ThromboLUX. The novel techniques used during this phase were the 
iZON nanoparticle analyser, the ThromboLUX platelet quality analyser, the ROTEM® 
thromboelastometry system and the AWE test. 
For the multiple site platelet concentrate exchange phase of the study, specimens were prepared 
and shipped to Oxford for testing from the NHSBT processing sites at Colindale and Brentwood, 
the Canadian National Blood Service and Sanquin in the Netherlands. Shipping methods varied 
from the controlled conditions used to transport clinical platelet concentrates to transport of 
capped containers at potentially inappropriate temperatures for platelet concentrate storage that 
should have induced poor quality. In addition to the Haematology Department at OUH Trust, 
testing was undertaken at the NHSBT Laboratory in Cambridge, the LightIntegra Laboratory in 
Vancouver, the Sanquin Research Laboratory in Leiden and the Haematology Department at the 
HAGA Hospital in The Hague. 
The fresh platelet concentrate phase of the study provided an opportunity to further test the 
ThromboLUX analyser since the upgrades and modifications made during the previous study 
stages and determine whether the sensitivity of the instrument to age related platelet quality 
deterioration had improved. Additional testing with the ROTEM instrument was also performed 
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3.3  In-Vitro Results of Reference Tests 
The results obtained during the development, characterisation and assessment of a panel of platelet 
quality reference tests in the laboratory are shown below. 
3.3.1 Automated blood cell analysis 
Automated platelet counting and sizing was carried out using automated Sysmex FBC analysers.  The 
Sysmex analysers use an impedance technique to determine the number of platelets in a sample and 
the overall proportion of the sample that is made up of platelets. MPV is then calculated from the 
impedance distribution. The concentrate volumes recorded by the NHSBT were used to calculate the 
platelet doses contained within the concentrates. In the initial validation stages of the study, results 
obtained from expired concentrates on the first day of testing (day 6, day 7 or day 9 after collection 
from the donor) were compared to results obtained on the final day of testing (day 11, day 12 or day 
13 after collection) to investigate the effects of age related deterioration on automated blood cell 
indices. The platelet count, MPV and platelet dose results for 25 expired concentrates are shown in 
Table 3.1. 
Table 3.1 also includes the results of T-tests carried out to compare the automated cell counting 
features of pooled and apheresis concentrates. These are shown at the bottom of the table. 
Unpaired, bi-directional T-tests were used to compare the two separate populations as the direction 
of change was unpredictable. It was found that the platelet count and dose differed significantly (P = 
≤0.01) between apheresis and pooled platelets, both at initial testing and final testing. However, the 
MPV showed no statistically significant change between the two collection types (P = 0.14 at initial 
testing and 0.23 at final testing). 
In addition, the automated blood count test results obtained on the first and final days of testing 
were compared. The results of both paired and unpaired T-tests are shown in the right hand column. 
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Uni-directional T-tests were used as it was anticipated that the platelet count would decrease due to 
aggregation and disintegration and that the MPV would increase due to aggregation. 
 
Table 3.1: Automated blood count indices for all 25 expired platelet concentrates, for pooled 
platelet concentrates and for apheresis platelet concentrates. The results of an unpaired, 
bi-directional t- test comparing the platelet count, platelet dose and MPV of apheresis 
and pooled platelet concentrates are shown in the bottom row. The results of paired and 
unpaired, uni-directional T-tests comparing the platelet count and MPV of platelet 
concentrates measured in initial and final tests are shown in the right hand column. 
 
  Initial Test 
(Day 6, 7 or 9) 
Final Test 























All (n=25)        Paired: 
Mean 212 1442 8.5 315 1349 8.7 301 0.00 0.03 
Maximum 300 1767 9.6 427 1749 10.7 376 Unpaired: 
Minimum 172 1028 7.4 215 1004 7.3 217 0.137 0.212 
Pooled 
(n=12) 
       
Paired: 
Mean 273 1259 8.7 371 1191 8.9 349 0.01 0.02 
Maximum 300 1628 9.1 427 1435 9.7 376 Unpaired: 
Minimum 257 1028 8.2 337 1004 8.4 326 0.36 0.22 
Apheresis 
(n=13) 
       
Paired: 
Mean 190 1573 8.4 294 1462 8.6 283 0.01 0.16 
Maximum 201 1767 9.6 348 1749 10.7 339 Unpaired: 
Minimum 172 1226 7.4 215 1161 7.3 217 0.36 0.22 
P-value of unpaired, 
bi-directional t- test 
comparing Pooled 
and Apheresis values 
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Platelet count and MPV differed significantly within the pooled concentrate group and the test 
sample as a whole when paired T-tests were used, indicating deterioration of specific concentrates. 
However, unpaired T-tests did not reveal significant changes, suggesting there was no clear 
separation between the newly expired and extremely aged concentrate groups as a whole. The 
apheresis concentrates also showed statistically significant reductions in platelet count using paired 
T-tests but the MPV did not change significantly. This may reflect decreased aggregation in apheresis 
concentrates, potentially indicating reduced quality deterioration, or it may be due to increased 
micro- vesiculation and thus possibly related to increased quality deterioration. Overall, the 
differences observed over time for individual concentrates were not great enough to overcome the 
high inter-concentrate variability that is shown in Table 3.2. 
 
Table 3.2: Co-efficient of variation (CV) for initial and final automated platelet count and volume 
results for all concentrates and for the pooled and apheresis concentrate sub-groups. 
 Platelet count MPV 
 Initial CV (%) Final CV (%) Initial CV (%) Final CV (%) 
All concentrates 16 15 6 9 
Pooled concentrates 14 13 4 5 
Apheresis concentrates 10 11 7 12 
 
 
The platelet count and calculated unit dose differed significantly (p = ≤0.01) between apheresis and 
pooled platelets but the MPV showed no difference. Platelet count deteriorated within individual 
units (apheresis p = 0.007, pooled p = 0.006) and MPV increased in pooled units (p = 0.019). These 
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3.3.2 pH measurement 
pH measurement was carried out during the ageing platelet concentrate phase of the study. For 
each concentrate the pH was initially between 7 and 7.5. It generally increased a little for the day 
two and five measurements, presumably as the platelets recovered from the sub-optimal 
conditions experienced during processing and transport and then began to drop again. One 
concentrate dropped below pH 7 on day 9, 8 concentrates had dropped below pH 7 on day 12 
and all concentrates had dropped below pH 7 by day 14. All concentrates recorded pH levels of 
less than 6.5 by the end of testing at day 16. See Figure 3.1. 
 
Figure 3.1: pH results for fresh platelet concentrates PC1-PC10. 
 
3.3.3 Swirl assessment 
As with pH measurements, swirl assessment was undertaken at OUH Trust from the ageing 
platelet concentrate phase of the study onwards. All purchased concentrates were initially swirl 
positive and each became swirl negative during the study period. However, the amount of time 
 
- 69 - 
for which they were swirl positive varied considerably between concentrates, with the first 
recorded swirl negative day being anywhere between day 5 and day 16. See Table 3.3. 
Table 3.3:  First swirl negative day for each concentrate. 












3.3.4 ESC and HSR assays 
HSR and ESC assays were carried out on four expired platelet concentrates. All were tested on at least 
two separate occasions, at least three days apart. The results obtained are shown in Table 3.4. 
 
Table 3.4: HSR and ESC results for expired concentrates stored under appropriate conditions. 
Concentrate ID number Day post collection HSR (%) ESC (%) 
104 D6 158 18.0 
 D9 70 11.2 
 D12 53 11.0 
 D15 27 5.2 
105 D6 69 28.0 
 D9 75 16.8 
 D12 57 19.5 
 D15 13 10.1 
106 D7 77 13.4 
 D10 55 8.8 
 D13 74 15.6 
107 D9 65 22.4 
 D12 24 8.8 
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Although there is no set normal range for these tests, Holme et al (1998) reported HSR results of 58-
81% and ESC results of 20-28% for fresh citrate phosphate dextrose (CPD) preserved PRP in a multi-
laboratory study. Most of the concentrates initially gave results within this range, which reduced over 
time as the platelets aged. 
To ensure that these techniques were able to detect extremely poor platelet quality, they were 
used to test platelet concentrate samples that had been kept at 37°C and -40°C for six days prior 
to undergoing testing on day 12 after collection. Storage at 37°C induces increased levels of 
platelet apoptosis and reduced platelet viability (Bertino et al, 2003). Freezing reduces both the 
quantity and viability of platelets in a sample (Taylor, 1981). The results of this experiment are 
shown in Table 3.5. 
Table 3.5: HSR and ESC results for expired concentrates measured on Day 12 after collection, 
following storage from Day 6 at standard, high and low temperatures. 
Concentrate Storage Condition HSR (%) ESC (%) 
104 22°C (standard) 53 11.0 
 37°C 4675 -7.3 
 -40°C 89 -0.9 
105 22°C (standard) 57 19.5 
 37°C 257 5.6 
 -40°C 113 1.6 
 
The HSR results were unexpectedly raised. This may have been due to increased osmotic fragility 
of the platelets, leading to rupture and associated increase in optical density within the test 
sample. The ESC was low in all samples as expected. These results suggested that the HSR test is 
unreliable in extremely poor quality platelet concentrates and that the ESC test is preferable. 
For the most part, the HSR and ESC tests both gave results within the expected range for the 
purchased ageing concentrates and dropped as the concentrates aged. There were occasional 
outliers and it was unclear whether these were caused by technical or concentrate related 
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factors. All tests were performed in duplicate and individual results that were obviously affected 
by error were discarded and repeated wherever possible. See Figures 3.2 and 3.3. 
 
Figure 3.2: HSR results for fresh platelet concentrates PC1-PC10. 
 
Figure 3.3: ESC results for fresh platelet concentrates PC1-PC10. 
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3.4 iZON Impedance Analyser In-Vitro Results 
The iZON impedance analyser was designed to measure small particles. Blood platelets are at the 
upper end of its detection limit. Within the early stages of this study, its ability to produce an 
accurate platelet distribution curve and determine platelet surface charge was investigated. 
The numbers of PMV (defined here as <2000nm particles) in some of the expired platelet 
concentrates was observed to increase as the concentrates aged. Figure 3.4 shows iZON platelet 
distribution peaks measured at three different time points from a single platelet concentrate that 
demonstrates appearance of a smaller MV peak separate from the main platelet population. As the 
presence of large MV in platelet concentrates is a potential marker of platelet activation during 
platelet storage (Harrison et al, 2010) the ability to detect this population may have utility. 
However, it was not possible to generate reliable charge measurements within this study. The 
instrument was difficult to use and setting up reliable measurements was very time consuming.  
Using the software available at the time, measurements at multiple analysis pressures were required. 
Recurrent pore blockages occurred, particularly at lower analysis pressures and with samples from 
older platelet concentrates, perhaps due to some degree of activation and / or aggregation of the 
sample. This made it impossible in some cases to obtain enough events for a reliable reading. There 
was also concern that some of the results eventually recorded after multiple measurement attempts 
were not representative of the true state of the sample. Restarting measurements and stopping and 
starting data acquisition multiple times within a single measurement may have led to inadvertent 
selection of less activated platelets within the measurement. It was decided at this point that the 
ability of the iZON instrument to measure platelet sized particles was not yet understood well enough 
to be a realistic prospect for use in future stages of the study. 
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Figure 3.4: iZON platelet distribution curves obtained at four different analysis pressures (red, pink, 
blue and green lines) for platelet concentrate 11 on days 6, 9 and 13 after collection 
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3.5  ThromboLUX Analyser In-Vitro Results  
The laboratory assessment of the ThromboLUX analyser is presented below. 
3.5.1 Initial laboratory assessment of the ThromboLUX 
The between batch precision of the first ThromboLUX analyser delivered to our laboratory (TL 1) 
was assessed using calibration beads supplied by LightIntegra Ltd. The company advised that 
scores of between 19 and 22 should be obtained when testing these beads. They were initially 
tested on eleven separate occasions and gave a CV of 11.3% as shown in Table 3.6. The average 
score was within the expected range. 
 
Table 3.6: Results of a between batch precision study using ThromboLUX scores for a 
commercial calibration bead preparation supplied by LightIntegra Ltd 
Test Date TL 1 Beads Score 
(Expected Range 19 – 22) 
24/11/2010  20.3 
25/11/2010  18.7 
26/11/2010  18.3   Average 20.0 
29/11/2010  20.0   SD 2.3 
30/11/2010  19.8   CV 11.3 
01/12/2010  18.5   Max 24.2 
02/12/2010  18.0   Min 17.1 
03/12/2010  23.5 
06/12/2010  17.1 
09/12/2010  24.2 
10/12/2010  21.3 
 
 
To give an indication of the within batch precision and assess the variability of results obtained 
from biological samples, an expired platelet concentrate was tested five times on day six after 
 
- 75 - 
collection, five times on day nine after collection and five times on day twelve after collection. The 
results are shown in Table 3.7. The co-efficient of variation (CV) observed within this experiment 
varied from 8.2% on day 6 after the platelets were collected from the donor to 18.8% on day 9 
after collection. 
 
Table 3.7: Results of a within batch precision study using ThromboLUX scores for an expired 
platelet concentrate. 
Day Score  TL 1 Results  
6 19.9    
 23.9  Average 22.8 
 23.2  SD 1.9 
 22.4  CV 8.2 
 24.8    
9 24.2    
 21.4  Average 22.2 
 20.9  SD 4.2 
 16.7  CV 18.8 
 28.0    
12 24.8    
 23.4  Average 27.0 
 31.6  SD 3.4 
 25.7  CV 12.6 
 29.3    
 
 
All platelet concentrates gave scores above the acceptable quality cut-off value advised at that time 
(>14) up to the end of testing, even when reference methods indicated a complete lack of viability 
within the concentrate. Some concentrates showed increasing quality scores with increasing age. This 
was in disagreement with the data of Maurer-Spurej et al (2009), who found that roughly one in six 
platelet concentrates gave a poor (<14) score prior to expiry at five days after collection from the 
donor. The study performed by Maurer-Spurej et al (2009) used the prototype version of the 
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ThromboLUX analyser. This data was the first indication that the two analyser models were not 
entirely equivalent. 
Due to these inconsistencies, a technical fault with the TL 1 ThromboLUX analyser was suspected and 
it was exchanged for a second device of the same specifications (TL 2) in the hope that this would 
resolve the issues observed. In addition, the analyser was moved to a room on its own, where 
interferences from other equipment could be ruled out, and powered through an uninterrupted 
power supply (UPS) to guard against irregularity of the power supply in case this was an interfering 
factor. However, the between batch precision, as measured using calibration bead preparations, 
remained unchanged with the new instrument as is shown in Table 3.8. 
 
Table 3.8: Repeated between batch precision study using ThromboLUX scores for calibration bead 
preparations using instrument 2 in conjunction with a UPS system 
Date TL 2 Beads Score 
(Expected Range 19 – 22) 
09/05/2011 23.4 
11/05/2011 23.1  Average 21.2 
13/05/2011 18.7  SD 2.1 
16/05/2011 24.3  CV 10.1 
20/05/2011 19.7  Maximum 24.3 





The change of instrument unfortunately made no difference to the unexpectedly high scores 
obtained for expired platelet concentrate samples. The specimens stored at 37°C and -40°C 
(discussed above in relation to the HSR and ESC tests) were also tested on the TL 2 analyser and the 
scores obtained are shown in Table 3.9. Although the sample stored at -40°C gave scores below the 
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cut-off of 14 for both samples, the 37°C samples still appeared to have acceptable quality and, in the 
case of concentrate 104, had even improved. 
 
Table 3.9: ThromboLUX scores for four expired platelet concentrates, including samples stored at 
inappropriate temperatures obtained using instrument 2. 
Days post collection / 
storage temperature 
ThromboLUX Score 
 Concentrate 104 Concentrate 105 Concentrate 106 Concentrate 107 
Day 6 31.2 36.5 21.8 (day 7)  
Day 9 30.9 33.1 36.6 (day 10) 21.5 
Day 12 28.2 23.4 33.5 (day 13) 19.9 
Day 15 25.3 31.3   
37°C 31.1 30.5   
-40°C 8.1 13.6   
 
 
3.5.2 Comparison of ThromboLUX at multiple sites 
Because of the apparent problems with sensitivity to poor platelet concentrate quality, the study 
went on to arrange and participate in a series of sample swapping exercises with other laboratories 
using the ThromboLUX device. At the beginning of this phase of the study, the TL 2 was exchanged 
for a third ThromboLUX analyser: TL 3. The initial sample swapping experiment was conducted using 
both TL 2 and TL 3 and served as a baseline comparison of the two machines. The details and results 
of five separate sample swapping experiments are documented below. See table 3.10 for an 
overview. 
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Table 3.10: Overview of testing carried out during the five sample exchange experiments 
 




Leiden 1 Tested on arrival Tested on arrival and after 
one week 
 Tested on day of 
arrival in Oxford 
  
Leiden 2 Tested on arrival Tested on arrival and after 
one week 
 Tested on day of 
arrival in Oxford 
  
Vancouver 1 Tested on arrival 
and following day 
Tested on arrival and 
following day 
    
Vancouver 2 Tested on arrival 
and following day 
Tested on arrival and 
following day 
    
Vancouver 3 Tested on arrival 
and following day 
Tested on arrival and 
following day 
    
Vancouver 4 Tested on arrival 
and following day 
Tested on arrival and 
following day 
    
Vancouver 1 
(frozen) 
Tested on day 
after arrival 
Tested on day after arrival     
Vancouver 4 
(frozen) 
Tested on day 
after arrival 
Tested on day after arrival     
Colindale 
Concentrates 
Colindale 1  Tested on days 1, 2, 3, 7 and 
9 after arrival. HSR, ESC and 
ROTEM tests also performed 
Tested on days 1, 2, 3, 6, 
8, 9 and 15 after arrival 
   
Colindale 2  Tested on days 1, 2, 3, 7 and 
9 after arrival. HSR, ESC and 
ROTEM tests also performed 
Tested on days 1, 2, 3, 6, 
8, 9 and 15 after arrival 





 Tested on day 11 after 
donation collection 
Tested on days 2, 11 and 
14 after donation 
collection. Kunicki score 
on days 10, 11 and 14 
   
Vancouver 
sample 2 
 Tested on day 11 after 
donation collection 
Tested on days 2, 11 and 
14 after donation 
collection. Kunicki score 
on days 10, 11 and 14 
   
 





 Tested in duplicate on day 
of arrival 
  Tested on day of 




 Tested in duplicate on day 
of arrival 
  Tested on day of 




 Tested in duplicate on day 
of arrival 
  Tested on day of 







 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 




 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 
Tested on day 
of arrival 
M) 20 day old 
concentrate 1 
 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 
Tested on day 
of arrival 
N) 20 day old 
concentrate 2 
 Tested on day of arrival  Tested on day of 
arrival 
Tested on day of 
arrival 
Tested on day 
of arrival 
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Leiden and Vancouver Concentrates - June 2011 
Capped specimens from two Dutch platelet concentrates that had been tested using a different 
ThromboLUX analyser at the Sanquin Research Laboratory in Leiden were sent to the 
Haematology Department in Oxford. Four additional platelet concentrates from Vancouver were 
also transported to Oxford at this time. All of these concentrates were tested on two separate 
ThromboLUX analysers in Oxford: TL 2 and TL 3, which was subsequently left at OUH in place of 
TL 2. The Vancouver concentrates were tested again on the following day. The Leiden 
concentrates were also tested using a different ThromboLUX analyser located in Leiden and after 
a further week stored without gas exchange.  Samples from two of the Vancouver concentrates 
were frozen and thawed prior to testing. All of these results are shown in Table 3.11. 
 
Table 3.11: ThromboLUX scores for four platelet concentrates produced in Vancouver, capped 
samples from two platelet concentrates produced in Leiden and samples taken from two 
of the Vancouver concentrates that were stored at inappropriate temperatures. 
Test Date Sample TL 2 TL 3 Leiden Result 
23/06/2011 2000nm Beads 23.8 24.1  
 Vancouver PC 1 16.6 21.4  
 Vancouver PC 2 4.4 9.6  
 Vancouver PC 3 20.4 31.1  
 Vancouver PC 4 31.2 28.3  
 Leiden PC 1 (exp 23/06) 18.3 25.5 22.4 
 Leiden PC 2 (exp 28/06) 5.5 3.2 11.2 
24/06/2011 2000nm Beads 22.5   
 Vancouver PC 1 23.6 17.9  
 Vancouver PC 2 5.5 7.7  
 Vancouver PC 3 26.1 28.8  
 Vancouver PC 4 19.9 24.3  
 Vancouver PC 1 (Frozen) 19.1 22.2  
 Vancouver PC 4 (Frozen) 23.9 28.0  
30/06/2011 Leiden PC 1 (exp 23/06)  19.4  
 Leiden PC 2 (exp 28/06)  7.4  
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Although there was notable inter-analyser variability, Leiden concentrate 1 consistently gave high 
scores and Leiden concentrate 2 gave low scores. However, Leiden concentrate 1 still gave a high 
score (19.4) when the concentrate reached 15 days old and Leiden concentrate 2 appeared to 
improve following storage without gas exchange for a week. 
The results produced by the two instruments were compared using a bi-directional paired T-test.  
This analysis identified the two sets of results as being significantly different (P = 0.036). Rather than 
showing that the initial ThromboLUX analyser demonstrated a positive bias, this experiment proved 
instrument 2 to produce significantly lower results than instrument 3. The correlation between 
results recorded by the two instruments was 0.66 as shown in Figure 3.5. 
 
  
Figure 3.5: Comparison of ThromboLUX scores obtained for the Vancouver and Leiden platelet 
concentrates using instrument 2 and instrument 3.  
y = 0.8197x + 6.352 






















Instrument 2 Score 
Difference between instruments 
 
- 82 - 
Despite some variability between the two instruments, both were able to identify two platelet 
concentrates as having scores below the cut-off value of 14. Vancouver concentrate 2 gave low 
scores on both days of testing and Leiden concentrate 2 produced a low score in the UK and in 
Leiden. ThromboLUX scores of these levels had not been seen at all in UK concentrates. The results 
for the frozen platelet concentrates unexpectedly indicated acceptable quality. These results 
suggested that a malfunction which only affected the analysers used locally for this study was 
unlikely because the problem was apparent with multiple instruments. 
 
Colindale Concentrates - September 2011  
Two platelet concentrates were collected at the NHSBT processing centre in Colindale, split into 
paediatric platelet bags and dispatched under controlled conditions (in an insulated blood box 
with a temperature logger) to both Oxford and Vancouver. ThromboLUX Scores obtained at both 
locations were mostly comparable and remained consistently above the cut-off value used to 
identify poor quality platelets until at least day 15 (tested in Vancouver only). A clearer 
deterioration was observed in the platelet only G value (EXTEM – FIBTEM) obtained using the 
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Figure 3.6: Quality test results for Colindale platelet concentrate 1. ThromboLUX scores were 
obtained on Oxford (TL Score - blue) and Vancouver (Van TL – red). HSR (purple), ESC 
(light blue) and ROTEM® (green) tests were also carried out in Oxford. ROTEM® 
results are expressed as platelet only G (EXTEM G – FIBTEM G). 
 
 
Figure 3.7: Quality test results for Colindale Platelet Concentrate 2. ThromboLUX scores were 
obtained on Oxford (TL Score - blue) and Vancouver (Van TL – red). HSR (purple), ESC 
(light blue) and ROTEM® (green) tests were also carried out in Oxford. ROTEM® 
results are expressed as platelet only G (EXTEM G – FIBTEM G). 
 
In addition, swirl assessments and microscopy were carried out in Vancouver. Swirl persisted for 
both concentrates until day nine and microscopy showed that a high percentage of discoid 
Days Post Collection 
Days Post Collection 
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platelets were present on day 2, indicating that the concentrates were of good quality at that 
point. See Figure 3.8. 
 
Figure 3.8: Phase contrast microscopy image of Colindale platelet concentrate 1 showing a high 
percentage of discoid platelets. Courtesy of the LightIntegra Laboratory, Vancouver. 
 
Vancouver Concentrates – October 2011 
Samples from two platelet concentrates were sent from the LightIntegra Laboratory in Vancouver 
to Oxford and tested in both locations. Additionally, Kunicki scores were generated in Vancouver. 
The results are shown in Figures 3.9 and 3.10. They showed concentrate 1 to be consistently poor 
quality from day 10 onwards and concentrate 2 to progressively deteriorate in quality. 
ThromboLUX scores obtained in Vancouver showed deterioration between days two and 11 but 
then increased on day 14. Neither concentrate gave scores below the cut-off of 14. The day 11 
Oxford scores were considerably higher than equivalent Vancouver measurements. 
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Figure 3.9: ThromboLUX scores from Vancouver (blue) and Oxford (red) and Kunicki scores from 
Vancouver (green) for Vancouver sample 1 
 
Figure 3.10: ThromboLUX scores from Vancouver (blue) and Oxford (red) and Kunicki scores from 
Vancouver (green) for Vancouver sample 2 
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Brentwood Concentrates – April 2012 
The Oxford analyser underwent maintenance and upgrades, including a switch to the external 
ThromboSight software, that were hoped to improve its sensitivity to poor quality concentrates 
prior to testing two capped platelet concentrate specimens and one bagged platelet concentrate 
from Brentwood. These samples had been tested in Cambridge the previous day. All three 
specimens were collected 11 days before testing in Cambridge and the capped specimens had 
been stored without gaseous exchange for four days. The specimens were transported under 
controlled temperature conditions and it was anticipated that they would give comparable scores 
between the two sites. However, as can be seen in Figure 3.11, the Cambridge scores were much 
higher than those obtained in Oxford, raising the possibility that the maintenance performed on 
the Oxford machine had, indeed, increased its sensitivity to poor platelet quality, at least in 
comparison to the Cambridge analyser. Both capped specimens gave markedly different results 
during repeat analysis (Oxford 2) compared to the initial scores (Oxford 1) but both Oxford results 
for the concentrate were similar. 
 
Figure 3.11: ThromboLUX scores from Oxford and Cambridge for one platelet concentrate (blue) 
and two capped specimens (red and green) taken from other concentrates. Tests 
were performed in duplicate at Oxford (Oxford 1 and Oxford 2) 





Brentwood Platelet Concentrates 
Capped Tube 2 
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Second Colindale Concentrates – July 2012 
A final comparative testing experiment was performed in July 2012. Three double dose apheresis 
platelet donations were collected in Colindale and split into 4 x 80mL breathable paediatric platelet 
bags and 12 x 10mL breathable sample pouches. The 10mL pouches were stored at either 37⁰C, 4⁰C 
or -40⁰C for 24 hours prior to dispatch. In addition, two 20 day old platelet concentrates were each 
split into four 80mL packs. One 80mL bag, one 37⁰C pouch, one 4⁰C pouch and one -40⁰C pouch from 
each of the three fresh donations and one 80mL bag from each of the out of date concentrates was 
sent to each of the following locations: Oxford, Cambridge, Leiden and The Hague. Each site received 
a total of 14 specimens for analysis three days after collection. The results are shown in Figure 3.12 
and summarised in Table 3.12. 
 
Figure 3.12: ThromboLUX scores from Oxford (blue), Cambridge (red), Leiden (green) and The Hague 
(yellow)  for three fresh platelet concentrates, stored at 22⁰C (D, H and L) and pouches 
derived from each of these stored at 37⁰C (A, E and I), 4⁰C (B, F and J) and -40⁰C (C, G 
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All platelet concentrates expected to be of good quality gave high scores at all four sites. However, 
the ThromboLUX was not sensitive to the age induced changes in platelet concentrate quality 
present in packs 4 and 5. In addition, the results for platelet concentrates stored at inappropriate 
temperatures, known to induce quality deterioration (Bertino et al, 2003; Taylor, 1981) were only 
intermittently reduced and a degree of variability was observed between the results obtained at the 
four different sites. See Table 3.12. 
 
Table 3.12: Qualitative summary of the results obtained for the 14 samples derived from five platelet 
concentrates tested in Oxford, at Cambridge, in Leiden and at The Hague. 
 
Pack 1 Treatment Qualitative Assessment of Results 
D Platelets (70ml) 22ºC storage (day 3) Good quality at all four sites 
A Pouch (8ml) 24h storage at 37ºC  Good quality at all sites except the Hague, 
which recorded borderline poor quality 
B Pouch (8ml) 24h storage at 4ºC Good quality at all four sites 
C Pouch (8ml) 24h frozen / thawed  Very poor quality at all sites except Cambridge, 
which recorded good quality 
Pack 2 Treatment Results 
H Platelets (70ml) 22ºC storage (day 3) Good quality at all four sites 
E Pouch (8ml) 24h storage at 37ºC  Good quality at all four sites 
F Pouch (8ml) 24h storage at 4ºC Good quality at all four sites 
G Pouch (8ml) 24h frozen / thawed  Very poor quality at all four sites 
Pack 3 Treatment Results 
L Platelets (70ml) 22ºC storage (day 3) Good quality at all sites except Oxford 
I Pouch (8ml) 24h storage at 37ºC  Borderline poor quality at all four sites 
J Pouch (8ml) 24h storage at 4ºC Borderline poor quality at all four sites 
K Pouch (8ml) 24h frozen / thawed  Borderline poor quality at all sites except the 
Hague, which recorded very poor quality 
Pack 4 Treatment  Results 
M Time expired (40ml)  (day 20) Borderline poor quality at Cambridge and the 
Hague, good quality at Oxford and Leiden 
Pack 5 Treatment  Results 
N Time expired (40ml)  (day 20) Good quality at all four sites 
 
A number of the samples tested gave consistent results at all four sites and some gave low results 
consistent with poor quality. However, a significant proportion of the results were still inconsistent 
or unexpectedly high, suggesting that the analytical issues were not completely resolved. 
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3.5.3 ThromboLUX ageing platelet concentrate results 
Ten platelet concentrates were purchased from the NHSBT and tested on days 1, 2, 5, 7, 9, 12, 14 
and 16 after collection using a variety of reference and experimental methods. Concentrate one 
was not tested on day 14 and concentrate five had additional testing carried out on days 19 and 
23 to determine whether the ThromboLUX score dropped in extremely aged concentrates. The 
results of all tests carried out are shown side by side for each of the ten concentrates in Figures 
3.13 to 3.22 below. The results of the reference tests were discussed in section 3.3 above. The 
results obtained using each of the novel tests will be discussed in the relevant section below. 
 
 
Figure 3.13: Platelet concentrate 1 results. The HSR % (blue), ESC % (red), ThromboLUX score 
(orange) and ROTEM® G/platelet (pink) are plotted against the primary y axis. pH 
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Figure 3.14: Platelet concentrate 2 results. The HSR % (blue), ESC % (red), ThromboLUX score 
(orange) and ROTEM® G/platelet (pink) are plotted against the primary y axis. pH 
(green) is plotted against the secondary axis.. 
 
Figure 3.15: Platelet concentrate 3 results. The HSR % (blue), ESC % (red), ThromboLUX score 
(orange) and ROTEM® G/platelet (pink) are plotted against the primary y axis. pH 
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Figure 3.16: Platelet concentrate 4 results. The HSR % (blue), ESC % (red), ThromboLUX score 
(orange) and ROTEM® G/platelet (pink) are plotted against the primary y axis. pH 
(green) is plotted against the secondary axis. 
 
Figure 3.17: Platelet concentrate 5 results. The HSR % (blue), ESC % (red), ThromboLUX score 
(orange) and ROTEM® G/platelet (pink) are plotted against the primary y axis. pH 
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Figure 3.18: Platelet concentrate 6 results. The HSR % (blue), ESC % (red), ThromboLUX score 
(orange) and ROTEM® G/platelet (pink) are plotted against the primary y axis. pH 
(green) is plotted against the secondary axis. 
 
Figure 3.19: Platelet concentrate 7 results. The HSR % (blue), ESC % (red), ThromboLUX score 
(orange) and ROTEM® G/platelet (pink) are plotted against the primary y axis. pH 
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Figure 3.20: Platelet concentrate 8 results. The HSR % (blue), ESC % (red), ThromboLUX score 
(orange) and ROTEM® G/platelet (pink) are plotted against the primary y axis. pH 
(green) is plotted against the secondary axis.. 
 
Figure 3.21: Platelet concentrate 9 results. The HSR % (blue), ESC % (red), ThromboLUX score 
(orange) and ROTEM® G/platelet (pink) are plotted against the primary y axis. pH 
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Figure 3.22: Platelet concentrate 10 results. The HSR % (blue), ESC % (red), ThromboLUX score 
(orange) and ROTEM® G/platelet (pink) are plotted against the primary y axis. pH 
(green) is plotted against the secondary axis. 
 
The ThromboLUX results for all ten concentrates are shown together in Figure 3.23. Some 
concentrates showed a degree of deterioration over time. However, the differences were usually 
small, after 15 days and it was difficult to pick out a potential ‘cut-off’ value with any confidence. 
Concentrate 5 was tested at two additional time-points. Even at 23 after collection days it did not 
show clear and definite deterioration of quality upon comparison to the previously defined cut-
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Figure 3.23: ThromboLUX results for fresh platelet concentrates PC1-PC10. 
 
Samples from Platelet Concentrate 1 were stored at 22°C (appropriately stored control), 37°C, 
50°C and -40°C (inappropriate storage temperatures known to damage platelet quality) prior to 
testing with the ThromboLUX analyser. Results were convincingly reduced for the sample stored 
at -40⁰C and slightly reduced for the sample stored at 50°C. No negative effect of storage at 37°C 
was observed. See Table 3.13. 
Table 3.13: ThromboLUX scores for platelet concentrate samples stored at various temperatures 
 




TL Score  TL Score 2  TL Mean  
22⁰C 1194 6.41 13.5 16.4 15.0 
37⁰C  1053  6.12  20.5  11.6  16.1  
50⁰C  418  6.24  12.4  13.4  12.9  
- 40⁰C  1183  6.99  7.6  6.1  6.9  
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3.6  ROTEM Thromboelastometry In-Vitro Results  
The laboratory assessment of the ROTEM analyser is presented below. 
3.6.1 Initial laboratory assessment of the ROTEM 
The EXTEM and FIBTEM tests available on the ROTEM® analyser underwent limited assessment 
within the expired concentrates stage of the study. Initial qualitative results for two of the expired 
platelet concentrates suggested a detectable difference with increasing age as shown in Figure 3.24. 
Day 6 
                    
EXTEM     FIBTEM 
                     
Day 11 
Figure 3.24: ROTEM® results for expired platelet concentrate 103 on days 6 (top) and 11 (bottom). 
The images are graphic representations of the clot firmness over time. The EXTEM test 
results are shown on the left and the FIBTEM results are shown on the right.  
Following this initial investigation, it was decided that future testing should use platelet concentrate 
samples diluted in fresh frozen plasma (FFP) to avoid exceeding the ROTEM®s upper limit of 
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batch of FFP, prepared from a pool of four units, was separated into multiple aliquots that were 
defrosted and used to dilute platelet samples when required.  The platelet concentrates were diluted 
to give a platelet count of 300 x 109 / L (± 10%) and gave qualitatively similar results. See Figure 3.25. 
Day 6 
                         
 
EXTEM     FIBTEM 
                                       
Day 12 
Figure 3.25: ROTEM® results for expired platelet concentrate 104 on days 6 (top) and 11 (bottom). 
The images are graphic representations of the clot firmness over time. The EXTEM test 
results are shown on the left and the FIBTEM results are shown on the right.  
The five expired platelet concentrates tested on dilution during the method development stage of 
the project were found to show reduced clot strength with increasing age. The results are shown in 
Table 3.14. Of note, the platelet concentrate specimens stored at 37°C and -40°C (discussed above in 
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Table 3.14: ROTEM® G value results obtained using the EXTEM and FIBTEM tests for five expired 










EXTEM – FIBTEM G 
(Dyne/cm2) 
104 Day 6 9209 1746 7463 
 Day 9 2746 1109 1637 
  Day 12 2250 1085 1165 
 Day 15 818 763 55 
  37°C 657 705 -48 
  -40°C 1323 1611 -288 
105 Day 6 7324 1059 6265 
 Day 9 1039 1093 -54 
  Day 12 2336 1176 1160 
 Day 15 1125 1153 -28 
  37°C 809 704 105 
  -40°C 1517 1270 247 
106 Day 7 6009 1579 4430 
 Day 10 3404 1757 1647 
  Day 13 3987 1353 2634 
107 Day 9 4619 1510 3109 
  Day 12 1644 1541 103 
108 Day 7 3328 1757 1571 
 Day 10 4264 1430 2834 
  Day 11 3336 1409 1927 
 
These results suggested that the ROTEM® could detect deterioration of platelet function with 
age. A paired, uni-directional T-test was performed to see whether deterioration was evident 
between the first and last day that expired platelet concentrates were tested. Significant 
differences were found between six to nine day old concentrates and twelve to fifteen day old 
concentrates in terms of their EXTEM (P = 0.02) and EXTEM – FIBTEM (P = 0.02) results. To 
compensate for activity differences due to slight variations in dilution platelet counts, it was 
decided that future results could also be expressed as (EXTEM G – FIBTEM G) / platelet. 
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3.6.2 ROTEM ageing platelet concentrate results 
The ROTEM results for all ten concentrates are shown alongside the pH, ESC, HSR and 
ThromboLUX results in Figures 3.13 – 3.22 that are presented above in section 3.5. They are also 
shown for all ten concentrates in Figure 3.26 below. For the most part, a general trend of 
deterioration over time is observed. However, there is a clear split in results: concentrates PC1 to 
PC3 gave much lower results at all time-points than concentrates PC5-PC10. Concentrate PC4 
initially gave low results but increased dramatically to give high results from day 9 onwards. The 
batch of EXTEM reagent was changed on day 9 of testing PC4 and the new batch continued to be 




Figure 3.26: ROTEM results for fresh platelet concentrates PC1-PC10. 
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The ROTEM® was able to detect storage at extreme temperatures with a high degree of 
sensitivity compared to an appropriately stored control sample. Samples of Platelet Concentrate 
1 were stored at 22°C (appropriately stored control), 37°C, 50°C and -40°C (inappropriate storage 
temperatures known to damage platelet quality). The results for all samples are shown in Table 
3.15. 
 
Table 3.15: ROTEM® results for platelet concentrate samples stored at various temperatures. 
G/PLT is the EXTEM G – FIBTEM G per platelet in the test sample. 
Storage Temperature EXTEM G FIBTEM G EXTEM-FIBTEM G G/PLT 
22⁰C 5,184 1,398 3,786 12.9 
50⁰C 1,544 1,072 472 4.2 
37⁰C 1,504 1,416 88 0.3 
-40⁰C 1,837 2,043 -206 -0.8 
 
3.7  AWE Test In-Vitro Results  
The laboratory assessment of the AWE test is presented below. 
3.7.1 Initial laboratory assessment of the AWE test 
In vitro assessment of the new AWE test, developed on the Sysmex CA 5100 automated 
coagulometer as part of this project, was carried out using three PRP samples taken for the 
purpose of method development, four fresh platelet concentrates purchased as part of the 
ageing platelet concentrates section of this study and six platelet concentrate samples that were 
included in the clinical trial (see chapter 4). PC7, PC8, PC9 and PC10 from the Ageing Platelet 
Concentrate section of the study were tested using the AWE test over a period of 16 days. See 
Figures 3.27 and 3.28. The tests carried out during this phase of the study were performed using 
the VAR and FIX test settings without stir-bars. 
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Figure 3.27: VAR measurement setting AWE test results for platelet concentrates PC7, PC8, PC9 
and PC10 from the in vitro stage of the study 
 
Figure 3.28: FIX measurement setting AWE test results for platelet concentrates PC7, PC8, PC9 
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These initial results suggested that the AWE test results may fall with increasing platelet 
concentrate age and deteriorating platelet function. It was decided that further validation of the 
method was indicated. 
The first platelet concentrate included in the clinical stage of the study was tested ten times for 
each of the four AWE test settings, using both neat and diluted samples, on the day of 
transfusion and again after storage in the laboratory for five days. The average results, standard 
deviation (SD) and CV for each parameter is shown in Table 3.16. 
Table 3.16: Average, SD and CV values for PC 001. All four measurement settings were applied to 
neat specimens and diluted specimens that were tested ten times each on two 
separate occasions. 
Sample Day Measure VAR FIX VSB FSB 
PC 001 Neat 11/09/2015 Average 0.13964 0.08295 0.12367 0.07079 
  SD 0.01490 0.00764 0.00549 0.00168 
  CV (%) 10.671 9.211 4.436 2.372 
 16/09/2015 Average 0.02306 0.02334 0.02437 0.02398 
  SD 0.00163 0.00106 0.00113 0.00064 
  CV (%) 7.051 4.540 4.648 2.680 
PC 001 Diluted 11/09/2015 Average 0.03644 0.02346 0.02721 0.01677 
  SD 0.00917 0.00253 0.00455 0.00149 
  CV (%) 25.152 10.782 16.710 8.853 
 16/09/2015 Average 0.00489 0.00697 0.00647 0.00750 
  SD 0.00044 0.00090 0.00136 0.00097 
  CV (%) 8.914 12.958 21.087 12.875 
 
 
The CV obtained for each test set range from 0.024 (FSB measurement settings for the neat 
sample tested on the day of transfusion) to 0.252 (VAR measurement settings for the diluted 
sample tested on the day of transfusion). With only one exception (PC 001 diluted sample, VAR 
test settings), the tests that used stir-bars showed better precision than the tests that did not. 
The tests that used fixed settings were always more precise than the ones that used variable 
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settings. Although some of the CV measurements show poor precision by traditional laboratory 
standards, they are not unusual for platelet tests, which are notoriously difficult to standardise. 
The ranges of the results obtained are also shown in a visual format in Figures 3.29 to 3.33. 
 
 
Figure 3.29: Graphical representation of all AWE VAR settings results (top left), FIX settings 
results (top right), VSB results (bottom left) and FSB results (bottom right) obtained 
for the PRP samples tested. Blue diamonds show Fresh PRP results, green triangles 
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Figure 3.30: VAR results obtained for all of the PC samples tested. Aged sample results are shown 
at positions of 1.5, 3.5 and 5.5 on the X axis for PC 001, 003 and 005. 
 
 
Figure 3.31: FIX results obtained for all of the PC samples tested. Aged sample results are shown 
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Figure 3.32: VSB results obtained for all of the PC samples tested. Aged sample results are shown 
at positions of 1.5, 3.5 and 5.5 on the X axis for PC 001, 003 and 005. 
 
 
Figure 3.33: FSB results obtained for all of the PC samples tested. Aged sample results are shown 
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All three PRP samples and four of the PC samples were tested at more than one time point. 
Between testing, the specimens were stored in a capped container in the laboratory without any 
agitation – conditions that are not considered compatible with maintenance of platelet viability. 
The three PRP samples showed clear deterioration between the two tests. See Figures 3.34 to 
3.36. 
 
Figure 3.34: Change in AWE results for PRP sample 1 
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Figure 3.36: Change in AWE results for PRP sample 3 
PC 001 also showed clear deterioration (see Figure 3.37). 
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Every test performed on PC 002 on the second test date gave a ‘No Polynomial Adjustment’ 
(NPA) error. This error is reported by the analyser when there is no detectable change in the OD 
during the measurement period. The NPA errors observed for platelet concentrate or PRP 
samples most likely occur because the platelets in the sample have deteriorated to the extent 
that they are no longer able to undergo measurable recovery from water uptake during the test. 
PC 003 showed deterioration by all of the settings that did not use stir-bars (see Figure 3.38). The 
diluted stir-bar test results did not deteriorate but the second testing time point was only one 
day after the day of transfusion and this may not have been sufficient time for the platelet 
function in the sample to deteriorate sufficiently for detection. 
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Only diluted test results were available at a second time-point for concentrate 005. As for 
concentrate 003, deterioration was more clearly evident using the non-stir-bar settings. See 
Figure 3.39. 
 
Figure 3.39: Change in diluted sample AWE results for PC 005 
There was no obvious relationship between concentrate age and the level of AWE test results. 
See Figures 3.40 and 3.41. 
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Figure 3.41: Platelet concentrate age against diluted sample test results 
A series of tests were carried out on PC 003 to determine whether the platelets in the specimens 
were settling out in the sample tubes prior to or during analysis. Samples were mixed and 
aliquotted into tubes ready for testing. The first set of samples was loaded onto the machine for 
testing at time 0 but the other sets were retained. Subsequent sets were analysed (without 
further mixing) at 6, 12, 18, 24, 60 and 120 minutes. The results are shown in Figures 3.42 – 3.45. 
There does not appear to be any appreciable settling effect, with the possible exception of the 
diluted samples tested at 60 and 120 minutes. In practice, this means that short delays in testing 
while the specimens are waiting for sampling on the analyser are unlikely to have a significant 
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Figure 3.42: Sample settling experiments for neat samples tested at 0, 6, 12, 18 and 24 minutes 
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Figure 3.44: Sample settling experiments for diluted samples tested at 0, 6, 12, 18 and 24 minutes 
 
 
Figure 3.45: Sample settling experiments for diluted samples tested at 0, 60 and 120 minutes 
 
In traditional HSR tests, the platelets response to water that is added to the test sample is 
blanked against a control test that uses isotonic OBS instead of water. This allows the results to 
be standardised to compensate for differences in the starting OD of the concentrates under 
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water expulsion response and ensure that the observed OD change is not due purely to a 
dilutional effect, a buffer control test was run alongside the PC 002 water tests. See Table 3.17. 
Table 3.17: Owren’s buffer experiment results for PC 002. The neat (N1, N2) and diluted (D1, D2) 
samples were tested using both water and buffer. The calculated results obtained by 
subtracting the buffer test results from the water test results are also shown. 
Test VAR FIX VSB FSB 
N1 0.12560 0.09287 0.09972 0.07148 
N2 0.14185 0.08728 0.10426 0.07475 
Buffer N1 0.01856 0.01854 NPA NPA 
Buffer N2 NPA 0.02599 NPA 0.00121 
N1 - Buffer 0.10704 0.07433 0.09972 0.07148 
N2 - Buffer 0.14185 0.06129 0.10426 0.07354 
D1 0.00800 0.01450 0.00470 0.00000 
D2 0.01180 0.01540 0.00343 0.00000 
Buffer D1 0.00260 NPA NPA NPA 
Buffer D2 NPA NPA 0.00670 NPA 
D1 - Buffer 0.00540 0.01450 0.00470 0.00000 
D2 - Buffer 0.01180 0.01540 -0.00327 0.00000 
 
More than half of the tests gave NPA errors as the OD changes in the Owren’s buffer tests were 
undetectable or negative. Those numerical results that were generated were so low that the 
effect of adjustment was negligible. The additional measurement did not increase the apparent 
precision of the results. It was suspected that the very slight OD changes that were detected in 
the AWE control tests represented the natural variation of OD in the sample, rather than any 
specific response or dilution effect. It was decided that the ‘control’ aspect of the test added no 
value and was a waste of resources so it was dropped from the study. 
3.7.2 AWE Test ageing platelet concentrate results 
The AWE test results for the final four patients were discussed in the test development section of 
the study (3.4.4) but are shown again here for convenience. See Figures 3.46 and 3.47. There are 
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only a limited number of results available but they did appear to show deterioration over time so 
the method was taken forward for further evaluation in the clinical phase of the study. 
 
Figure 3.46: VAR setting AWE Test results for PC7 to PC10 
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3.8  In Vitro Results Discussion 
In this initial stage of the study, significant differences were observed between pooled and 
apheresis platelet concentrates in terms of platelet count and total platelet dose. Some 
differences were also found between the way the two groups of concentrates deteriorated with 
age, which would be consistent with the observations of Paglia et al (2014, 2015) that apheresis 
and pooled platelet concentrates deteriorate in different ways. 
The HSR, ESC, pH and swirl control tests were set up and observed to be working satisfactorily. All 
showed the expected deterioration of results over time for the ten fresh platelet concentrates 
tested. The ESC and HSR tests both gave abnormal results after the platelet concentrate quality 
was artificially reduced in the laboratory. Unfortunately, the expertise to use the technically 
challenging Kunicki scoring method with confidence was not available and attempts to source a 
suitable image capture system within the budget of the study were not successful. Although 
disappointing, this test was not felt to be critical to the success of the project due to availability 
of the alternative control methods listed above. 
Three of the fresh platelet concentrates purchased from the NHSBT (PC2, PC3 and PC6) lost their 
capacity to ‘swirl’ before the end of day seven and were, presumably, of poor quality after this. 
The results given for these concentrates by the other reference tests were amongst the lowest 
observed but did not in any case stand out as obvious outliers. They were evenly spread across 
the range of results obtained using the ThromboLUX and ROTEM analysers. 
The two experimental methods originally identified for investigation, the iZON and the 
ThromboLUX, both failed to perform as expected. The iZON had not previously been used to 
analyse platelets or platelet concentrate derived specimens. The results it generated were poorly 
reproducible and difficult to process. As this method was in the relatively early stages of 
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development and solutions to these problems were not within the scope of the study, this line of 
investigation was not pursued. 
The ThromboLUX method was at a later stage of development, having undergone initial 
assessment for use with platelet concentrate samples by its inventor (Maurer-Spurej et al, 2006; 
Maurer-Spurej et al, 2007; Maurer-Spurej et al, 2009; Xu et al, 2010). The method was simple to 
use and the results easy to interpret. However, the results generated were not as expected and 
differed from those obtained by the developers in Canada. LightIntegra were confident that only 
a few minor adjustments were needed to make it ready for clinical application so it was decided 
to continue assessing the ThromboLUX in the subsequent stages of the study. 
Studies were carried out to try and understand why the ThromboLUX results generated for this 
study in Oxford did not show any deterioration as platelet concentrates aged. This pattern of 
results had not previously been reported by the development team in Canada. By sharing 
samples with other beta evaluation sites elsewhere in the UK, in Europe and in Vancouver it was 
established that the problem affects multiple analysers. The insensitivity was not restricted to 
platelet concentrates produced in one particular country. This argued against subtle 
manufacturing differences between concentrates produced in Canada and elsewhere that may 
also affect the ThromboLUX quality score. It was determined, therefore, that the source of the 
problem most likely stemmed from technical factors related to the methodology or manufacture 
of the analyser. 
Although the tests performed to compare ThromboLUX results across multiple sites were very 
useful and enabled progress with development of this test, they could have been improved by 
wider application of appropriate control testing. In all but one case, no alternative tests for 
assessing the true quality state of the platelets under investigation were carried out. However, 
the platelets obtained from Colindale in September 2011 were tested by a variety of other 
methods including HSR, ESC and ROTEM analysis of platelet G value. Although none of these 
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methods is established as a reliable indicator of platelet quality in isolation, the consensus of 
these tests, in contrast to the ThromboLUX, suggested a gradual deterioration in platelet 
concentrate quality over time. The only other experiment that included testing by alternative 
methods was that carried out on Vancouver platelet concentrates in October 2011. However, the 
value of the Kunicki scores in this case is limited by the fact that they were not performed prior to 
10 days after collection of the platelet concentrates. 
LightIntegra initially advised ThromboLUX users that there was a single, centrally defined ‘quality 
cut off value’. This value was sometimes changed with analyser or software modifications but 
was still assumed to be the same for all instruments. After the sample exchange experiments 
performed as part of this study made it clear that quite different results were obtained at 
different sites, LightIntegra decided that an individual, locally defined cut-off value should be 
established for each instrument/ location combination. 
Although the issues regarding sensitivity to poor quality concentrates was not entirely resolved, the 
instrument upgrade prior to testing the Brentwood concentrates appeared to have led to an 
increased frequency of low scores at Oxford and the range of scores observed seemed to have 
widened. It was hoped that this possible improvement would be carried forward into the ageing 
platelet concentrates phase of the study but unfortunately this did not turn out to be the case. 
Although some concentrates showed marginal deterioration of results over the period of testing, 
others did not and low scores were not consistently observed following artificial induction of poor 
quality in the laboratory. Results remained higher than those originally reported by the inventor. Due 
to numerous and regular changes to the analytical system and the data analysis methods by 
LightIntegra, it was not possible to obtain enough data generated under one single, consistent set of 
conditions, to attempt to determine a poor quality ‘cut off’ score with any confidence. 
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Initial assessment of the ROTEM method appeared promising. The method was sensitive to 
inappropriate sample storage and results deteriorated as the platelet concentrates aged. Although 
the sensitivity of the method to subtle changes in platelet concentrate quality was uncertain, the 
instrument’s ability to detect gross quality impairment induced in the laboratory was encouraging. 
Due to its ease of use and the existing availability of the analysis equipment in many clinical 
environments it fulfilled the study criteria for an inexpensive and easily applicable test method 
especially well. However, the inter-batch variability of the ROTEM may limit its useful application. It 
would be desirable to source a single batch of each reagent in great enough quantities to carry out 
any further evaluation.  
The AWE test also utilised equipment that would already be available in a number of laboratories 
and fulfilled the ease of use requirements of the study. Furthermore, as an adaptation of an 
existing reference method that is known to give results that correlate with clinical efficacy of 
transfusion, it is likely that the AWE test results would reflect transfusion outcome too.  The 
technical performance of this assay was deemed to be acceptable and it was found to be 
sensitive to laboratory induced poor quality. The results generally decreased as PRP or platelet 
concentrate samples underwent storage in the laboratory, eventually reaching levels that 
indicated complete depletion of platelet activity in many cases. This method would undoubtedly 
benefit from further technical development, some of which would require greater input from 
Sysmex, but it appeared to show considerable promise. 
 
3.9  In Vitro Results Summary 
 Reference tests, including platelet count, MPV, HSR, ESC were set up using out of date 
platelet concentrates 
 Ten fresh platelet concentrates were purchased from the NHSBT and tested over 16 days 
using the following methods: swirl, pH, HSR, ESC, ROTEM and ThromboLUX. 
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 Four of the fresh platelet concentrates were also tested over 16 days using the AWE Test 
- an automated HSR-like method performed on a Sysmex coagulometer 
 Swirl was apparent in the fresh platelet concentrates for between four and 15 days 
 pH reduced from more than 7 to less than 6.5 for each concentrate over the period of 
testing 
 The pH results were intermediate low for the 37⁰C and 50⁰C samples but relatively high 
for the -40⁰C sample taken from fresh Platelet Concentrate 1 
 HSR reduced from between 35% and 55% to less than 15% for each concentrate over the 
period of testing. However, some concentrates showed ‘spikes’ in the pattern of results 
over time, rather than a consistent deterioration 
 ESC reduced from between 18% and 30% to less than 10% for each concentrate over the 
period of testing. However, some concentrates showed ‘spikes’ in the pattern of results 
over time, rather than a consistent deterioration 
 The iZON impedance analyser was used to generate platelet distribution curves for out of 
date platelet concentrates that indicated the presence of increasing numbers of small 
particles as the concentrates aged but reproducibility was poor 
 iZON charge measurements were found to be unsuitable for this study 
 The between batch CV of the TL 1 analyser was found to be 11.3% 
 The within batch CV of the TL 1 analyser was found to be 8.2, 18.8 and 12.6% on three 
different occasions 
 The ThromboLUX analyser was subsequently replaced with a  different instrument for 
further evaluation (TL 2 2) 
 TL 2 gave a between batch CV of 10.1 
 Instrument 2 was sensitive to quality deterioration caused by storage at -40⁰C but not to 
quality deterioration caused by storage at 37⁰C or platelet concentrate age 
 25 out of date platelet concentrates tested on TL 1 and TL 2 all gave ThromboLUX scores 
associated with acceptable quality up to 15 days after collection 
 Platelet concentrates from the UK, Holland and Canada were tested at Oxford and at 
other ThromboLUX evaluation sites in an attempt to determine why all results were high 
 The ThromboLUX sensitivity to concentrate age and platelet storage temperature were 
poor and varied significantly between analysers at different sites 
 The ThromboLUX results did not change dramatically over the period of testing for any of 
the fresh platelet concentrates purchased from the NHSBT 
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 The ThromboLUX gave low (<14) scores for the Platelet Concentrate 1 samples stored at -
40⁰C and 50⁰C and a borderline (16.1) score for a sample stored at 37⁰C 
 Platelet G measured by the ROTEM decreased with platelet concentrate age and 
appeared sensitive to quality deterioration caused by storage at -40⁰C and 37⁰C 
 For most of the fresh concentrates purchased from the NHSBT, the ROTEM results 
decreased fairly steadily over time. However, there appeared to be a shift in the level of 
results between testing of PC3 and testing of PC5 that corresponded to an EXTEM 
reagent batch change. 
 The AWE test was set up on the Sysmex CA5100 coagulometer and validated using PRP 
and platelet concentrate samples 
 AWE test results appeared to drop with advanced platelet concentrate age 
 The reproducibility of AWE test results was acceptable when compared to other platelet 
tests 
 The AWE test was sensitive to deterioration of platelet quality induced by inappropriate 
in vitro storage conditions, specifically lack of agitation or oxygen exchange 
 There was no obvious relationship between AWE test results and platelet concentrate 
age in the non-expired residual platelet concentrate samples tested in the clinical study 
 There was no appreciable effect of sample settling during the test process over a period 
of at least 24 minutes 
 There was no obvious benefit to running a buffer control with each test using the current 
test settings 
 Although the four fresh platelet concentrates tested using the AWE test showed some 
‘spikes’ in the pattern of results over time, all demonstrated definite deterioration by the 
end of testing 
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4 CLINICAL TRIAL 
 
4.1  Clinical Trial Introduction 
Full ethical approval was granted in April 2015 for the following study: 
 
Study title:  The evaluation of novel platelet concentrate quality tests and their 
ability to predict response to platelet transfusion  
REC reference:  15/SC/0155  
IRAS project ID:  131997  
 
This pilot study aimed to demonstrate a method of investigating the predictive value of the 
selected in vitro quality assessment techniques by comparing the results they generated for 
individual platelet concentrates to efficacy of transfusion. Both clinical bleeding assessments 
(taken via self-assessment questionnaire) and platelet count increments (calculated from pre and 
post-transfusion platelet counts) were used to estimate clinical efficacy. The group invited to 
participate in the study consisted of MDS patients attending the Haematology Day Unit of OUH 
Trust. This group was chosen because they represented a relatively stable patient population in 
terms of their clinical condition. 
 
4.2  Clinical Trial Methods 
The following tests were carried out as part of the clinical study: 
Participants Pre and Post-transfusion Samples 
 Automated platelet count and size measurements 
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Residual Platelet Concentrate Samples 
 Automated platelet count and size measurements 




 AWE test 
 ThromboLUX testing 
 ROTEM analysis 
For each study participant, pre and post-transfusion platelet counts were carried out on a Sysmex 
XN10 analyser using both impedance and fluorescent methods. The residual platelet concentrate 
sample was also tested using the XN10 FBC analyser. The platelet counts obtained for both the 
patient samples and the platelet concentrate were used to calculate CCI using the standard 
formula shown below, as recently described by Tobian et al (2015). 
                    (PLT count post – PLT count pre) × 1011 × body surface area (m2 ) 
  CCI =         --------------------------------------------------------------------------------------- 
                                            Number of platelets transfused x 1011 
The body surface area (BSA) was calculated using the Du Bois formula (Du Bois et al, 1916): 
BSA = 0.007184 x W0.425 x H0.725 
All platelet concentrate sample dilutions were prepared using CryocheckTM pooled normal plasma 
(Precision BioLogic, Canada). Each platelet concentrate sample was diluted to give a platelet 
count of 300 x 103 / µL ± 10% in order to standardise them and compensate for differences in the 
test results that were entirely due to variation in platelet concentration within the test sample. 
Diluted samples were used to perform the ESC, HSR, ROTEM and AWE tests. 
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4.3  Clinical Trial Progress and Individual Participant Results 
A retrospective power calculation using the data produced by Maurer-Spurej et al (2009) 
indicated that 71 transfusion episodes were required to identify a correlation of 0.6 between 
platelet count increments and the ThromboLUX results with 80% power at a 5% significance level.  
This was not felt to be achievable with the resources available to this study and the initial 
recruitment target was transfusion episodes, with the hope that additional staff-time and 
resources would become available to continue expanding recruitment in the future. 
It rapidly became clear that recruitment would be problematic under the original conditions. One 
of the exclusion criteria for the study was ‘receipt of a previous platelet transfusion within the 
past 7 days’. Many MDS patients attending OUH Trust for platelet support were receiving twice 
weekly platelet transfusions, making them ineligible for the study. It was felt that this group could 
still provide relevant data for the study and that the measures of platelet efficacy would not be 
unduly compromised by any platelets that remained in the circulation from earlier transfusions 
so an amendment to the study protocol was prepared and submitted to IRAS for ethical approval 
in October 2015. At this point, approval was granted to change the previous platelet transfusion 
exclusion criteria to ‘receipt of a previous platelet transfusion within the past 48 hours’. 
Two patients were recruited to the study at around this time. Participant 001 unfortunately 
suffered a suspected transfusion reaction, causing his platelet transfusion to be cut short and 
preventing completion of his transfusion efficacy assessment. It was, however, possible to 
retrieve the remains of his platelet concentrate and undertake testing on it as originally planned. 
All tests were carried out according to the study protocol for participant 002. 
4.3.1 Transfusion episode 001 
Patient 001 was a 79 year old male, attending the haematology day unit for weekly platelet 
transfusions to treat bleeding, secondary to MDS. His blood group was O+ and the group of the 
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platelet concentrate he received was A+. The platelet concentrate was collected using apheresis, 
had a volume of 179mL and was 4 days old at the time of transfusion. He weighed 81kg at the 
time of his visit and was 187cm tall. The available results for participant 001 are shown in Tables 
4.1, 4.2, 4.3, 4.5 and Figure 4.1. 
Table 4.1: Reference method test results for study transfusion episode 001 
FBC PLT F PLT I PDW MPV P-LCR 
Pre Tx 17 17 13.4 11.4 34.6 
Post Tx ------------------------------No Result Available------------------------------ 
PLT count increase ------------------------------No Result Available------------------------------ 
PC 1649 1290 8.4 8.8 14.7 
Swirl Pos     
pH 7.74     
ESC (%) ESC ESC 2 ESC Mean   
 12.5 No Result Available    
HSR (%) HSR HSR 2 HSR Mean   
 30.1 35.3 32.7   
 
It was not possible to determine the increase in platelet count for participant 001 as no post-
transfusion platelet count was performed and it was not possible to determine, exactly, what 
volume of his platelet concentrate was transfusion before the transfusion was stopped. 
Table 4.2: AWE test results for study transfusion episode 001 
Test Settings Test 1 Test 2 Mean 
Neat VAR 0.1323 0.1484 0.1404 
Neat FIX 0.0755 0.0951 0.0853 
Neat VSB 0.1176 0.1186 0.1181 
Neat FSB 0.0738 0.0693 0.0716 
Diluted VAR 0.0353 0.0264 0.0309 
Diluted FIX 0.0202 0.0233 0.0218 
Diluted VSB 0.0261 0.0211 0.0236 
Diluted FSB 0.0150 0.0164 0.0157 
 
The results of tests that used stir-bars (neat VSB, neat FSB, diluted VSB and diluted FSB) were 
slightly lower than the results of tests that did not use stir-bars (neat VAR, neat FIX, diluted VAR, 
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diluted FIX). The results of tests carried out on diluted samples (diluted VAR, diluted FIX, diluted 
VSB and diluted FSB) are all lower that the results of tests carried out on neat samples (neat VAR, 
neat FIX, neat VSB and neat FSB). The results of tests carried out using the 80 second fixed time 
measurements (neat FIX, neat FSB, diluted FIX and diluted FSB) were all lower that the tests 
carried out using the 15 second variable time measurement settings (neat VAR, neat VSB, diluted 
VAR and diluted VSB). 
Table 4.3: ROTEM results for study transfusion episode 001 
ROTEM EXTEM G FIBTEM G EXTEM-FIBTEM G G/PLT 
Diluted: 6340 2074 4266 15 
 
Participant 001’s ROTEM tests were only carried out on a diluted sample. The results fell within 
the expected range for non-expired (<7 days old) concentrates as determined by observation of 
aging platelet concentrates during the previous in vitro stage of the study. See Table 4.4. 
Table 4.4: Minimum and maximum ROTEM results obtained for non-expired (<7 day old) 
platelet concentrates during in vitro stages of the study 
Max EXTEM 18,415 Max FIBTEM 3107 Max E-F G 16,344 Max G/PLT 55 
Min EXTEM 3,817 Min FIBTEM 1,398 Min E-F G 2,405 Min G/PLT 10 
 
The results obtained from the ThromboLUX instrument for participant 001 are shown in Table 4.5 
and in graphical form in Figure 4.1. When the score calculation was applied to the duplicate test 
runs, both gave the same score of 18.9. However, as the graphs show, the particle size 
distributions obtained at the three test temperatures varied somewhat between runs. The 
proportion of light intensity from the MV fraction over the average distribution was 18%. 
Table 4.5 Duplicate and mean ThromboLUX results for study transfusion episode 001 
TL (1) TL (2) TL Mean MV (1) % MV (2) % MV Mean Beads (1) Beads (2) Beads Mean 
18.9 18.9 18.9 19 16 17.5 4.8 No Result 4.8 
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Figure 4.1: Duplicate ThromboLUX results for study transfusion episode 001. Platelet and MV size distributions are shown as measured first at 37⁰C 
(top), then at 20⁰C (upper middle) and finally at 37⁰C (lower middle). The average distribution is shown at the bottom.
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4.3.2 Transfusion episode 002 
Patient 002 was a 69 year old female, attending the haematology day unit for bi-weekly platelet 
transfusions to treat bleeding, secondary to MDS. Her blood group was O+ and the group of the 
platelet concentrate she received was O+. The platelet concentrate was collected using 
apheresis, had a volume of 197mL and was 4 days old at the time of transfusion. She weighed 
79kg at the time of her visit and was 157cm tall. Participant 002’s results are shown in Tables 4.6, 
4.7, 4.8, 4.9 and Figure 4.2. 
Table 4.6: Reference method test results for study transfusion episode 002 
FBC PLT F PLT I PDW MPV P-LCR 
Pre Tx 3 2 ------------No Result Available------------ 
Post Tx 27 26 11.3 11.7 36.5 
PLT count increase 24 24    
PC 1578 1377 10 10.1 24.2 
Swirl Pos     
pH 7.40     
ESC (%) ESC ESC 2 ESC Mean   
 13.0 14.3 13.65   
HSR (%) HSR HSR 2 HSR Mean   
 10.6 16.6 13.6   
 
Table 4.7: AWE test results for study transfusion episode 002 
Test Settings 1 2 Mean 
Neat VAR 0.1256 0.1419 0.1337 
Neat FIX 0.0929 0.0873 0.0901 
Neat VSB 0.0997 0.1043 0.1020 
Neat FSB 0.0715 0.0748 0.0731 
Diluted VAR 0.0080 0.0118 0.0099 
Diluted FIX 0.0145 0.0154 0.0150 
Diluted VSB 0.0047 0.0034 0.0041 
Diluted FSB No Result Available  No Result Available No Result Available 
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Again, the stir-bar test results were lower than the non-stir-bar results and the diluted test results 
were lower than the neat test results. On this occasion however, the diluted FIX result was higher 
than the diluted VAR result and no diluted FSB result was available. 
Table 4.8: ROTEM results for study transfusion episode 002 
ROTEM EXTEM G FIBTEM G EXTEM-FIBTEM G G/PLT 
Neat: 18262 7358 10904 7 
Diluted: 6383 2835 3548 13 
 
 
As expected, the ROTEM results obtained from the neat sample were considerably higher than 
those obtained from the diluted sample. However, the G/PLT result was lower. Participant 002’s 
diluted sample results fell within the expected range. 
The ThromboLUX scores obtained for concentrate 002 were 15.9 and 17.5. The duplicate runs 
appear more consistent in terms of size distribution patterns than those obtained for participant 
001. The proportion of light intensity from the MV fraction over the average distribution was 7%. 
 Table 4.9: Duplicate and mean ThromboLUX results for study transfusion episode 002 
TL (1) TL (2) TL Mean MV (1) % MV (2) % MV Mean Beads (1) Beads (2) Beads Mean 
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Figure 4.2: Duplicate ThromboLUX results for study transfusion episode 002. Platelet and MV size distributions are shown as measured first at 37⁰C 
(top), then at 20⁰C (upper middle) and finally at 37⁰C (lower middle). The average distribution is shown at the bottom. 
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Unfortunately, the study began to experience further recruitment issues after this. The clinical 
contact assisting with identification of potential participants left work temporarily on paternity 
leave and was then unavailable over the Christmas period. After this, his own research 
commitments meant that he was not available to search for potential participants for several 
weeks and there was some delay in communicating this information. A new clinical contact was 
eventually established and recruitment began again with the enrolment of participant 003 in the 
spring of 2016 (see below). An additional patient was also approached but declined to be 
included in the study at this point. 
4.3.3 Transfusion episode 003 
Participant 003 was a 91 year old male, attending the haematology day unit for bi-weekly platelet 
transfusions to treat bleeding, secondary to MDS. His blood group was A+ and the group of the 
platelet concentrate he received was A+. The platelet concentrate was prepared from pooled 
platelets in additive solution and plasma, had a volume of 305mL and was 7 days old at the time 
of transfusion. He weighed 72kg at the time of his visit and was 173cm tall. His results are shown 
in Tables 4.10, 4.11, 4.12, 4.13 and Figures 4.3 and 4.4. 
 
Table 4.10: Reference method test results for study transfusion episode 003 
FBC PLT F PLT I PDW MPV P-LCR 
Pre Tx 2 6 ------------No Result Available------------ 
Post Tx 39 65 ------------No Result Available------------ 
PLT count increase 37 59    
PC 1093 845  No Result Available 9.6  No Result Available 
Swirl Pos     
pH 7.24     
ESC (%) ESC ESC 2 ESC Mean   
 13 14.3 13.65   
HSR (%) HSR HSR 2 HSR Mean   
 10.6 16.7 13.7   
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Table 4.11: AWE test results for study transfusion episode 003 
Test Settings 1 2 Mean 
Neat VAR 0.0962 0.1188 0.1075 
Neat FIX 0.0639 0.0575 0.0607 
Neat VSB 0.0802 0.0859 0.0831 
Neat FSB 0.0476 0.0529 0.0503 
Diluted VAR 0.0194 0.0238 0.0216 
Diluted FIX 0.0177 0.0176 0.0177 
Diluted VSB 0.01174 0.01558 0.0137 
Diluted FSB 0.0097 0.00871 0.0092 
 
The pattern of AWE test results obtained for the different test settings for participant 003 
matches that of participant 001. 
 
Table 4.12: ROTEM results for study transfusion episode 003 
ROTEM EXTEM G FIBTEM G EXTEM-FIBTEM G G/PLT 
Neat: 2279 539 1740 2 
Diluted: 3170 1365 1805 6 
 
 
Participant 003’s neat sample ROTEM results were unexpectedly lower than the diluted sample 
results. In addition, the EXTEM response graph for the neat samples showed clot retraction, as 
evidenced by the sudden decrease in observed MCF (see Figure 4.3). Clot retraction can be 
distinguished from fibrinolysis, which would result in a more gradual tailing off of MCF (Bontekoe 
et al, 2014). The diluted sample results were lower than any observed for non-expired 
concentrates during the in vitro stages of the study. 
 
- 132 - 
  
Figure 4.3: Normal EXTEM response graph (left) and EXTEM response graph for participant 003 
showing clot retraction (right) 
 
The scores generated from them were 19.1 and 13.2. Again, the particle size distribution graphs 
differ considerably in appearance between the two runs. The proportion of light intensity from 
the MV fraction over the average distribution was 7%. 
 
Table 4.13: Duplicate and mean ThromboLUX results for study transfusion episode 003 
TL (1) TL (2) TL Mean MV (1) % MV (2) % MV Mean Beads (1) Beads (2) Beads Mean 
19.1 13.2 16.2 8 5 6.5 4.9 5.8 5.4 
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Figure 4.4: Duplicate ThromboLUX results for study transfusion episode 003. Platelet and MV size distributions are shown as measured first at 37⁰C 
(top), then at 20⁰C (upper middle) and finally at 37⁰C (lower middle). The average distribution is shown at the bottom. 
 
 
4.3.4 Transfusion episode 004 
Patient 004 was a 68 year old female, receiving weekly platelet concentrate transfusions as part 
of her MDS therapy at her local district general hospital. On the day that she participated in this 
study she had come to the referral centre at OUH NHS Trust for her regular weekly platelet 
transfusion prior to bone marrow biopsy. Her blood group was O-, as was the group of the 
platelet concentrate she received. The platelet concentrate was collected using apheresis, had a 
volume of 207mL and was 5 days old at the time of transfusion. She weighed 66kg at the time of 
her visit and was 161cm tall. Her results are shown in Tables 4.14, 4.15, 4.16, 4.17 and Figure 4.5. 
Table 4.14: Reference method test results for study transfusion episode 004 
FBC PLT F PLT I PDW MPV P-LCR 
Pre Tx 16  18 ------------No Result Available------------ 
Post Tx 53 57  10.0  10.1  24.7  
PLT count increase  39    
PC 1471 1113 7.6  8.6 13 
Swirl Pos     
pH 7.54     
ESC (%) ESC ESC 2 ESC Mean   
 13.0 14.9 14.1   
HSR (%) HSR HSR 2 HSR Mean   
 24.1 34.7 29.4   
 
Table 4.15: AWE test results for study transfusion episode 004 
Test Settings 1 2 Mean 
Neat VAR 0.2013 0.242 0.2217 
Neat FIX 0.0795 0.0988 0.0892 
Neat VSB 0.1868 0.1859 0.1864 
Neat FSB 0.0821 0.0836 0.0829 
Diluted VAR 0.0348 0.0272 0.0310 
Diluted FIX 0.0181 0.0197 0.0189 
Diluted VSB 0.02064 0.022 0.0213 
Diluted FSB 0.0159 0.0143 0.0151 
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Again, the pattern of AWE test results obtained for the different test settings for participant 004 
matches that of participant 001. 
 
Table 4.16: ROTEM results for study transfusion episode 004 
ROTEM EXTEM G FIBTEM G EXTEM-FIBTEM G G/PLT 
Neat: 28203 2932 25271 17 
Diluted: 10314 1783 8531 28 
 
 
Participant 004’s neat sample ROTEM results were higher than the diluted sample results. All of 
the diluted sample results were within the expected range for non-expired platelet concentrates. 
The results obtained for platelet concentrate 004 are, however, considerably increased compared 
to those observed for concentrates 001 – 003. 
Again, there is some variation between the duplicate particle size distributions measured by the 
ThromboLUX analyser. The calculated scores for the two tests were 20.0 and 16.8. The 
proportion of light intensity from the MV fraction over the average distribution was 17%. 
 
Table 4.17: Duplicate and mean ThromboLUX test results for study transfusion episode 004 
TL (1) TL (2) TL Mean MV (1) % MV (2) % MV Mean Beads (1) Beads (2) Beads Mean 
20.0 16.8 18.4 14 19 16.5 4.5 4.2 4.4 
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Figure 4.5: Duplicate ThromboLUX results for study transfusion episode 004. Platelet and MV size distributions are shown as measured first at 37⁰C 
(top), then at 20⁰C (upper middle) and finally at 37⁰C (lower middle). The average distribution is shown at the bottom.
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Participant 004 was the first study patient to return her bleeding questionnaires. During the time 
she was filling out her self-assessment bleeding questionnaires, she was hospitalised for a high 
temperature at one of the nearby district general hospitals. Prior to receiving the platelet 
transfusion that was included in the study, participant 004 noted a small amount of blood on the 
tissue after blowing her nose but had no other bleeding symptoms. She had no bleeding 
symptoms whatsoever for the two days following her transfusion, suggesting a good response to 
the platelets she received. For the three days following that, she noted increasing amounts of 
blood upon brushing her teeth and blowing her nose before receiving a further platelet 
transfusion at the end of the third day. On the next and final day of assessment she still 
experienced a little bleeding after brushing her teeth and blowing her nose but it was less 
extensive than the previous day. 
4.3.5 Transfusion episode 005 
Platelet concentrates 005 and 006 were both transfused to the same individual who had also 
previously participated in the trial as participant 003. His clinical condition and weight had not 
changed notably since his previous participation in the study. The platelet concentrate transfused 
during study episode 005 was prepared from pooled platelets in additive solution and plasma, 
had a volume of 288mL and was four days old at the time of transfusion. The concentrate and the 
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Table 4.18: Reference method test results for study transfusion episode 005 
FBC PLT F PLT I PDW MPV P-LCR 
Pre Tx  7 7 -------------No Result Available------------- 
Post Tx 40 42 13.4 12.2 40.6 
PLT count increase 33 35    
PC 906 813 11.3 10.5 28.1 
Swirl Pos     
pH 7.54     
ESC ESC ESC 2 ESC Mean   
 5.2 5.7 5.45   
HSR HSR Ratio HSR 2 Ratio 2 HSR Mean 
 25.5 1.7 31.3 1.6 28.4 
 
 
Table 4.19: AWE results for study transfusion episode 005 
Test Settings 1 2 Mean 
Neat VAR 0.0631  No Result Available 0.0631 
Neat FIX 0.0466  No Result Available 0.0466 
Neat VSB 0.0561  No Result Available 0.0561 
Neat FSB 0.0342  No Result Available 0.0342 
Diluted VAR 0.02 0.0202 0.0201 
Diluted FIX 0.0168 0.0145 0.0157 
Diluted VSB 0.0102 0.0041 0.0072 
Diluted FSB 0.00901 0.0084 0.0087 
 
 
As with the previous AWE tests, the stir-bar results were lower than the non stir-bar results, the 
diluted sample results were lower than the neat sample results and the fixed end-point results 
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Table 4.20: ROTEM results for study transfusion episode 005 
ROTEM EXTEM G FIBTEM G EXTEM-FIBTEM G G/PLT 
Neat: ------------------------------No Result Available------------------------------ 
Diluted: 8196 1565 6631 24 
 
 
There was not enough of the residual platelet concentrate to perform neat ROTEM analysis on 
platelet concentrate 005. The results obtained for the diluted sample were at a similar level to 
those observed for concentrate 004 and, again, showed a notable increase from the earlier 
concentrates included in the study. The proportion of light intensity from the MV fraction over 
the average distribution was 22%. 
 
Table 4.21: Duplicate and mean ThromboLUX results for study transfusion episode 005 
TL (1) TL (2) TL Mean MV (1) % MV (2) % MV Mean Beads (1) Beads (2) Beads Mean 
11.7 8.2 10.0 19 24 21.5 4.0 4.2 4.1 
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Figure 4.6: Duplicate ThromboLUX results for study transfusion episode 005. Platelet and MV size distributions are shown as measured first at 37⁰C 
(top), then at 20⁰C (upper middle) and finally at 37⁰C (lower middle). The average distribution is shown at the bottom.
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The particle size distributions are similar for the two test runs. The calculated ThromboLUX scores 
were 11.7 and 8.2. These were the lowest scores observed in the study and fall below any of the 
previously defined cut-off values for ‘poor quality’ concentrates. 
Participant 005 returned a full set of completed self-assessment bleeding questionnaires after 
this transfusion episode. He reported ‘bruised, swollen or painful joints or muscles’, ‘red / purple 
spots (known as petechiae / purpura)’ and ‘one or two bruises, each measuring 2-10cm’ on the 
day he was recruited to the study and these symptoms persisted throughout the monitoring 
period despite administration of the platelet transfusion. Two days after the transfusion he 
reported blurred vision, which then persisted until monitoring stopped on day five. On day two 
the petechiae / purpura also became more widespread before gradually receding to their 
previous level by day five. The patient noted a new appearance of oral blood blisters on day five, 
which were not bleeding or painful at that time. 
4.3.6 Transfusion episode 006 
The results obtained for the final transfusion episode included in the study (006) are shown 
below in Tables 4.22, 4.23, 4.24, 4.25 and Figure 4.7. Concentrate 006 was obtained using 
apheresis and had a volume of 234mL. It was four days old at the time of transfusion and was 
ABO /RhD identical to the recipient (A+). 
Table 4.22: Reference method test results for study transfusion episode 006 
FBC PLT F PLT I PDW MPV P-LCR 
Pre Tx 4 4 ------------No Result Available------------ 
Post Tx 43 45 9.5 10.5 26.3 
PLT count increase 39 41    
PC 1355 1074 7.9 8.6 12 
Swirl Pos     
pH 7.6     
ESC ESC ESC 2 ESC Mean   
 13.9 14.1 14.0   
HSR HSR Ratio HSR 2 Ratio 2 HSR Mean 
 27.3 1.7 26.5 2 26.9 
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Table 4.23: AWE results for study transfusion episode 006 
Test Settings 1 2 Mean 
Neat VAR 0.1526 0.1341 0.1434 
Neat FIX 0.0699 0.0721 0.0710 
Neat VSB 0.1082 0.1125 0.1104 
Neat FSB 0.0737 0.0735 0.0736 
Diluted VAR 0.0255 0.0429 0.0342 
Diluted FIX 0.0257 0.0289 0.0273 
Diluted VSB 0.0225 0.02077 0.0216 
Diluted FSB 0.01317 0.01338 0.0133 
 
Again, the relative pattern of AWE test results obtained using the different test settings was the 
same as for the majority of other concentrates. 
Table 4.24: ROTEM results for study transfusion episode 006 
ROTEM EXTEM G FIBTEM G EXTEM-FIBTEM G G/PLT 
Neat: 28614 2905 25709 85 
Diluted: 9524 1618 7906 26 
 
The pattern of ROTEM results is as expected, with the neat results substantially higher than the 
diluted results and the G/PLT result for the diluted sample at around the same level as the results 
for concentrates 004 and 005. The neat G/PLT result is, however, considerably higher than that 
obtained for concentrate 004. 
Table 4.25: Duplicate and mean ThromboLUX results for study transfusion episode 006 
TL (1) TL (2) TL Mean MV (1) % MV (2) % MV Mean Beads (1) Beads (2) Beads Mean 
24.0 21.6 22.8 5 4 4.5 5.3 3.8 4.6 
 
Again, there is very little difference between the particle size distributions obtained for the two 
test runs. The calculated ThromboLUX scores were 24.0 and 21.6. The proportion of light 
intensity from the MV fraction over the average distribution on this occasion was 5%. 
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Figure 4.7: Duplicate ThromboLUX results for study transfusion episode 006. Platelet and MV size distributions are shown as measured first at 37⁰C 
(top), then at 20⁰C (upper middle) and finally at 37⁰C (lower middle). The average distribution is shown at the bottom. 
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A full set of completed self-assessment bleeding score questionnaires were returned by the 
participant after study transfusion episode 006. As during his previous participation in the study, 
‘bruised, swollen or painful joints or muscles’, ‘red / purple spots (known as petechiae / purpura)’ 
and ‘one or two bruises, each measuring 2-10cm’ were consistent clinical features. On this 
occasion, the petechiae / purpura were present at a consistent, intermediate severity throughout 
the course of the study but there were no instances of blurred vision or oral blood blisters. 
 
4.4  Clinical Trial Results for Each Test 
The clinical trial results for each of the reference and novel test methods are presented below. 
4.4.1 Clinical trial swirl, pH and platelet count results 
All six platelet concentrates tested were swirl positive and had pH results that suggested 
acceptable quality. The differences between the fluorescent, optical and impedance counts 
(wherever available) appear negligible for all but one of the low platelet counts obtained from 
the patient samples (see below) but are more marked at the high levels observed in the platelet 
concentrate samples. On each occasion the platelet concentrate fluorescent count was 
considerably higher than the impedance count. 
It was not possible to determine the increase in platelet count for participant 001 because his 
involvement in the study was terminated early due to his suspected transfusion reaction. 
Fluorescent platelet count increases of 24, 37, 37, 35 and 39 x 109/L were observed for 
participants 002, 003, 004, 005 and 006 respectively. Their impedance platelet counts showed 
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4.4.2 Clinical trial CCI results 
The overall platelet content of each concentrate was calculated using both the fluorescent 
platelet count and the impedance platelet count. The total platelet content of each unit, as 
assessed using the fluorescent count, was 2.95, 3.11, 3.33, 3.04, 2.61 and 3.17 x 1011 platelets per 
concentrate for concentrates 001, 002, 003, 004, 005 and 006 respectively. The equivalent figures 
calculated using the impedance count were 2.31, 2.71, 2.58, 2.30, 2.34 and 2.51 x 1011 platelets 
per concentrate. See Table 4.26. 
Participant 002 had a BSA of 1.798, participant 003 had a BSA of 1.855 and participant 004 had a 
BSA of 1.697. Participants 005 and 006 were, in fact, the same individual as participant 003 and 
his weight did not change significantly during the course of the study. The BSA of participants 005 
and 006 was, therefore, also 1.855. CCI was calculated using both the fluorescent platelet count 
results (fCCI) and the impedance platelet count results (iCCI) for each participant. The results are 
shown in Table 4.26. In each case the impedance CCI was higher than the fluorescent CCI. All CCI 
results indicated an acceptable response to transfusion (Slichter et al, 2005). 
Table 4.26: BSA, Total Platelet Concentrate Platelet Content and CCI values for all participants 
Participant 
Number 








001 2.063 2.31 x 10^11 2.95 x 10^11 - - 
002 1.798 2.71 x 10^11 3.11 x 10^11 15,923 13,875 
003 1.855 2.58 x 10^11 3.33 x 10^11 42,420 20,611 
004 1.697 2.30 x 10^11 3.04 x 10^11 28,775 20,654 
005 1.855 2.34 x 10^11 2.61 x 10^11 26,160 24,875 
006 1.855 2.51 x 10^11 3.17 x 10^11 30,301 22,822 
 
The iCCI value calculated for participant 003 was more than double that of the fCCI and was 
considerably higher than all of the other iCCI results observed in the study. This participant was 
the only one with marked differences between his pre and post-transfusion impedance and 
fluorescent platelet count results. The impedance platelet count increased from 6 to 65 x 109/L 
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and the fluorescent platelet count increased from 2 to 39 x 109/L. This was thought to be the 
likely cause of his unusual pattern of CCI results. Both the pre and post-transfusion platelet 
counts performed for participant 003 generated abnormal platelet distribution errors by the 
impedance method and defaulted to report the fluorescent count. It is possible that small 
platelet clumps, red cell fragments or microcytes were present in the sample and were counted 
as platelets during the impedance test, falsely raising the impedance platelet count. When the 
increment obtained using fluorescent measurements was used to calculate the CCI with the 
impedance PC platelet count a value of 26,603 was reported, which is much more in line with the 
iCCI results generated for the other trial episodes. 
Participant 003’s pre and post-transfusion fluorescent platelet counts were unaffected by the 
analytical error observed for his pre and post-transfusion impedance platelet counts. These low 
level impedance counts have been observed to be very similar to the fluorescent counts in other 
pre and post-transfusion samples, with the main difference between iCCI and fCCI values for the 
other participants being a consequence of the more divergent impedance and fluorescent counts 
obtained from the platelet concentrates. This makes it likely that the modified CCI result 
prepared for participant 003 still represents the ‘true’ iCCI result that would have been calculated 
had there been no analytical issue affecting his pre and post-transfusion platelet counts. 
4.4.3 Clinical trial ESC results 
ESC was tested in duplicate for all samples except concentrate 001. Results of between 12.5% 
and 14.9% were obtained, with the exception of concentrate 005, which gave results of 5.2% and 
5.7%. All duplicate results matched up well, with a difference of <2% in each case and none of the 
aggregometry traces showed any evidence of technical anomalies. Holme et al (1998) quote a 
reference range of 15-25% for five day old platelets stored under optimal conditions. The 
discrepancy between this figure and the scores recorded is thought to reflect the less than 
optimal storage conditions of the concentrate prior to, during and after the transfusion. The 
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result obtained for concentrate 005 shows clear separation from the other results and may 
indicate a quality difference with this pack. There is no obvious correlation between the ESC 
results and the CCI values. 
4.4.4 Clinical trial HSR results 
The mean HSR results for concentrates 001, 004, 005 and 006 (32.7%, 29.4%, 28.4% and 26.9% 
respectively) are considerably higher than the results for concentrates 002 and 003 (13.6% and 
13.7% respectively) (see Figure 4.8). In all cases, the results are lower than the reference range of 
40-80% for five day old platelets stored under optimal conditions quoted by Holme et al (1998). 
Again, this likely reflects non-optimal storage for the duration of the transfusion. The higher 
results obtained for participant 001 may be due to the fact that participant 001’s transfusion was 
stopped prematurely due to a suspected transfusion reaction. The greater volume of platelet 
concentrate remaining in the bag and the shorter duration between cessation of agitation and 
laboratory testing may have contributed to the more ‘normal’ HSR result obtained. 
 
Figure 4.8: ESC and HSR results for all six platelet concentrates shown alongside the fluorescent 
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There was no correlation between the ESC and HSR results (R² = 0.0882). Furthermore, the HSR 
results did not show any clear relationship with the fCCI values (R² = 0.5098). However, if the iCCI 
result for participant 003 (previously identified as being suspect) is excluded, there may be some 
correlation between the HSR and iCCI results for the remaining participants (see Figure 4.9). 
 
Figure 6.9: Correlation between the HSR and iCCI results for participants 002, 004, 005 and 006. 
4.4.5 Clinical trial ThromboLUX results 
All platelet concentrate samples were tested in duplicate using the ThromboLUX analyser. Results 
were highly reproducible for the first two concentrates tested at the end of 2015 but became less 
reproducible in the later stages of the clinical study. There was no change in sample collection, 
storage practice, test performance technique or analytical environment. It is unclear whether the 
observed difference is due to coincidence or whether there is some instability inherent to the 
ThromboLUX system. Although calibration and adjustment of laser alignment is carried out upon 
installation, routine maintenance is not recommended by LightIntegra. Calibration beads 
continued to indicate acceptable analytical performance throughout the study. At first glance, 
there did not appear to be any relationship between the ThromboLUX results and the CCI results 
(see Figure 4.10).  
y = 822x + 5091.3 
















HSR vs iCCI 
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Figure 4.10: Duplicate and mean ThromboLUX results and CCI values for each participant 
However, if the second ThromboLUX result (and the mean result) is disregarded and the 
recalculated CCI result as discussed in the CCI results section above is used, the two 
measurements do seem to reveal an association (see Figure 4.11). As previously noted, the 
impedance CCI calculated for participant 003 was likely to be spurious, due to inaccuracies in the 
pre and post-transfusion impedance platelet counts. In addition, this data point was subjectively 
identified as an outlier on all graphs prepared to study correlation between the ThromboLUX 
results and CCI.  
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The concentrate 005 results were clear outliers in the correlation graphs prepared for the 
ThromboLUX and CCI results. See Figure 4.12. 
  
 
Figure 4.12: TL1 vs. CCI results for all concentrates (top) and using the recalculated iCCI result for 
concentrate 003 and with concentrate 005 excluded (bottom) 
The ThromboLUX result for concentrate 005 was below any previously defined quality ‘cut-off’ 
values. In addition, this concentrate gave a low ESC result and did not appear to produce any 
significant clinical benefit according to the clinical bleeding assessment. This transfusion episode 
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relationship. All other iCCI results were markedly higher than the fCCI results obtained for the 
same concentrate. The iCCI and fCCI results obtained for platelet concentrate 005 showed 
relatively little separation, suggesting the possibility that either the fluorescent platelet count 
result for concentrate 005 was suppressed or the impedance platelet count result was increased. 
There is no indication in the platelet count results of any errors or anomalies so it is thought to be 
most likely that this outlying result was caused by factors related to the platelet concentrate 
condition. Correlation between CCI and ThromboLUX scores improved dramatically if the result 
for concentrate 005 was excluded. See Table 4.27. 
 
Table 4.27: Correlation (R2 values) between TL1 results and calculated CCI for each platelet 
concentrate. Impedance CCI (iCCI) and fluorescent CCI (fCCI) results are shown for the 
entire dataset (the dubious result for concentrate 003 has been exchanged) and for 
each dataset with the concentrate 005 results excluded. All correlations of >0.80 are 
shown in bold. Logarithmic trend lines were used. 
CCI Correlation 
fCCI 0.0066 
fCCI (Outlier 005 Excluded) 0.8758 
iCCI (Dubious 003 Result Exchanged) 0.1939 
iCCI (Dubious 003 Result Exchanged, Outlier 005 Excluded) 0.8351 
 
It was not possible to determine a definite ‘quality cut-off score’ with the latest version of the 
analyser used in this study, which was modified shortly before the clinical trial began. All platelet 
concentrates, except for concentrate 005, gave average scores of more than 16 – a level higher 
than any of the ‘cut-off’ values employed in previous phases of the study. Platelet concentrate 
005 had a considerably lower ThromboLUX score than all the other concentrates tested (average 
9.95). This result would have been below any of the previously defined ‘cut-off’ values associated 
with this test method. 
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During this phase of the study the relative light intensity of the MV fraction was made routinely 
available in the ThromboSight software. The results obtained for the six clinical trial samples fell 
into two neatly disparate groups. Three samples gave results of between 5 and 7 and the other 
three samples gave results ranging from 17 to 22. These MV intensity results did not show any 
sign of correlation with any of the other tests performed. However, it could potentially be of note 
that the three patients who received the higher MV concentrates were all qualitatively linked by 
their clinical features. Participant 001’s transfusion was halted due to a suspected transfusion 
reaction, participant 004 was hospitalised due to fever in the days following her transfusion and 
participant 005 experienced very little clinical benefit from his platelet transfusion. 
 
4.4.6 Clinical trial ROTEM results 
When considered as a whole, the ROTEM results do not show a clear relationship with either 
fluorescent or impedance CCI. See Figure 4.13. 
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Figure 4.13: EXTEM, EXTEM – FIBTEM and G per platelet results obtained from neat (top) and 
diluted (bottom) samples shown alongside fluorescent and impedance CCI values 
 
All results were considerably lower for concentrate 003 than the other concentrates and than 
expected. As concentrate 003 had given abnormal result graphs and unexpectedly lower results 
for the neat sample than for the diluted one, a sample anomaly was suspected. Upon exclusion of 
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Good correlation figures were obtained for the neat samples once concentrate 003 was excluded 
(see Table 4.28). However, these datasets only include three study episodes each because there 
was not sufficient sample to run a neat test for concentrate 005. 
Table 4.28: Correlation (R2 values) between EXTEM, EXTEM – FIBTEM and G/PLT results and 
calculated CCI for each platelet concentrate. Fluorescent CCI (fCCI) results are shown 
for the entire dataset and with the result for concentrate 003 excluded. Impedance 
CCI results are shown with the dubious result for concentrate 003 exchanged and 
with the result for concentrate 003 excluded. All correlations of >0.80 are shown in 
bold. Logarithmic trend lines were used. 
CCI NEAT DILUTED 
 EXTEM E - F G/PLT EXTEM E - F G/PLT 
fCCI  0.0006 0.0146 0.1604 0.0639 0.1747 0.1665 
fCCI (Concentrate 003 Excluded) 0.9581 0.9537 0.8138 0.4519 0.6503 0.716 
iCCI (Dubious 003 result exchanged) 0.0025 0.0385 0.1758 0.0713 0.1808 0.1473 
iCCI (Concentrate 003 excluded) 0.9953 0.9936 0.6966 0.9026 0.9696 0.955 
 
Unfortunately, it was necessary to change lots of EXTEM reagent during the study. Recruitment 
was not fast enough to complete the study before the original lot expired and a new lot was used 
for study episode 004 onwards. A shift in results is apparent in the data (see Figure 4.13) 
4.4.7 Clinical trial AWE test results 
The average AWE test results for all six concentrates are shown in Figures 4.15 (neat samples) 
and 4.16 (diluted samples). Every concentrate was tested in duplicate using each of four test 
settings for the neat samples and the same four test settings for the diluted samples. For the neat 
samples, the results for concentrates 003 and 005 are reduced compared to those obtained for 
the other concentrates because these were pooled platelet concentrates, with lower platelet 
concentrations than all of the other (apheresis) concentrates included in the study.  
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Figure 4.15: AWE Test results obtained from neat samples using a variety of test settings and 
shown alongside the fluorescent and impedance CCI values for each participant 
 
 
Figure 4.16: AWE Test results obtained from diluted samples using a variety of test settings and 
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The results obtained using the diluted samples show better correlation with CCI than those 
obtained using neat samples. For the diluted samples, correlation was usually better if a 
logarithmic trend line was used. See Table 4.29. Of the four test settings investigated, the diluted 
VAR settings show the best correlation with both iCCI and fCCI. 
The impedance CCI for concentrate 003 lay outside of the general pattern of results for all sample 
and measurement variations. When it was excluded from analysis, the correlation of the diluted 
VAR results with iCCI increased from 0.3461 to 0.9723. The correlation of iCCI with AWE results 
using all other test settings also improved substantially. The iCCI result for concentrate 003 was 
also exchanged for one calculated using the fluorescent pre and post-transfusion platelet counts 
with the impedance concentrate count as described for the ThromboLUX and ROTEM tests (see 
‘Exchange 003’ results in Table 4.29). Improved correlation was maintained after the substitution. 
Table 4.29: Correlation (R2 values) between neat and diluted AWE results and CCI for each 
concentrate. Results are shown for the entire dataset, for each dataset with one 
outlying result excluded (Exclude 003 / 005) and for the impedance CCI datasets after 
the iCCI result for concentrate 003 was recalculated (Exchange 003). All correlations 
of >0.80 are shown in bold. Logarithmic trend lines were used. 
 NEAT DILUTED 
 VAR FIX VSB FSB VAR FIX VSB FSB 
iCCI 0.0029 0.1516 0.0046 0.0526 0.3461 0.1195 0.4211 0.0967 
iCCI (Exclude 003) 0.0207 0.0905 0.0428 0.0006 0.9723 0.5311 0.8241 0.0967 
iCCI (Exchange 003) 0.0152 0.0999 0.0310 0.0026 0.9632 0.5046 0.8251 0.6813 
fCCI 0.1611 0.5467 0.1057 0.2924 0.5467 0.1609 0.2828 0.1889 
fCCI(Exclude 005) 0.0265 0.3149 0.0335 0.0100 0.9330 0.6929 0.9345 0.1889 
To a lesser degree, the fluorescent CCI obtained for participant 005 (previously identified as 
potentially poor quality by the ESC and ThromboLUX results) also lay outside of the general 
pattern of results. When the fCCI value for participant 005 was excluded from the analysis, the 
correlation of the diluted VAR results with iCCI increased from 0.5427 to 0.8699 and the 
correlation of fCCI with AWE results using all other test settings also improved. See Figure 4.17. 
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Figure 4.17: Correlation between diluted VAR tests and CCI. The graphs show the original results 
for all study participants (top), all results except the impedance results for 
participant 003 and the fluorescent result for participant 005 (middle) and the results 
for all study participants after participant 003’s impedance result has undergone re-
calculation using his fluorescent pre and post-transfusion platelet counts (bottom). 
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Of all the AWE results, the diluted VAR results showed the best correlation with the HSR results, 
however, this was not very good.  The correlation improved from 0.5402 to 0.7888 if the result 
for concentrate 003 was excluded from the analysis. See Figure 4.18. 
 
 
Figure 4.18: Correlation between AWE and HSR results 
 
There was also a possible slight correlation between the neat FSB result and the neat EXTEM and 
EXTEM – FIBTEM results. See Figure 4.19. However, only four results are available for each of 
these ROTEM parameters so any potential association is a little dubious. 
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Figure 4.19: Correlation between neat AWE and neat EXTEM results (top) and neat AWE and neat 
EXTEM-FIBTEM results (bottom) 
 
Correlation between neat diluted AWE results and the ThromboLUX results (mean or TL1 results) 
was poor but seem to show general trend in the same direction. See Figure 4.20. 
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Figure 4.20: Correlation between diluted AWE results and ThromboLUX (TL1) results 
No correlation was observed between TL mean or TL1 results and ROTEM results for neat or 
diluted samples. 
 
4.5  Clinical Trial Discussion 
Performing a clinical trial to assess platelet quality assessment methods with sufficient numbers 
to achieve statistical significance was known to be outside the scope of this study. It was felt, 
however, that performing a pilot study to work through the analytical and organisational aspects 
of an appropriate study design would be a novel undertaking of benefit to the field. 
The pilot study enabled development of the technical aspects of the trial, aiding improvement of 
protocols for retrieval of the residual platelet concentrate and completing testing in an efficient 
and timely fashion to ensure results were generated using as ‘fresh’ a specimen as possible. 
Methods of participant identification, patient approach and consent, were refined and new 
contacts were made amongst the Clinical Haematology medical and nursing staff. 
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All of the study patients recruited experienced adequate increments at 1 hour post-transfusion, 
which are defined by Askari et al (2002) as a CCI of >7000. The fluorescent and impedance 
platelet counts obtained on the Sysmex XN analysers appear to be effectively interchangeable at 
the low levels observed in the patient samples but the fluorescent counts are considerably higher 
at the levels observed in the platelet concentrate samples. There is very little information 
available in the literature regarding the relative accuracy of the two methods at high platelet 
counts so it is difficult to be sure which CCI measurement is most representative of the patient’s 
true increment. It may transpire that the relationship between the calculated iCCI and fCCI 
parameters is itself informative regarding platelet function. 
Every concentrate was swirl positive and had pH values well above 7, making it unlikely that the 
quality of any of them was very poor. However, the ESC and HSR results for all concentrates were 
below the normal ranges stated by Holme et al (1998) for fresh platelet concentrates stored 
under optimal conditions. The ESC and HSR tests are known to be more sensitive to deterioration 
of platelet concentrate quality than swirl assessment or pH measurement so these observations 
are not necessarily contradictory (Holme et al, 1998. Shivastava, 2009). It is likely that the lack of 
agitation during the transfusion and laboratory processing and the sub-optimal oxygen exchange 
conditions for the platelet concentrate sample in the lines of the transfusion giving set and 
laboratory sample pot account for the reduction in ESC and HSR results.  
The duplicate ThromboLUX results for PC 003, 004, 005 and 006 were discrepant. In all cases, the 
second test gave a lower result than the first one. It is possible that the platelet quality becomes 
progressively compromised as the sample is stored in a capped, airtight container during 
laboratory processing. This does not explain why some concentrates give discrepant results while 
others do not appear to. The durations of storage before testing were similar for all concentrates. 
It is possible that environmental factors (e.g. temperature in the laboratory) or concentrate 
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specific factors (e.g. duration for which the concentrate was removed from agitation prior to 
transfusion) influences the degree of discrepancy observed.  
Although by no means conclusive, there does appear to be some relationship between the 
ThromboLUX score (if only the first test result is considered) and the CCI values obtained for the 
participants. The only concentrate that did not fit into this relationship was concentrate 005, 
which had been independently identified as potentially poor quality or ‘odd’ by the ESC test and 
an abnormal fCCI / iCCI relationship. It is unclear why the second ThromboLUX measurements for 
each concentrate differ so much from the first. It seems most likely that storing the sample in a 
capped container without adequate oxygen exchange or agitation even for a short period has a 
dramatic effect on the ThromboLUX score. If this effect is due to lack of agitation, it could imply a 
similar degree of previous deterioration that began before the sample was collected due to lack 
of agitation during the transfusion process. 
It is not clear why the ROTEM result for concentrate 003 was so much lower than those obtained 
for the other concentrates, or why the relationship between the neat and diluted sample results 
was non-typical. If this result is excluded, there is a degree of correlation between the remaining 
results. 
The results for concentrates 001 to 003 are substantially lower than those for 004 to 006. This is 
likely due to the change in EXTEM reagent batch that occurred at this point. As previous stages of 
this study (the Aging Platelet Concentrate Study – 5.3.6) have noted changes in results between 
reagent batches, it was highly desirable to use a single batch of reagents for all testing within a 
particular set of experiments. In practice, this was not possible due to the short shelf-life of the 
reagents provided by TEM. This centre’s relationship with TEM is relatively new and small-scale. It 
is hoped that the promising results of this study would aid future requests for the supply of long 
dated products. 
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The AWE test results generated in the clinical phase of this study add to previous suggestions that 
this test has potential for future development. The diluted VAR test settings appear to give the 
most clinically significant results at present. Further investigation is required to further 
investigate this relationship with greater study numbers, to compare with 24 hour increments 
and possibly to apply different variations of the current test settings. However, the possibility of 
performing the test without using specialised Stir-Bar cuvettes would decrease the costs of the 
assay and enable samples to be ran routinely without loading non-standard consumables. An 
additional priority for future improvement of the AWE test is the development of a suitable 
means of quality control testing. 
Participant 004s transfusion appeared to prevent the manifestation of any clinical bleeding 
symptoms in the days immediately following her transfusion but she experienced the onset of some 
minor clinical bleeding after three days. Participant 005 had a higher baseline level of clinical 
bleeding that did not appear to be improved by this transfusion. However, when the same patient 
participated in the trial again as participant 006 his clinical bleeding symptoms appeared to be 
marginally less severe following transfusion. It is tempting to link the apparent lack of clinical effect 
observed after transfusion 005 to the low ESC and ThromboLUX results and would be very interesting 
to expand this clinical bleeding assessment aspect of the clinical trial to determine whether this 
pattern is repeated. 
Concentrate 005 was identified as possibly poor quality by several of the laboratory methods 
used in this study and also by the clinical bleeding assessment. The CCI values for this 
concentrate, however, were not notably reduced. The transfused platelets may have survived for 
long enough to give a normal 1 hour CCI but been defective enough to perform poorly in some of 
the platelet quality tests and in vivo. Had the study incorporated 24 hour increment, it may have 
been found that the platelets in concentrate 005 had reduced survival and gave a low 24 hour 
CCI. Incorporation of a 24 hour CCI would be a great benefit to any future study. 
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It is notable that the two concentrates that gave outlying or spurious results and the only 
concentrates for which there was any suggestion of poor quality were the only two pooled buffy 
coat concentrates included in the study (concentrates 003 and 005). Although the numbers 
included in this study are far too low to make any conclusions, this raises the possibility that the 
quality of pooled concentrates, as assessed using routinely applicable in vitro assessment 
techniques, is generally lower than that of apheresis concentrates. Alternatively, there could be 
some factor inherent to pooled concentrates, perhaps something related to the platelet donation 
processing procedure, which causes these concentrates to respond differently in the laboratory 
without affecting their clinical efficacy. Ideally, the in vitro assessment of pooled and apheresis 
platelet concentrate quality would be studied in separate studies or in studies large enough to 
compare the two groups and look for differences between them. 
In summary, all technical aspects of the clinical trial worked broadly as expected from previous 
stages of the study, although no clear and definite relationship was observed between 
transfusion efficacy and any of the measures under investigation. The major difficulty was 
recruitment, which was problematic largely because the study was performed remotely from the 
clinical location of potential participants. Several steps were taken to combat this, including 
modification of exclusion criteria and working more closely with the medics based on the 
Haematology Day Unit. 
 
4.6  Clinical Trial Summary 
 Ethical approval was granted for a pilot study that aimed to assess the ability of in vitro 
platelet concentrate quality assessment tests to predict transfusion outcome, as 
determined by CCI and bleeding score, in MDS patients 
 The tests carried out on the residual platelet concentrate sample were platelet count, 
swirl assessment, pH measurement, ESC, HSR, AWE, ThromboLUX testing and ROTEM 
analysis 
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 Recruitment was problematic but six participants were recruited to the study 
 Two pooled platelet concentrates and four apheresis concentrates included in the study 
 Participant 001’s transfusion was stopped early due to a suspected transfusion reaction 
so it was not possible to calculate CCI values but these are available for all other 
participants 
 Impedance and fluorescent platelet count results similar for patient samples but 
fluorescent counts higher than impedance counts for platelet concentrate samples 
 CCI was calculated using both impedance and fluorescent platelet counts 
 All CCI results suggest acceptable response to transfusion 
 Participant 003’s iCCI result (and possibly participant 005’s fCCI result) was dubious  
 All residual platelet concentrate samples were swirl positive at the time of testing 
 All pH results suggested acceptable platelet concentrate quality 
 All of the ESC results obtained in the clinical study were lower than those previously 
reported for acceptable quality platelets that had been stored appropriately 
 All of the HSR results obtained in the clinical study were lower than those previously 
reported for acceptable quality platelets that had been stored appropriately 
 ESC and HSR did not show any clear relationship either with each other or with the CCI 
values 
 The reproducibility of the ThromboLUX results declined over the period of the study 
 TL1 results showed good correlation with CCI when concentrate 005 was excluded from 
the analysis and the recalculated iCCI result for concentrate 003 was used 
 Concentrate 005 was identified as poor quality by the ThromboLUX analyser and the ESC 
result. It was also identified as non-typical by its platelet count / CCI results 
 It was not possible to determine a definite ‘quality cut-off value’ for the ThromboLUX 
 The ThromboLUX % MV intensity results fell into two disparate groups but did not show 
correlation with any of the other quantitative test results 
 Apparent shift in ROTEM results with lot change between participants 003 and 004 
 Participant 003’s ROTEM results were lower than expected for non-expired platelet 
concentrates 
 There was a possible relationship between the ROTEM result and CCI values after the 
outlying result for concentrate 003 was excluded 
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 Diluted sample AWE tests showed better correlation with the CCI values than neat tests 
 Diluted VAR settings showed the best correlation with both iCCI and fCCI 
 Relatively good correlation was observed between AWE results and CCI values after 
exclusion of dubious CCI results (the 003 iCCI result and the 005 fCCI result) 
 There were some possible loose associations between the AWE results and the HSR, 
ROTEM and ThromboLUX results 
 Three out of the six participants returned their bleeding questionnaires 
 Participant 004’s bleeding questionnaires suggest good initial response to the study 
transfusion, followed by gradual worsening of bleeding symptoms until another 
transfusion was administered five days after the study transfusion 
 Participant 005’s questionnaire shows little clinical response to platelet transfusion, 
although bleeding symptoms continued to worsen throughout the period of monitoring 
 Participant 006 (who was the same individual as participant 003 and 005) experienced 
some clinical benefit from his platelet transfusion on this occasion 
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5  DISCUSSION 
5.1  General Observations 
Platelet concentrate quality testing is a fairly specialised undertaking and, therefore, not 
something that gains a lot of commercial interest. Potentially useful testing techniques are often 
designed for different purposes and require a significant amount of modification in order to apply 
them to platelets. Furthermore, platelets are quite complex cells, with a variety of different 
functions, not all of which are completely understood. This means that the way they react during 
different in vitro testing is not always easy to predict or interpret. This general observation has 
been borne out during all phases of the study. 
It is possible to pick out individual concentrates that do not fit into the general trend when 
observing a group of results (e.g. 003 and 005 from the clinical trial – sections 4.3 and 4.4). 
However, the ability to do this is of very little use in clinical practice as, in most cases, there 
would only be a single result available in isolation from both other concentrates and other testing 
time points for the same concentrate. 
 
5.2  Pooled vs. Apheresis Concentrates 
Pooled platelet concentrates generally have lower platelet concentrations and higher overall 
volumes than apheresis ones, as observed in the in vitro stage of the project (section 3.3.1). 
Although the greater volume of the pooled concentrates compensates for the reduced platelet 
concentration in terms of total number of platelets transfused to the patient, there is no 
comparable compensating effect in many of the available laboratory tests. The practice of 
diluting platelet concentrate specimens in normal plasma to give a standardised count 
compensates for these differences to a degree and may, additionally, mimic the revitalising effect 
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of normal plasma that has previously been described for post-transfusion platelets (Berger et al, 
1998; Ishikawa et al, 1987; Miyaji et al, 2004; Rinder et al, 2003). 
The number of samples tested during this project was, for the most part, not sufficient to 
separate the results for pooled and apheresis platelet concentrates into different subgroups for 
analysis. As supply of suitable test samples was often problematic, it was not possible to restrict 
testing to a particular type of concentrate. However, pooled and apheresis concentrates are 
widely accepted to differ in several respects, even if the clinical relevance of these differences are 
not always clear (Reviewed in van der Meer, 2013; Ali, 2011). Even concentrates of the same type 
produced using different collection systems are found to differ in their biological characteristics. 
Macher et al (2010) describe differences in glucose, pH, lactate and lactate dehydrogenase (LDH) 
between apheresis concentrates produced by different collection systems. 
 Observations of differences between the mechanisms in which the two types of concentrates 
deteriorate with age further complicate this picture. Paglia et al (2014 and 2015) describe a 
complex platelet concentrate deterioration process that involves discrete phases dominated by 
different biochemical processes. Crucially, they found the phases of deterioration and the times 
at which the shifts occurred to differ between apheresis and pooled buffy coat concentrates to 
differ. Added to this complexity, a large number of different additive solutions and anti-microbial 
treatments are under development, all of which have the potential to affect platelet quality and 
deterioration characteristics in their own, as yet undefined ways (Bergmeier et al, 2003; Cardigan 
et al, 2008; Deyhim et al, 2015; Kostelijk et al, 2000; Leitner et al, 2016; Lin et al, 2004; van der 
Meer, 2016; Osman et al, 2016; Ostrowski et al, 2011; Pienimaeki-Roemer et al, 2014; Védy et al, 
2009; Wagner et al, 2009, Zhuang et al, 2014). 
Added together, these factors make the need for a simple, easily applicable measure of platelet 
quality all the more desirable but have the potential to greatly complicate the development and 
assessment of tests in the future. The best approach wherever possible would be to ensure that 
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all concentrates tested were produced using the same methodology. However, this would greatly 
restrict the ability of smaller teams to carry out platelet concentrate research and effectively limit 
it almost entirely to blood service laboratories and institutions able to source large enough 
numbers of specific types platelet concentrates from them. The studies carried out under such 
circumstances would likely be of a higher quality but ideas and innovations that may be 
generated during the undertaking of more numerous, smaller studies could be passed over. 
Ultimately, this is a question of research ethics that should be taken into consideration at the 
point of blood donation. 
 
5.3  Control Tests 
A wide variety of control methods were available for potential inclusion in the study but this was 
drastically reduced by selecting only those that had previously been found to correlate with 
clinical efficacy. It would have been helpful to include the Kunicki score in the study control panel 
but this was not possible as the specialist experience or image capture equipment deemed 
necessary to make this highly subjective method work reliably was available. This was 
unfortunate as being able to observe the quality of the platelets visually may have helped identify 
problems with the results of other control and experimental methods, as well as aiding 
identification of platelet samples in which the quality was not as expected. 
The swirl and pH tests were not initially included in the study due to their reported insensitivity 
to the low levels of poor quality likely to be found in clinically available concentrates. Both were 
added to the study test repertoire to aid identification of very poor quality concentrates tested in 
the ThromboLUX. As expected, the platelet concentrates tested as they aged in the laboratory did 
not show abnormalities in these parameters until relatively late and all concentrates tested in the 
clinical trial gave normal results for both tests. However, the swirl test in particular is a simple, 
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inexpensive method that could be widely applied immediately. The sensitivity may be low but it 
could, at least, be used as a quick check for severely compromised units. 
The ESC and HSR were more informative and showed clear deterioration of results as platelet 
concentrates aged. However, neither showed a convincing relationship with CCI in the clinical 
phase of this study, raising the possibility that the retrospective sampling method employed was 
not optimal. However, the reproducibility of both tests is known to be poor so it is quite possible 
that clearer relationships would become apparent if more samples were tested.  
Despite these drawbacks, the ESC and HSR assays are widely used in assessment of platelet 
concentrate quality for research and production development (Kiminkinen et al, 2016; Kraemer 
et al, 2015; Ringwald et al, 2012; Sandgren et al, 2012; Sandgren et al, 2015). Even though 
neither is optimal in terms of technical performance and correlation with platelet transfusion 
outcome, their automation would likely offer benefits in terms of making them more easily 
applicable, better standardised and more readily performed by a wider staff group. 
Straightforward automation of the standard HSR / ESC methods would probably lead to 
improvements in precision and accuracy of results by reducing the potential for human error in 
pipetting and timing of test steps. Although analysis of data by the analyser is more complex 
because it requires additional steps, the relative stability of reagents required for these assays 
makes them more readily automatable than the automated platelet aggregation panel that 
Sysmex now offers for use in the diagnosis of platelet function disorders as described by Lawrie et 
al (2014). 
 
5.4  iZON Instrument 
As a technique that had not initially been designed for studying platelets, the iZON analyser did 
appear to have some potential for future use. It was shown that the test could be potentially 
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applied to the measurement of platelets and MV in ageing platelet concentrates. However, it was 
quickly found to require a substantial input of time and expertise that were felt to be beyond the 
scope of this study. In addition, there was no reason to believe that it would produce information 
of use for the rather specific purpose of studying platelet concentrate quality. It would be 
preferable to establish the features and limitations of this method using a better characterised 
sample type, such as fresh PRP, to gain an understanding of the expected ‘normal’ results. It 
could be compared with other impedance platelet counting / sizing techniques and a reference 
range for platelet charge could be established. The use of fresher samples would, hopefully, 
enable easier acquisition of a sufficient number of data points that were less likely to be affected 
by selection of the less activated platelets in the sample. Test results from ageing platelet 
concentrate samples, which are relatively poorly characterised and difficult to process, as well as 
platelets stored under non-physiological conditions could then, perhaps, be better interpreted 
against this benchmark. 
 
5.5  ThromboLUX Analyser 
The ThromboLUX analyser was at a different stage in development, having been extensively 
tested and trialled by its developers in Canada as a prototype. It was anticipated that this 
instrument would need a minimal amount of in house validation, before an extensive in vitro 
study of ageing platelet concentrates was carried out, followed by a clinical trial. Funding was 
secured for these investigations and plans were made to undertake them alongside NHSBT trials 
and projects at various centres. However, the ThromboLUX analyser did not perform as expected 
from the outset. 
Since the beginning of this study the ThromboLUX analyser has been evaluated in a number of 
laboratories internationally. It appeared to show great promise in terms of its ease of use and 
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clinical relevance as evidenced by the large scale clinical trial carried out by the developer using a 
prototype instrument (Maurer-Spurej et al, 2009). Unfortunately, this success has not been 
replicated during the beta evaluation phase of the second generation instrument. Light scattering 
measurements require precise alignment of the sample in 3 dimensions. The prototype 
ThromboLUX used capillary tubes inserted into a sample holder by hand to place the sample into 
the light path. The second generation ThromboLUX first received for use in this study had 
undergone a radical redesign, including the introduction of a sample presentation system that 
used disposable sampling sets manufactured and sold by LightIntegra. This change in the analyser 
set up may have introduced a degree of variability into the alignment of the sample in the light 
path, potentially affecting the DLS results recorded by the instrument. The third and fourth 
ThromboLUX instruments used in this study (from the beginning of the sample exchange 
experiments described in chapter 3 onwards) reverted to using a syringe and capillary tube 
system but the internal optical elements were not otherwise reengineered. 
The ThromboLUX has been found unable to identify bacterially contaminated platelet 
concentrates (Taha et al, 2016), not to correlate with the ESC and HSR assays (Kraemer et al, 
2015) and insensitive to inappropriate storage of platelets in EDTA (Raczat et al, 2014). The 
publication bias towards scientific studies with positive results is widely known (Dirnagl et al, 
2010), making the appearance of negative ThromboLUX evaluations in the literature all the more 
relevant. The ThromboLUX appears to have some potential utility as a method for the 
quantitation and sizing of PMV and this feature has been of prominent focus in recent 
publications by the development team (Labrie et al, 2013; Maurer-Spurej et al, 2016). 
The inability of the ThromboLUX to reliably identify aged or inappropriately stored samples by 
returning a low score caused considerable concern and was, ultimately, a problem that was never 
resolved. LightIntegra were unable to explain this observation and were hesitant to advise 
whether other centres were experiencing the same problems. They maintained that they had not 
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experienced these features in their initial trials of the instrument but these were performed on a 
previous, prototype version of the analyser, rather than the mass produced second generation 
version that was on loan for the current study. This issue clearly affects the potential clinical 
utility of the ThromboLUX analyser as a pre-transfusion quality screen because inappropriate 
storage or accelerated age related deterioration of platelet concentrates are both issues that 
could, theoretically at least, occur quite commonly in the hospital transfusion laboratory 
environment. 
Several changes and upgrades to the ThromboLUX equipment have slowed the progress of this 
study without leading to significant improvements to results. Significant technical changes to the 
analyser and the way it is set up, in addition to alterations to the data processing algorithms have 
prevented accumulation of large sets of data relating to individual analyser / software 
combinations. After each change, LightIntegra advised that previous problems with sensitivity 
had been resolved and results up to that date were no longer representative of the current 
system. It can be clearly seen, in retrospect, that there were no sudden and significant 
improvements in the performance of this test but that does not mean that there were not 
changes in the way it worked so combining all of the smaller datasets remains erroneous. 
In order to establish a new local cut-off value for each ThromboLUX machine / location 
combination, it will be necessary to test a relatively large number of concentrates at different 
time points to determine the range of results that can be expected for concentrates of varying 
quality throughout the ageing process. In order to ensure that they relate to post-transfusion 
platelet efficacy, the ThromboLUX scores of transfused platelet concentrates should also be 
compared to transfusion outcome to determine whether the new cut-off value is of any clinical 
relevance. Clearly this will be impractical in the vast majority of cases. Furthermore, it is unclear 
how great the changes to an analyser or its location must be to invalidate a previously defined 
cut-off value. Will routine analytical upgrades or moving the analyser to a different room in the 
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same laboratory necessitate extensive testing to establish a new cut-off value? These are 
questions that must be addressed by LightIntegra before the ThromboLUX could be safely 
introduced into clinical practice. 
Despite the sensitivity concerns surrounding the ThromboLUX, it did appear to show some 
correlation with CCI and detected a suspected poor quality platelet concentrate in the clinical 
trial (see section 4.4.5). It is quite possible that the analyser is able to identify some types of 
impaired quality but not others, for instance it may detect some aspects of inter-donor variability 
in platelet quality that can lead to differences in clinical response to transfusion. It may be of use 
as part of a panel of methods employed in a research and development setting, if not the 
exclusive screening tool it was initially marketed as. Alternatively, further characterisation of 
how, exactly, the raw ThromboLUX measurements relate to platelet function and quality may 
facilitate development of the analytical system or result interpretation algorithm to enable the 
instrument to fulfil its original brief. 
The availability of relative MV contribution to light scattering intensity may be of interest to 
future researchers. The data obtained during the clinical trial appeared to show the possibility of 
a relationship between the MV level within a platelet concentrate and clinical transfusion 
outcomes. However, this interesting measurement feature was, unfortunately, made available 
too late for us to fully characterise and utilise within this study. 
 
5.6  ROTEM Analysis 
The ROTEM results have consistently shown deterioration with platelet concentrate age and the 
method is sensitive to temperature induced platelet damage. Changes are large enough to show 
clear distinction between different time-points and seem to correlate, to a degree, with control 
tests. This method is an easy to use, established, standardised, commercially available CE marked 
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test that is widely used for routine diagnostic purposes. As such, it appears eminently suitable to 
apply to the problem of measuring platelet concentrate quality. In addition, the ‘global’ nature of 
thromboelastometry tests means that this method has a good chance of relating to post-
transfusion platelet function in vivo. 
McNulty et al (1997) harvested platelets from volunteers and then added them to blood samples 
to investigate whether they had any effect on TEG measurements including the maximum 
amplitude (MA), alpha-angle and R-time. Addition of platelets treated with liquid nitrogen to 
diminish quality resulted in increased MA comparable to that measured in samples treated with 
appropriately stored (presumably higher quality) platelets. On the basis of this observation the 
authors predicted that platelet transfusion would lead to increased clot strength if their blood 
was tested immediately after treatment. This raises the possibility that thromboelastography 
results obtained for platelet concentrate samples would be primarily determined by the number 
of platelets present, rather than their functionality. In this study however, platelet G was found 
to decrease as concentrates aged independent of platelet concentration and clotting factor 
concentrations (using samples diluted to a standard count in a normal plasma diluent). 
The maximum clot firmness (MCF) and MA parameters reported by the ROTEM and TEG 
instruments respectively are influenced by both the elasticity and viscosity of the clot containing 
sample. The platelet component of clot strength is better represented using measures of the 
force with which the forming clot resists movement of the pin which are more representative of 
clot elasticity (CE).  The direct measurement of this force is reported in the ROTEM software as 
the ‘G’ value in units of dyne/cm2 (Solomon et al, 2015). The relationship between clot amplitude 
and force / elasticity measurements is not linear. Because of this, subtracting FIBTEM MCF values 
from EXTEM MCF values does not give a result that is representative of the platelet contribution 
to the clot. Force / elasticity based measurements must be used for assessment of platelet 
function (Solomon et al, 2015). 
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More recently, a number of studies have used thromboelastography or thromboelastometry as a 
measure of platelet concentrate quality under various circumstances (Bynum et al, 2016; 
Ostrowski et al, 2011; Ponschab et al, 2015; Svendsen et al, 2007). However, these studies did 
not examine the relevance and reliability of the method and no justification given for its use. Two 
recent studies have investigated the applicability and relevance of the TEG system (Bontekoe et 
al, 2014) and the TEG and ROTEM systems (Arbaeen et al, 2016) to assessment of platelet 
concentrate quality. Both Arbaeen et al (2016) and Bontekoe et al (2014) used amplitude based 
measurements, rather than force based measurements for their analysis. Both of these studies 
may benefit from reanalysis of the data using parameters that better reflect clot elasticity. 
Bontekoe et al (2014) tested 19 apheresis platelet concentrates on days 1, 5, 8 and 12 after 
collection from the donor with the TEG system and found changes over storage. They used 
Octoplas as a MV free diluent and kaolin and collagen activators. MA was chosen as the primary 
measurement. The authors note that MA was not very sensitive to changes in platelet count 
within the range of 100 – 1000 x 109/L so very dilute samples were used in an attempt to increase 
the sensitivity of the method to differences in platelet quality. Again, little distinction is made 
between platelet quantity and platelet quality. Rather than diluting to a standard platelet count, 
1 in 10 dilutions were used for all samples in order to ensure that fibrinogen levels introduced in 
the diluent were relatively constant. This was a valid option due to the design of this study, which 
used apheresis concentrates produced with the same technology meaning the range of initial 
platelet counts was small. 
Clot retraction was observed in several of the samples tested by Bontekoe et al (2014). This 
manifests as a sudden reduction in the clot amplitude that can be visualised on the graph as the 
clot suddenly detaches from the pin. It can be distinguished subjectively from fibrinolysis, which 
appears as a more gradual decrease in clot amplitude. Bontekoe et al (2014) noted that clot 
retraction became less prominent as platelet quality declined. Clot retraction was noted in the 
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clinical trial sample from participant 003 in this study (see Figure 4.3). This feature may be an 
interesting target for future investigations of the relationship between thromboelastography / 
thromboelastometry and platelet concentrate quality. 
Bontekoe et al (2014) found accurate pipetting in terms of volume and timing to be critical to the 
reproducibility of TEG results. This is one possible benefit to the ROTEM system, which has an 
integrated pipette, controlled by the analyser software. Liquid is drawn up by an automated 
vacuum system rather than manually controlled plunger and the test timings follow on screen 
prompts. If critical test timings are not met the test is cancelled and must be restarted. These 
features may lead to the generation of more reliable test results with the ROTEM system.  
This study used the standardised and commercially available EXTEM and FIBTEM reagents 
supplied by ROTEM, which use TF as an activator with and without the cytochalasin D platelet 
inhibitor respectively. Bontekoe et al, (2014) used kaolin and collagen and Arbaeen et al (2016) 
used kaolin. It may be of interest for future studies to investigate the effects of a wider range of 
platelet activators within thromboelastography / thromboelastometry systems but the use of a 
widely applied and validated reagent combination seems reasonable in the present study. 
Arbaeen et al (2016) used both the TEG and ROTEM systems to assess eight platelet concentrates 
on days two, five and eight after collection. Again, amplitude based measurements, rather than 
force based ones, were used. They investigated the effect of using diluents with high of low MV 
levels and found that use of MV enriched diluent led to increases in the TEG MA value. The 
CryoCheck normal plasma used for this study was not specifically low in MV but was unlikely to 
be as high as the MV enriched diluents used by Arbaeen et al (2016). Also, only a single batch of 
normal plasma diluent was used in this study so any MV effect would be consistent across all 
tests. 
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Arbaeen et al (2016) also tested samples diluted to give a range number of different platelet 
concentrations (400, 300, 200 and 100 x 109/L) and found the MA to decrease as platelet 
concentrate decreased but presented no convincing reason for favouring one dilution over 
another. The diluted sample ROTEM tests presented in this thesis were all carried out on samples 
standardised at counts of 300 x 109/L ± 10%. This level was used as it was representative of a 
normal platelet count at the level comfortably within the range the analyser would be expected 
to encounter and measure reliably in its usual application as a whole blood measurement tool. 
Also, 300 x 109/L is the platelet concentration recommended for HSR and ESC testing, suggesting 
that this level enables the platelets to react in a way representative of their overall quality. 
Although the justifications for the concentration used in this study remain valid according to the 
evidence that is currently available, a more comprehensive study of the platelet dilution level 
that results in the most clinically relevant ROTEM test results could be of future benefit to the 
field. 
The fact that MA decreased as platelet biomass decreased in the more diluted samples was given 
as justification for its use as the primary measurement by Arbaeen et al (2016). However, the MA 
does not separate the effects of viscosity (related to platelet biomass) and elasticity (related to 
platelet function) and is therefore unable to distinguish reliably between changes in platelet 
concentration and platelet activity within a platelet concentrate sample. 
In contrast to Bontekoe et al (2014), they did not observe any significant deterioration of the TEG 
results as the platelets aged. This may have been because they concluded testing two days earlier 
in the platelet storage period or may have been linked to some other methodological difference 
between the two studies. In the fresh platelet concentrate study performed in Oxford, 
deterioration of ROTEM results by day ten after collection was clear with the initial lot of EXTEM 
reagent but less so with the second batch. Reduction of thromboelastometric potential did not 
become obvious for all concentrates tested with the second batch of EXTEM reagent until day 14 
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after collection (see Figure 3.26). Arbaeen et al (2016) found the TEG system MA measurement to 
be sensitive to artificially induced poor platelet quality caused by lack of agitation, reduced 
oxygen permeability of container and inappropriate storage temperature (30⁰C) mirroring the 
reduced ROTEM G results observed for inappropriately stored samples in this study. 
The results generated in the clinical pilot study hinted at a possible relationship between the 
ROTEM results and transfusion efficacy. However, several factors complicated this and would 
need to be addressed in future studies. The first was the lot specific effect on results discussed 
previously. It may be possible in future studies to standardise the ROTEM results obtained for 
different lot numbers, perhaps by presenting them as a ratio of a ‘normal’ value. A ‘normal’ 
control sample (e.g. fresh PRP taken from a volunteer) could be tested five or ten times using the 
ROTEM for each new batch of EXTEM and FIBTEM. The platelet concentrate G results could then 
be expressed as ratios of the average normal control results for the appropriate test. The FIBTEM 
ratio could be subtracted from the EXTEM ratio to give a platelet only ratio. Sourcing a suitable 
and representative ‘normal’ platelet quality control sample is a challenge during the application 
of any platelet quality test but overcoming it could potentially reap great benefits. 
In addition to the problem of standardising results across different reagent lots, at least one 
concentrate (003) was found to give atypical results for no discernible reason. It may be that the 
very low results, the atypical relationship between neat and diluted sample results and the clot 
retraction observed for this sample provide usable information about platelet concentrate quality 
but the factors leading to these unusual results are not yet understood. It is also not clear 
whether the ROTEM is sensitive to the low level impairment of platelet concentrate quality that is 
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5.7  AWE Test 
The AWE test also appears to have some potential as a routinely applicable laboratory marker of 
platelet concentrate quality. The HSR test is one of the few laboratory measurements that have 
consistently been shown to correlate with the clinical efficacy of platelet concentrates (Holme et 
al, 1998; Shivastava, 2009) and the AWE test showed the best correlation with CCI out of all the 
experimental methods assessed in the clinical study. As an automated and simplified version of 
the HSR, the AWE test is potentially quicker and easier to perform, less prone to operator error 
and more standardised in terms of technical performance. However, the number of samples 
tested during this project is too low to draw any firm conclusions, particularly when the results 
generated for particular samples were questionable and needed to be excluded. 
The precision of the AWE test was acceptable when compared to that of other platelet quality 
tests and the test results do not appear to undergo any significant changes due to settling of the 
samples during processing on the analyser. All of the samples tested showed deterioration when 
they were stored in sub-optimal conditions, with the exception of a single sample stored for one 
day only that may potentially have undergone a degree of revival due to the addition of normal 
plasma. There is not yet enough data to favour any particular test setting over the others. If it is 
proven that stir-bar cuvettes are not needed the cost of the assay would be reduced and the 
inconvenience of loading non-routine consumables entirely removed. See section 3.7.1. 
The HSR test is performed in duplicate using water for the ‘test’ sample and Owren’s buffer for 
the ‘control’ sample. The isotonic buffer is not taken up by the platelets and so does not trigger 
any ‘recovery’ response during which it is pumped back out. The change in OD due to dilution 
when a volume of water or buffer is added to a sample varies from specimen to specimen 
depending upon the colour of the original sample. In the HSR test, this initial change in OD is 
measured and taken into account during calculation of results to effectively blank the specimen 
and compensate for differences in specimen colour that may affect the degree of change in OD. 
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This enables the results to be expressed as a percentage ‘response’ – the percentage by which 
the OD of the test sample corrects towards that of the control sample. It is likely that this practice 
increases the accuracy of the HSR result. 
The Sysmex analysers are only able to report measurements across one time span so the initial 
decrease in OD due to the addition of diluent (either water or buffer) is not recorded or included 
in the calculation of results. Rather, the absolute value of the OD change from the point of 
maximum water uptake to various endpoints during the recovery phase is considered. It would 
be preferable to express results as a percentage recovery and control for variations in 
concentrate colour but that would require considerable changes to the Sysmex CA5100 software 
that are currently beyond the scope of this study. 
A possible avenue for further study would be automation of the ESC test on a similar platform. All 
of the same potential benefits would apply to ESC automation as apply to the HSR and data 
processing could potentially be simpler within the existing setup. It is possible that the two tests, 
performed side by side, may give more information in combination than either could individually. 
 
5.8  Future Clinical Trial 
The next logical step to build on the progress made so far by this study would be to perform a 
larger clinical trial that would reach clinically significant numbers. This would enable investigators 
to determine whether the possible associations detected between transfusion efficacy and the 
experimental laboratory tests assessed in the pilot study achieve significance with greater 
numbers. A retrospective power calculation using the data produced by Maurer-Spurej et al 
(2009) indicates that 71 transfusion episodes are required to identify a correlation of 0.6 between 
platelet count increments and the ThromboLUX results with 80% power at a 5% significance level. 
Any future study should aim to achieve a sample size of at least 70 transfusion episodes.   
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Recruiting the numbers required would be more easily achieved if any future trial was carried out 
in closer partnership with the clinical side of the service as recruiting patients was a major 
stumbling block for the pilot study. It might be possible to include inpatients in future study but it 
is not certain that this would be desirable as inpatients are clinically less stable and would be 
more likely to experience changes to their platelet count due to non-study related factors such as 
treatment or rapid clinical deterioration. It may be preferable to extend the study to other 
centres (although this would make it difficult to standardise laboratory testing) or other 
participants with different diagnoses (although this would make it difficult to standardise the 
participant’s clinical condition).  
The 1 hour post-transfusion increment measures platelet recovery, indicating how many of the 
transfused platelets were taken up into the patient’s blood stream and avoided immediate 
removal due to mechanical or biological mechanisms. A 24 hour increment is sometimes used to 
give additional information about platelet survival and can be a useful indicator of reduced 
platelet quality that reduces the lifespan of the transfused platelets (Slichter et al, 2005). 
Unfortunately, it was not possible to measure 24 hour increments in this study as the patient 
population consisted of outpatients who were not available for repeat venepuncture on the day 
after their platelet transfusion. Using Haematology inpatients as a study group would likely make 
it easier to obtain additional participant platelet counts that could be used to calculate 24 hour 
increments but may not be desirable for the reasons discussed above. 
At 50%, return of self-assessment bleeding questionnaires was quite poor in this pilot study. A 
post-transfusion contact step may have encouraged better compliance with this part of the trial. 
Future studies should incorporate a telephone interview at two days post-transfusion to assess 
clinical bleeding and check for any problems completing the questionnaires. 
There is some question over whether the giving set samples used in the pilot study were 
representative of the whole concentrate. It would be preferable to take a sample from the 
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concentrate just before the transfusion was begun, although this would be more difficult in 
ethical and organisational terms. It would be necessary to convince an ethics panel that all risks 
of contaminating the concentrate and therefore exposing the participant to infection had been 
nullified, possibly by using a closed system for sampling (Védy et al, 2009). In addition, the first 
patient contact in the pilot study design was on the morning of transfusion when the patient 
arrived at the day unit. Potential participants were able to reflect on whether to participate or 
not in the time during which their transfusion was carried out before sampling at the end of the 
transfusion. Sampling at the beginning of the transfusion would necessitate an earlier patient 
contact step.  This could be achieved if a member of the clinical team spoke to potential 
participants during a prior appointment so that, if the participant was agreeable, consent could 
be obtained when they arrived at the Haematology Day Unit on the day of their transfusion. 
If prospective sampling is not possible, the next best thing would be to retain agitation and good 
oxygen transfer conditions in the platelet concentrate sample until the laboratory analysis is 
performed. It would be comparatively simple to transfer platelet concentrate samples to 
breathable containers and ensure they undergo a period of upon arriving in the laboratory to 
ensure adequate re-suspension of all platelets in the sample prior to analysis. Specimens could 
also be stored on an agitator between sampling for tests. 
In future clinical studies, it would be advisable to store stained blood films from the pre and post-
transfusion platelet count samples taken from the participants. These films would have allowed 
the validity of platelet counts to be checked and aided investigation of any suspected problems 
with the results. This would have been very useful in the pilot study for participants 003 and 005. 
 
5.9  Novel Contribution 
Several aspects of this study have been novel contributions to the field. No attempt has been 
made elsewhere to analyse platelet samples using the iZON system. Although development of a 
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fully optimised and reliable platelet analysis method  was ultimately deemed to be outside of the 
scope of this study the basic application was proven to have potential (see Figure 3.1). 
The clinical section of this project represented the first trial of the ThromboLUX analyser outside 
of the original development team (Maurer-Spurej et al, 2009). This study uniquely included 
clinical bleeding assessments, an outpatient population with a specified haematological diagnosis 
(MDS) and a range of other platelet concentrate quality tests. For the first time, the ThromboLUX 
score was performed alongside pH, HSR, ESC, ROTEM analysis and the new AWE test. 
This was the first occasion on which both impedance and fluorescent platelet count CCI values 
were available for platelet concentrates generally and for comparison with ThromboLUX results 
in particular. Fluorescent platelet concentrate platelet counts were observed to be consistently 
higher than impedance platelet concentrate platelet counts (see Tables 4.1, 4.6, 4.10, 4.14, 4.18 
and 4.22). The availability of two different types of CCI values enabled identification of two 
possible outlying results (one for each type of CCI value) and exclude them from data analysis, 
revealing a possible relationship between the ThromboLUX score and both CCI measurements 
(see Figure 4.12 and Table 4.27), the ROTEM results and iCCI (see Figure 4.14 and Table 4.28) and 
the AWE test results and both CCI measurements (see Figure 4.17 and Table 4.29). 
Previous assessments of the utility of thromboelastography in platelet concentrate quality 
assessment have concentrated mainly on the TEG instrument, have been restricted to in vitro 
analysis and have used clot amplitude based measurements (Arbaeen et al, 2016; Bontekoe et al, 
2014). The use of the ROTEM instrument in a clinical trial here is novel, as is analysis of force 
based measurements that better relate to clot elasticity. The standard reagent combination of 
EXTEM and FIBTEM reagents developed and optimised for routine clinical diagnostic use had not 
previously been used. This study has uniquely demonstrated a substantial difference in the 
results generated for platelet concentrate samples using different EXTEM reagent batches (see 
Figure 3.26). 
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The AWE test was exclusively developed for use in this study and appears to show some potential 
for the measurement of platelet concentrate quality (see Figure 4.17 and Table 4.29). There is no 
published literature relating to any previous attempt to automate any variation of either the HSR 
or ESC test and the concept appears to be entirely novel to this study. Although there is much 
scope for further development and investigation of this methodology, the work presented here 
forms a sound basis to build upon. 
 
5.10  Conclusion 
Several of the experimental test methods investigated through the course of this study show 
some potential for utility as a widely applicable screening test of platelet concentrate quality. 
More testing is required for any statistically significant conclusions to be made about any of 
them. However, the ground work for designing an appropriate clinical trial has been laid. It seems 
likely though, due to the difficult nature of platelet testing in general, that any single screening 
test would be at most the first line investigation, with concentrates that give abnormal results 
requiring further investigation or confirmation. 
Ultimately it may be found that problems with different platelet function pathways can only be 
detected using different techniques and the goal of a single, easily applicable screening test is not 
achievable. Rather, a carefully selected panel of tests, each targeted at a different aspect of 
platelet function may be required. This does not necessarily mean that routine or at least more 
easily carried out testing will not be possible in the future. With the rapid development, 
automation and miniaturisation of laboratory techniques, tests that were once considered 
specialised are now regularly carried out on a routine or even point of care basis. This trend is 
likely to continue in the future and may eventually make even complex platelet concentrate 
quality testing commonplace.  
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